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GENEraL INtrODUCtION & 
aIMS aND OUtLINE OF tHIS tHESIS
9IntroductIon
1geneRal intRodUction
An old concept of exploiting viruses for human clinical use is that of viral 
therapy of cancer (1). The initial incentive for using viruses for this purpose 
came from reports that cancer patients occasionally experienced partial clinical 
remission upon contraction of an infectious disease. These early observations 
(from up to more than a hundred years ago), as well as more recent ones, 
mostly concerned leukemia or lymphoma patients who had contracted either 
influenza (2), chickenpox (3), measles (4-8), hepatitis (9), or glandular fever (i.e. 
Epstein-Barr virus) (10). Thus, stimulated by such cases, researchers ventured 
to deliberately use natural viruses to combat various types of cancer. In this 
regard, several early clinical virotherapy trials that showed significant results 
made use of for example hepatitis B virus (11), West Nile virus (12), adenovirus 
(13), and mumps virus (14). However, despite the occasional evidence of an 
anti-tumor effect, oncolytic virotherapy using unmodified viruses generally 
lacked in efficacy and/or safety (1).
With the advent of recombinant DNA technologies (15), it became possible 
to specifically modify viral genomes and to develop viruses that incorporate 
foreign genes (16-18). This development marked the birth of the concept 
‘viral gene therapy’ (19), which entails virus-mediated transfer of therapeutic 
genes into target cells. Compared to previous, non-viral ‘gene therapy’ 
methods, virus-mediated gene delivery represented a dramatic advancement 
regarding the efficiency of gene transfer. As a result, the original idea of gene 
therapy – i.e. in vivo or ex vivo transfer of therapeutic genes into cells in order 
to complement for a genetic defect or to counteract a disease phenotype – 
became a much more realistic prospect.
Ever since the first promising results of efficient gene transfer using 
retroviruses in 1981 (17,18), many different viruses – enveloped or non-
enveloped, DNA- or RNA-based, with or without host genome integration 
ability – have been explored as platforms for gene delivery (20,21). In this 
regard, several types of replication-incompetent gene transfer vectors are 
currently being developed. For example, vectors are being developed not only 
for the purpose to ‘heal’ cells by gene correction or augmentation, but also to 
kill cancer cells by the introduction of lethal genes (e.g. for prodrug-converting 
enzymes, cytokines, or fusogenic or apoptotic proteins). Further, replication-
defective vectors are also being engineered to serve as viral vaccine vectors 
that encode and/or display pathogenic antigens (22,23). Finally, revisiting the 
old concept of viral therapy of cancer, the modern molecular design approaches 
are also being used in the context of replication-competent vectors, i.e. to 
generate more selective and effective oncolytic viruses (24,25).
Human adenoviruses (Ads) are the most widely used viruses as vectors for 
gene delivery or oncolytic virotherapy (26,27). Reasons for the popularity of 
Ad-based vectors include Ad’s relative non-pathogenicity in immunocompetent 
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adults, its genetic stability, and its ability to infect a wide range of cells, both 
quiescent and replicating. Furthermore, Ad’s biology has been extensively 
studied, both regarding natural infection in humans and in the context of 
experimental infections with wild-type or recombinant Ad in humans and 
animal models. Also, Ad has been used as a model for multiple cellular or 
viral processes. For example, early work on Ad has led to the discovery of 
RNA splicing (28), while work on Ad replication provided the first example 
of a mammalian cell-free DNA replication system (29). Thus, fundamental 
knowledge about Ad, combined with the availability of methods for genetic 
modification of Ad, has allowed for the development or improvement of 
Ad-based gene delivery vehicles and oncolytic agents.
All-important for any Ad vector – replication-competent or not – is that 
transduction of the target cells is sufficiently efficient and specific (21,30,31). 
However, especially for systemically administered Ad vectors this has been 
difficult to achieve. Blood-borne Ad is known to quickly become localized 
mainly to the liver, putatively as a consequence of the larger size of the 
endothelial fenestrations of the liver compared to those of other organs. 
Consequential to this biodistribution, Ad is readily taken up by scavenging 
liver macrophages (Kupffer cells) or, alternatively, efficiently transduces 
hepatocytes (mainly via interaction with blood coagulation factor X). These 
mechanism, as well as those involving other interactions with blood and/or 
cellular components, make that intravenously administered Ad is very poorly 
available for transduction of target cells.
Thus, major topics in Ad vectorology are de- and retargeting, both at 
the level of biodistribution and cell transduction (30,32). An ideal Ad vector 
would be modified to avoid sequestration by macrophages and blood 
components, be ablated for direct and indirect interactions with its native 
receptors, and, importantly, would efficiently and specifically enter cells via 
a new target receptor. Ways to achieve this are genetic capsid modifications 
and/or chemical modification of Ad. 
aims and oUtline oF this thesis
The overall aim of this thesis is to contribute to the engineering of more 
selective and effective oncolytic Ad vectors. Two general approaches are taken 
for this purpose: (i) genetic capsid modification to achieve Ad retargeting 
(chapters 2 to 4), and (ii) directed evolution to improve the cytolytic potency 
of Ad (chapter 5). In order to provide some context for these approaches, 
chapter 1, part ii gives a brief background on Ad biology and vectorology. 
Further, in chapter 1, part iii, a broad overview is provided of the ways 




chapters 2 and 3 focus on the modification of the minor Ad capsid protein 
IX (pIX). pIX is present on the faces of the Ad capsid icosahedron, functioning 
as ‘cement’ between the much larger hexon proteins (33). Previously, the 
C-terminus of pIX proved serviceable as an anchor for the genetic capsid 
incorporation of targeting ligands and other heterologous moieties (34-36). 
In chapter 2, a new system is described that allows for the rapid functional 
testing of new pIX-ligand fusion proteins. In this system, lentiviral vectors are 
used to generate cells stably expressing the pIX variant of interest. Large-scale 
infection on such cells with a pIX-deleted Ad vector subsequently yields an 
Ad vector preparation phenotypically pseudotyped with the new pIX variant. 
This system thus allows rapid analysis of new pIX-ligand fusions in the context 
of the Ad capsid without having to genetically modify the Ad genome. In 
chapter 3, the lentiviral vector-based pIX-pseudotyping system is put to use 
for the analysis of a new pIX fusion protein harboring a single-chain T-cell 
receptor (scTCR) as a targeting ligand. The concerning scTCR was directed 
against the intracellular cancer-testis antigen melanoma-associated antigen-
A1 (37-39). Importantly, this chimeric pIX molecule proved to be efficiently 
incorporated into the Ad capsid. Moreover, Ad transduction studies showed 
evidence of the capsid-displayed scTCR to mediate a degree of specific 
target cell transduction via the cognate peptide-MHC complex. 
Analogously as done for pIX, chapter 4 describes a phenotypical 
pseudotyping approach for fiber. The Ad-encoded fiber protein is present as 
a trimeric rod-like structure that extends from the vertices of the Ad capsid 
icosahedron (40). Its outward-facing, C-terminal ‘knob’ domain is responsible 
for binding the Coxsackie and adenovirus receptor (CAR), Ad’s in vitro primary 
cell surface attachment protein (41,42). With its prominent role in native 
receptor binding, the Ad fiber is logically subject to many capsid modification 
strategies that aim at altering Ad tropism (30). Thus to facilitate expedited 
testing of new fiber variants, a lentiviral vector-based, fiber-pseudotyping 
system was set up. This involved optimization of the fiber (variant) expression 
cassettes by inclusion of the tripartite leader sequence of Ad’s major late 
transcription unit (28). A second objective of this study was to functionally 
assess a new chimeric fiber harboring a tumor antigen-directed single-chain 
variable fragment (scFv) antibody (43). Although this fiber variant showed 
some degree of target binding and formed stable trimers, it displayed 
problems regarding capsid incorporation ability, functionality within the 
capsid, and folding of its scFv constituent. Thus, this particular fiber proved 
not suitable for Ad retargeting. 
Finally, chapter 5 describes the development and validation of a novel 
evolution-based engineering approach for Ad. To date, most Ad-based 
vectors have been generated through molecular design. Although this 
rational tailoring of Ad has led to significant vector improvements, it is often 
still hampered by our limited understanding of the intricate viral function-
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structure relationships. Therefore, ‘random’ virus engineering strategies (see 
chapter 1, part iii) may be a useful alternative or complementary approach 
for the generation of new or improved viral vectors. In this regard, the high 
mutation rates of RNA viruses have proven readily exploitable in adaptation 
studies to achieve vectorological goals (44-54). Thus, it was hypothesized that 
a mutator Ad polymerase-based, ‘accelerated evolution’ procedure would 
likewise be of use for Ad vector engineering. To develop such a system, 
the intrinsic mutation rate of Ad replication was sought to be increased by 
modification of the Ad-encoded DNA polymerase (Ad pol) (55). This was done 
by mutation of residues within regions putatively important for nucleotide 
selection or proofreading. A mutation-accumulation and deep sequencing 
strategy was subsequently used to identify any mutators among the Ad pol 
mutants. Finally, the mutator polymerase-based directed evolution approach 
was validated by conducting an evolution procedure aimed at increasing 
Ad’s oncolytic potency, and by subsequent characterization of resultant 
bioselected virus populations and isolated clones.  
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Human adenoviruses, of family Adenoviridae, genus Mastadenovirus, are a 
frequent cause of respiratory, gastrointestinal, urogenital, and ocular infections 
(1). Adenovirus infections in healthy individuals are mostly associated with 
only mild symptoms, but occasionally they can take a more severe course, 
leading to, for example, gastroenteritis or pneumonia (especially in children) 
(2-6). The diversity among adenoviruses is great: for human adenovirus there 
are 51 ‘serotypes’ identified by traditional immunochemical methods, and 4 
more ‘types’ defined recently by genomics (1,3,7-9). These different viruses 
are chronologically numbered 1 to 55 and further subgrouped in 7 distinct 
species, A to G. Human adenoviruses of serotypes 2 and 5 (Ad2 and Ad5), of 
species C, were thus among the earliest to be discovered and have been best 
characterized. Here we focus mainly on Ad5, the virus used most for gene 
therapy purposes.
virus structure and cell entry mechanisms
Adenovirus is a non-enveloped, icosahedral virus with a linear double-stranded 
DNA genome (10). The capsid, of about 90 nm, is formed by three major 
proteins, ‘hexon’ (II), ‘penton base’ (III), and ‘fiber’ (IV), in addition to four 
minor polypeptides (IIIa, VI, VIII, and IX). Hexons make up the greater part of 
the capsid, with each of the 20 icosahedron faces being formed by 12 hexon 
homotrimers. The penton base proteins in turn are located at the 12 vertices 
of the virus particle, with per vertex one penton base homopentamer. Further, 
from each of these vertices protrudes a trimeric fiber, each N-terminally 
anchored to the penton base structure. For prototypic Ad5, the genome 
contained within the capsid is about 36 kb long, has 103-nucleotide long 
inverted terminal repeats (ITRs) (11,12), and is covalently linked – at either 
of its 5’ ends – to a terminal protein (TP) (13). Besides with TP, the genome 
is associated with several other core proteins (V, VII, and µ) (14). Further 
contained within the viral capsid is the Ad protease, which plays an important 
role in viral maturation (15) as well as in Ad cell entry (16-18).
Adenoviruses enter cells through specific interactions with cell surface 
receptors. Such interactions may occur directly – between capsid protein 
and receptor – or indirectly via a ‘bridging’ function provided by a soluble 
host factor (19). In vitro, Ad5 infects cells via a well-defined 2-step process. 
First, the C-terminal ‘knob’ domain of Ad fiber binds to the Coxsackie and 
adenovirus receptor (CAR), which is a primary cell surface attachment molecule 
for members of species A, C, D, E, and F (19-21). Second, an RGD motif 
within the penton base protein binds to cellular integrins, thereby providing 
a trigger for internalization via receptor mediated endocytosis (22). This CAR-
mediated infection pathway is a highly efficient process, making that CAR-
18
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expressing cells are highly permissive to Ad5 infection, while non-CAR cells 
are comparatively virtually refractory.
In vivo, however, the canonical CAR-mediated cell entry mechanism is not 
the (only) major pathway of Ad5 infection. For example, CAR does not mediate 
the predominant transduction of the liver seen upon intravascular delivery of 
Ad5 (23,24). Instead, the hepatic tropism of blood-borne Ad5 is largely due to 
interaction of the virus with the blood coagulation factor X (FX) (25-27). In this 
regard, FX was shown to specifically bind Ad5 hexon and thereby to provide 
a bridging function to interact with heparan sulfate proteoglycans on the cell 
surface (26). Like CAR-mediated entry, this FX-mediated infection pathway is 
dependent – for efficient internalization via endocytosis – on integrin binding 
via penton base (28). Interestingly, besides being responsible for hepatocyte 
transduction by Ad5 present in blood (an artifactual situation), this FX-based 
cell entry pathway may also be relevant in the context of the natural, primary 
infections of respiratory or ocular epithelial cells (19,29). 
early viral transcription
Following their internalization via receptor-mediated endocytosis (22), 
partially dismantled adenoviruses disrupt the endosome (17,30), transport to 
nuclear pore complexes (31), and release their core protein-coated genomes 
into the nucleoplasm to allow viral transcription and replication to take place. 
The transcription program that subsequently begins can be divided into an 
early and a late phase, with the latter starting upon the onset of viral DNA 
replication. The early transcription phase has several general aims: to coax 
the infected cell (e.g. a terminally differentiated epithelial cell) to enter the 
S phase of the cell cycle, which is necessary to allow viral DNA synthesis; to 
suppress intra- and extracellular antiviral responses; and, finally, to produce 
the proteins necessary to carry out viral replication. 
Transcription units expressed in the early transcription phase can be 
divided in the ‘immediate early’ (E1A) and ‘early’ (E1B, E2A, E2B, E3, and 
E4) units. As a consequence of differential splicing and alternative use of 
start codons and/or polyadenylation signals, these units generate multiple 
distinct mRNAs encoding more than 25 proteins in total  (32). The first viral 
transcription unit to be expressed after Ad infection is E1A (33). The protein 
products of E1A, which are essential for efficient transcription of the other 
early units, function by directly and indirectly influencing viral and cellular 
gene expression as well as cellular regulatory pathways. For example, E1A 
proteins 12S and 13S, which for the largest part overlap in amino acid 
sequence, act by sequestration of retinoblastoma tumor suppressor pRb 
(34), thereby freeing the transcription factor complex E2F (35). Free E2F in 
turn promotes transcription of cellular genes important for the regulation of 
cell cycle progression, thereby forcing cell cycle progression to the S phase. 
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Additionally, the freed cellular E2F promotes transcription of the viral E2A 
unit (36).
Subordinately to E1A activation, the other early transcription units are 
activated (32,33,36). Early transcription unit E1B encodes two proteins, 
E1B 55K and E1B 19K. E1B 55K acts to prevent p53-dependent apoptosis 
by inhibiting the transactivating function of p53 (37). Additionally, in a 
complex with E4 ORF6, E1B 55K functions to promote p53 degradation by 
proteasomes (38). The other E1B protein, E1B 19K, is a functional homologue 
of cellular apoptosis suppressor Bcl-2 and acts to prevent p53-independent 
apoptotic pathways (32). Transcription units E2A and E2B, the former of 
which is activated earlier than the latter, harbor genes required for viral DNA 
replication (39-41).  E2A encodes the single-stranded DNA-binding protein 
(DBP), while E2B encodes the precursor of the terminal protein (pTP) and the 
Ad DNA polymerase (Ad pol). Further, transcription unit E3 encodes several 
proteins that counteract or prevent host innate and cellular immune responses 
to the infected cell (42,43). For example, E3 gp19K, a membrane glycoprotein 
that localizes to the endoplasmic reticulum, functions to avoid recognition of 
the infected cells by cytotoxic T lymphocytes (CTLs). It does so by blocking 
the transport of major histocompatibility complex class I antigens (MHC-I) 
to the cell surface, thereby preventing the display of MHC-I-complexed viral 
peptides to CTLs. Finally, transcription unit E4 encodes proteins with various 
different functions: influencing viral mRNA transport and splicing, promoting 
virus DNA replication, and forcing shutoff of host protein synthesis (32,44). 
In this regard, a complex containing E4 ORF6 and E1B 55K would function 
to bring about selective nuclear export of late viral mRNAs and to inhibit 
transport of host mRNAs (45).
viral genome replication
As a result of the coordinated action of the immediate early and early 
transcription events, replication of the viral genome begins about 5 to 
6 hours after infection (46). Adenovirus genome replication takes place 
via a protein-primed strand-displacement mechanism that requires at 
least three adenovirus-encoded proteins: pTP, Ad pol, and DBP  (40,41). 
Additionally, several cellular factors are necessary for efficient replication, 
including the transcription factors NFI/CTF and NFIII/Oct-1, and the type I 
DNA topoisomerase NFII. Ad genome replication can start at both the left 
and right ITR. The 103-bp long ITR consists of a terminal sequence of two 
3-bp direct repeats (positions 1 to 6), a pTP/pol binding site (position 9 
to 18), and an auxiliary region (positions 19 to 49) (40). The latter contains 
binding sites for transcription factors NFI/CTF and NFIII/Oct-1. Prior to 
DNA replication, Ad pol and pTP already associate to form a heterodimer 
complex (47,48). When bound to the ITR, the pTP/pol complex together 
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with host transcription factors NFI/CTF and NFIII/Oct-1 represents the pre-
initiation complex (41).
Upon formation of the pre-initation complex, replication is initiated using 
a ‘jumping back’ mechanism (41,49). First, using pTP as a protein primer, Ad 
pol carries out template-directed DNA polymerization starting at position 4 of 
the ITR. The first nucleotide to be incorporated, dCTP, is covalently attached 
to a Serine at position 580 of pTP, thereby creating ‘pTP-C’. Then, after the 
addition of two more nucleotides (i.e. dATP and dTTP), the resultant ‘pTP-CAT’ 
molecule jumps back three positions, allowing the pTP-linked nascent primer 
strand (i.e. CAT) to hybridize with the complementary first three positions of 
the template strand. After this operation, DNA synthesis by Ad pol commences 
again, quickly causing the pTP/pol complex to dissociate (after incorporation 
of the 7th nucleotide). Ad pol subsequently replicates the complete duplex 
genome, meanwhile displacing the nontemplate strand. DBP, which coats 
the displaced strand during replication, assists in the elongation process by 
helping to unwind the parental duplex DNA (50).
late viral transcription and virus assembly
With the onset of Ad DNA replication, the late transcription phase starts. 
General aims of this phase of the infection cycle are to produce the structural 
and regulatory proteins required for efficient virus assembly and release. 
During this phase, the so-called ‘intermediate’ (IVa2 and IX) and ‘late’ (major 
late transcription unit, MLTU) transcription units are activated.
The intermediate units, IVa2 and IX, are activated at the beginning of viral 
DNA synthesis (51,52). For IVa2, the mechanism of this replication-dependent 
activation is based on the relief from a titratable cellular transcriptional 
repressor (53). In case of IX, the basis for replication dependence is thought 
to lie in IX being entirely contained within the E1B transcription unit (54). 
Due to this nested arrangement, active E1B transcription would occlude 
the IX promoter, and IX expression would thereby only be possible using 
newly replicated templates not committed to E1B transcription (54). The 
single gene product encoded by IX, protein IX (pIX), has a structural role 
as a minor capsid protein and further has several regulatory functions (55). 
The other intermediate gene product, pIVa2, is an essential, multifunctional 
protein that supports encapsidation of the viral genome (56,57), assists in 
capsid assembly (58), and acts as a transcriptional enhancer of the viral major 
late promoter (MLP) (59-61). In this latter role, pIVa2 is instrumental for the 
replication-dependent activation of the MLTU.
The primary major late transcript extends from the MLP all the way to the 
right end of the viral genome. By alternative use of five polyadenylation sites 
and through the excision of multiple introns, this 30-kb primary transcript 
gives rise to five different families of late mRNAs (L1 to L5) (62). Attached 
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to the 5’ end of all major late mRNAs is a ~200-nucleotide leader sequence 
consisting of three noncoding exons. This ‘tripartite’ leader (TPL) sequence 
ensures that Ad’s late mRNAs are efficiently translated in the face of a general 
shutoff of protein synthesis induced by viral protein 100K (63-67). 100K, a 
protein encoded by L4 transcripts, blocks the function of host cell translation 
initiation factor eIF-4F (a cap-binding protein complex), thus causing a 
general inhibition of mRNA translation (65). Ad’s late mRNAs are not affected 
by this shutoff because their TPL sequences facilitate an alternative, eIF-
4F-independent form of translation initiation (called ‘ribosome shunting’) 
(68). Apart from the TPL, additional leader sequences can be found in late 
transcripts. For example, in case of the fiber-coding L5 transcripts, so-called 
x-, y-, and z-leaders are sometimes found spliced – alone or combined – 
between the TPL and the fiber sequence (69). The presence of such ancillary 
leaders within the L5 transcripts has been found to directly correlate with the 
efficiency of fiber synthesis (70).
The late mRNA transcripts encode proteins that make part of the Ad 
capsid, that assist in virus assembly (e.g. L1 52/55K and IVa2), or that have 
other regulatory functions (32,62). The assembly of progeny Ad particles 
begins about 8 hours after infection and takes place in the nucleus (71,72). 
It proceeds in an ordered series of steps involving the successive generation 
of several defined assembly intermediates. Light particles consist of all major 
capsid proteins, are devoid of DNA, and contain several non-capsid proteins, 
putatively for scaffolding purposes. Heavy intermediate particles contain all 
outer capsid proteins as well as the viral DNA genome complexed with the 
core proteins. Mature particles finally have undergone numerous proteolytic 
cleavages by the co-packaged Ad-encoded protease (18). These proteolytic 
cleavages are essential for full infectivity of the virus. At 30 to 40 hours after 
infection, the nucleus of the cell is packed with 104 to 105 progeny viruses (46). 
Subsequent viral release from the cell involves the action of the Adenovirus 
Death Protein (ADP), an Ad species C-specific glycoprotein that promotes 
cell lysis through an as yet unknown mechanism (73,74). The gene for ADP 
is embedded in Ad’s E3 region but it makes part of both the E3 and the ML 
transcription units (75). While the level of E3-derived ADP mRNAs remains 
low throughout infection, ML-derived ADP mRNAs become highly abundant 
at late stages of infection.
adenoviRal vectoRs
Adenoviruses display many qualities that favor them as vectors for gene 
therapy. Such qualifying traits include the ability to infect many different 
cell types, the capacity of generating high amounts of progeny, and genetic 
and physical stability (76). Furthermore, the sustained build-up – since the 
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early 1950’s – of fundamental insights into adenovirus (Ad) biology and 
genomic organization has made genetic manipulation of adenoviruses a 
straightforward practice and, concomitantly, has provided the vectorologist 
with leads for developing safe and effective gene therapy vectors (77,78). As 
a consequence, the field has seen many incremental improvements in vector 
technology, successful cases of preclinical assessments, and progression to 
clinical trials (77-79). 
There are various gene therapy and vaccination purposes for which 
adenoviruses have been studied and altered. Major aims in this regard are 
to use adenoviruses as replication-incompetent gene delivery vehicles for 
gene augmentation therapy, suicide gene therapy, and immonotherapy (76). 
Additionally, replication-incompetent recombinant adenoviruses are currently 
extensively being developed as vaccine vectors that can induce immune 
responses against antigenic polypeptides displayed on the viral capsid and/
or against antigens encoded for by the viral vector (80). Finally, another major 
aim is to use replication-competent adenoviruses as oncolytic vectors, i.e. to 
harness their replicative ability to fight cancers (81). 
gene delivery vectors
First-generation Ad gene delivery vectors are deleted for the E1 region, and 
sometimes additionally for the E3 region (76). The deletion of the E1 region 
serves to rid the virus of the essential transactivation and regulatory functions 
of E1. The absence of these functions prevents setting off the adenoviral 
gene expression program and thus essentially avoids viral replication. For 
their propagation, E1-deleted vectors are dependent on E1 proteins being 
provided in trans. E1-complementing cell lines used for this purpose are 293 
(82), 911 (83), PER.C6 (84), and N52.E6 (85), which are all cell lines transformed 
through the uptake in their genomes of E1 coding sequences. Unlike the 
E1 region, the E3 region, which mostly encodes immunoregulatory functions 
(42,43), is dispensable for viral growth in vitro. Consequently, its deletion in 
E1- and E3-deleted vectors needs not to be complemented for. The lack of 
E1 and E3 sequences together provides space for up to 8 kb of transgenic 
insertions.
Although these first-generation vectors have proven effective gene delivery 
vehicles in vitro and in vivo (86), there have been some limitations. Most 
prominently, the vectors elicited strong innate and adaptive (cell-mediated 
and humoral) immune reactions, thus curtailing prolonged transgene 
expression and making repeated administrations ineffective (87,88). Cell-
mediated immune responses causing eradication of transduced cells were 
found to be directed against the transgene product, but also against viral 
gene products, thus implicating low-level viral gene expression despite 
the E1 deletion. Another issue with the first-generation vectors was the 
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emergence during virus propagation of E1-positive, replication-competent 
viruses due to recombination with the E1 sequences genomically present 
in the complementing cell line (89). However, the risk for the occurrence of 
such replication competent Ads (RCAs) has been virtually eliminated with 
the newer E1-complementing cell lines whose integrated Ad sequences lack 
homology with E1-deleted viral vector genomes (84,85).
Second-generation Ad vectors have been made in which more of the early 
genes were deleted (76). This was done mainly with the aim to further restrict 
viral protein expression in order to avoid eliciting the cell-mediated immune 
response. Additional aims were to increase the genetic space for transgenes 
and to practically exclude the risk for RCAs. The observed low-level expression 
of viral genes observed in the first generation vectors might partially be a 
consequence of some residual replication of the viral genome. Therefore, new 
vectors contained deletions or mutations affecting the E2 genes for proteins 
necessary for replication (90-94). Additionally, vectors were engineered to 
lack E4 genes (95,96). To propagate these viruses, cell lines were developed 
expressing E2 or E4 genes either in a constitutive or inducible manner. The 
viruses carrying these additional deletions were found to elicit reduced innate 
and cell-mediated responses and, importantly, showed prolonged transgene 
expression.  
Finally, third generation or ‘high-capacity’ vectors are devoid of all viral 
genes (76,97,98). The only viral sequences their genomes contain are the ITRs 
and the packaging signal. These vectors have to be grown using a helper virus 
that provides all the viral functions and structural proteins in trans. Important 
for this approach is to avoid that the final high-capacity vector preparations are 
contaminated with helper viruses (be they replication-competent or not). One 
strategy that limits contamination entails the inclusion within the helper virus 
genome of recombinase recognition sites flanking the viral packaging signal 
(98,99). In this way, helper virus genomes are excluded from encapsidation 
when co-propagated – with the high-capacity vector – on cells expressing 
the recombinase. With viral genes completely lacking, these vectors have the 
unique capacity to incorporate up to 35 kb of heterologous sequence and, 
furthermore, would in principle be unable to elicit a cell-mediated immune 
response. Indeed, high-capacity vectors have been reported to maintain 
transgene expression in immune competent animals for durations much 
longer than previous generations (100-102).
The optimal vector design depends of course on the specific gene therapy 
goal. For gene augmentation applications (e.g. to counteract a monogenic 
effect by the introduction of a functional gene), where long-term expression 
is desired, the choice of vector might be for one deleted for multiple or all 
viral genes, as these are associated with reduced eradication of transduced 
cells by the immune system. However, the retention or reintroduction of 
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some of the viral genes might be beneficial. For example, E3 genes with 
anti-immune function may help prolong the survival of the transduced cells 
(103). Further, the inclusion of E4 ORF3 might be necessary for maintaining 
sufficient levels of transgene expression (104,105). For other applications, 
vector-induced immunity may be a primary goal [e.g. for immunotherapy of 
cancer (106,107) or viral vector-based vaccination against pathogen antigens 
(80)] or a potentially beneficial circumstance [e.g. for approaches that combat 
cancer by p53 gene replacement therapy (108,109) or by suicide gene therapy 
using prodrug-activating enzymes (110,111)]. Thus, for these applications an 
E1-deleted vector (with or without E3) may be a more likely choice.
For safety and efficacy reasons, a common goal for many gene therapy 
applications is to direct gene delivery and expression to specific target cells 
or tissues. Therefore, much research has focused on endowing vectors with 
target cell specificity (112-114). Distinct approaches taken to achieve target 
specificity are transcriptional and transductional retargeting. Transcriptional 
retargeting entails restricting the expression of a transgene to desired targets 
by making use of tumor- or tissue-specific promoters (TSPs). For example, 
genes for prodrug-converting enzymes have been put under the control of 
TSPs to mitigate the toxicity of suicide gene therapy (115).  Further, retargeting 
at the transductional level involves modification of the adenoviral capsid 
such that Ad more efficiently and/or selectively transduces certain target 
cells. Transductional retargeting of Ad can be induced by genetic means, 
e.g. through the incorporation of polypeptide targeting ligands into major 
or minor capsid components of Ad, or by non-genetic means like chemical 
modification or usage of bi-specific adaptor molecules (113,114). Ad targeting 
through genetic capsid modification is discussed in more detail below. 
oncolytic vectors
A unique gene therapy approach to the treatment of cancer is oncolytic 
virotherapy  (116,117). This approach makes use of the natural ability of lytic 
viruses to kill their host cells and to amplify their cell-lytic effect by replication 
and viral spread. Thus, unlike replication-incompetent gene delivery vectors, 
oncolytic viruses must express all viral genes necessary to efficiently perform 
their lytic life cycles. Further, for extra efficacy, they may be armed with 
therapeutic genes or modified with respect to their immunomodulatory 
functions. Most importantly, however, in order to kill tumors while leaving 
non-malignant tissues intact, they must be cancer selective.  
Adenovirus is not particularly cancer selective by nature and must therefore 
be rendered such. There are two general approaches by which this achieved. 
First, Ad can be rendered defective for functions that are essential for growth 
in normal cells but are redundant in tumor cells. For example, Ad5-Δ24 carries 
a 24-bp deletion in E1A, and the modified E1A gene products fail to bind the 
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cellular protein Rb for induction of S-phase (118). Due to this defect Ad5-Δ24 
exhibits selective replication in cells in which induction of S-phase is not 
necessary, e.g. most tumor cells. The second general approach to render 
Ad cancer-selective involves replacement of endogenous viral promoters 
with TSPs. TSPs have mostly been placed to control E1A, sometimes in 
combination with distinct TSP driving another early gene like E1B or E4 (112). 
The above approaches for selectivity have also been combined with a TSP 
driving the 24-bp deletion mutant of E1A (119,120). 
genetic capsid modification for ad retargeting
Despite the many advances made for both replication-defective and 
replication-competent Ad vectors, major barriers persist, especially relating 
to the specificity and efficiency of target cell transduction. In this regard, one 
of the most testing issues has been that intravenously injected Ad5-based 
vectors preferentially transduce hepatocytes (121), which severely limits the 
availability of these vectors for transduction of non-liver target cells. This 
phenomenon, which was found to be largely independent of binding to the 
known Ad5 receptors, (23,24,121,122) has recently been demonstrated to be 
primarily attributable to interaction of Ad with coagulation factor (F)X, which 
was found to provide a bridging function between Ad hexon and cell surface 
heparan sulfate proteoglycan (26,123). Another long-standing issue with 
intravenously injected Ad is the high uptake by the scavenging action of hepatic 
macrophages (i.e. Kupffer cells) (124-126). Although the exact mechanism is 
unknown, Ad clearance by these cells has been found to be predominantly 
mediated by scavenger receptors, with a contributory role for opsonization (by 
natural antibodies and complement) and interaction with platelets (127-130). 
Furthermore, alongside sequestration by the liver, an additional challenge is 
potential vector uptake by (other) non-target tissues owing to the widespread 
distribution of the primary receptor for Ad5, the coxsackievirus and adenovirus 
receptor (CAR). All these matters of off-target transduction limit bioavailability 
of the vector and may cause side-effects. This, together with the fact that many 
target cell types are relatively refractory to CAR-dependent transduction, has 
thwarted the systemic use of Ad5-based vectors. 
A rational way to overcome the obstacles associated with native Ad tropism 
is represented by transductional retargeting by genetic capsid modification 
(113,114). The main goals for genetic Ad retargeting is to restrict Ad’s broad 
infectivity profile and, simultaneously, to redirect Ad infection to specific target 
cells. To achieve the former of these goals, researchers have previously sought 
to ablate the direct interactions between capsid components and cellular 
receptors, including those between fiber and CAR (23), and penton base and 
integrins (131-134). While these interventions were successful in avoiding 
infection through the concerned receptors, they did not greatly influence Ad’s 
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hepatotropism or general biodistribution after systemic delivery. However, 
the recent elucidation of the FX-mediated infection pathway provided a new 
rationale for avoiding liver transduction (26). Mutation of hexon to disrupt 
binding of FX binding indeed resulted in viruses with markedly lower liver 
cell transduction (135). Moreover, FX-binding ablation of Ad5 combined with 
incorporation of a CD46-targeted fiber (specifically, a high affinity Ad35 fiber) 
yielded viruses showing much better lung targeting than control viruses (136). 
Thus these data indicate that genetic strategies to ablate liver tropism of Ad 
are feasible and, moreover, can be successfully combined with modifications 
that introduce new receptor specificities.
In this regard, genetic capsid modification strategies aimed at introducing 
new receptor specificities have been numerous and involved alteration of 
the major capsid proteins fiber, penton base (137-139), and hexon (140-142), 
as well as minor capsid protein pIX (143-148). With its role as Ad’s primary 
receptor-binding protein (in vitro at least), fiber was the first Ad capsid protein 
to be modified for retargeting purposes. Ad5 fiber consists of three domains: 
(1) an N-terminal ‘tail’ sequence that provides anchorage to the capsid via 
penton base, (2) a rod-like ‘shaft’ domain consisting of 22 β-spiral repeats, 
and (3) a C-terminal globular ‘knob’ domain consisting of a β-barrel structure 
and harboring the CAR-binding motifs. Fiber modifications to affect Ad 
tropism included swapping of the fiber knob domain (149,150), the fiber knob 
and shaft domains (151), or the complete fiber (152), with those of non-CAR 
binding Ad serotypes. These approaches led to Ad5 vectors displaying new 
receptor specificities, e.g. for CD46. Another approach is the incorporation 
of targeting ligands. Locations in the knob domain that have been found to 
tolerate ligand insertions are the C-terminus and the so-called HI loop (i.e. 
a certain exposed loop located between β-strands ‘H’ and ‘I’ of the fiber 
knob) (153-156). Especially the HI loop has been shown to tolerate ligands of 
considerable size (157-159). Finally, the complete fiber knob domain (possibly 
combined with all or part of the shaft) can be deleted and replaced with a 
targeting ligand. Strategies that took this approach have compensated for the 
loss of the trimerization functionality contained intrinsically within the knob. 
This has been accomplished by the inclusion of either the trimerization domain 
of a retroviral envelope glycoprotein (160), the neck region peptide (NRP) of 
human surfactant protein D (161), the ‘foldon’ domain of the bacteriophage 
T4 fibritin protein (162), or the oligomerization domain of the reoviral σ1 
protein (163). However, another study found that inclusion of such extrinsic 
trimerization domains was not necessary owing to a putative trimerization 
initiation ability contained within the shaft (164). Although general issues 
regarding the encapsidation of such rigorously modified fibers seem to exist, 
this strategy was successful in displaying different types of large and/or 
complex ligands on Ad (164-167).
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Protein IX (pIX) has also been extensively exploited for displaying targeting 
ligands on Ad. pIX is the smallest of the minor capsid proteins and is located 
in the crevices between the hexons that constitute the faces of the capsid 
icosahedron. It is involved in stabilizing the interactions between neighboring 
hexons (168), and is known to be necessary for packaging of full-length viral 
genomes (169). Present with 240 monomer copies per particle, pIX is about 
7 times more abundant than fiber, and therefore represents an interesting 
locale for incorporation of targeting ligands, vaccine antigens, or other 
functional groups. The C-terminus of pIX was found to be accessible in the 
context of the intact particle and (170), moreover, proved to tolerate genetic 
anchorage of targeting peptides (143). Further it was found that inclusion of 
α-helical spacer sequences increased the accessibility and targeting ability 
of peptide ligands (148). Finally, many later studies showed that different 
classes of large and complex moieties (e.g. single chain antibody fragments, 
green fluorescent protein, pathogen antigens) were readily displayed on Ad 
by genetic fusion to pIX (144-147,171,172).
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Numerous viruses have been explored for their applicability as gene delivery 
vehicles or as oncolytic agents (1,2). By nature, viruses are well-suited for 
employment for these purposes. They are inherently able to introduce their 
genomes into cells, to reproduce themselves, and, in case of lytic viruses, to kill 
their host cells. However, despite these abilities, viruses – or the vectors derived 
from them – often still fall short regarding both the efficiency and the selectivity 
with which they deliver therapeutic genes or eradicate cancer cells. Therefore, 
viruses are being genetically altered to better fit our therapeutic needs. 
 Before the introduction of recombinant DNA technologies, genetically 
altered viruses with desired traits could only be obtained by way of phenotypic 
screens on genetically diverse virus populations. Such classical or ‘forward’ 
genetics procedures typically made use of chemical or physical mutagens 
to randomly mutate viral genomes. Alternatively, these procedures relied 
on spontaneous mutation during repeated viral passaging. In either case, 
following the selection for a particular phenotype, genetic analysis of isolated 
viral variants allowed for the identification of the underlying genotypes.
Later, with the advent of molecular cloning techniques (3), it became possible 
to genetically modify viruses through ‘reverse’ genetics: viruses could now be 
specifically genetically modified at will, after which recombinant viruses could 
be phenotypically tested. This development allowed for the reengineering of 
viruses based on rational design, and, with the novel possibility to introduce 
heterologous genes into viral genomes, made possible the concept ‘viral 
gene therapy’ (4). Thus, fundamental knowledge of viral life cycles, cellular 
targets, and therapeutic genes could now be applied to viral vector design. 
This led to many improvements to viral gene delivery vehicles and oncolytic 
vectors (1,2).
However, we still lack a full understanding of the many aspects relevant to 
successfully reengineer or create a particular viral trait. Viruses have evolved 
compact genomes in which many coding and non-coding functions overlap. 
For example, many viral genes are expressed through intricate alternative 
splicing dynamics. This serves to save space and also to allow for the execution 
of balanced and time-regulated gene expression programs. However, due to 
these and other functional and structural constraints, not much of the viral 
genome can be changed without affecting functions critical for virus viability. 
As a consequence, the outcome of rational engineering of viruses is inherently 
unpredictable and often unsuccessful.
Therefore, there has been a renewed interest in random virus engineering 
approaches. These approaches include conventional forward genetics 
(involving the use of mutagens for whole-genome random mutagenesis), 
but also for instance strategies that employ in vitro genetic diversification. 
Regarding the latter, owing to the availability of modern molecular cloning 
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techniques and efficient library generation methods, virus engineering 
approaches can now benefit from powerful randomization procedures such 
as PCR-based mutagenesis and in vitro DNA shuffling (5-11). Thus, presently, 
many random engineering approaches – both classical and modern – are 
undertaken. These approaches are aimed to avoid the need for any detailed 
mechanistic knowledge and, furthermore, to allow for the unprejudiced 
selection of (possibly new types of) virus engineering solutions.
Here, we explore the various random engineering approaches that have 
been used to obtain genetically modified viruses with desired traits. Besides 
giving an overview of the different methods, we provide examples of how and 
to what ends they were employed to various different viruses. First, this review 
covers the classical genetics procedures that depend on either spontaneous 
viral mutation or on mutagen-induced mutagenesis. Subsequently, we 
describe several ways by which phage display strategies have been used for 
virus targeting purposes. Further, we review the various viral library-based 
engineering strategies. These approaches – employing in vitro randomization 
techniques and viral library-based selection – have been especially fruitful for 
some viruses with relatively small genomes and for which sufficiently complex 
viral libraries are readily made. 
spontaneoUs mUtation
One way to obtain genetically altered viruses with desired new phenotypes 
is to exploit the natural ability of viruses to evolve. Spontaneous mutations 
(including recombination events) occurring during viral replication are the 
major source of a virus’ potential to adapt to new circumstances. Whether this 
adaptive potential can be effectively used to purposely generate viruses with 
desired phenotypes depends both on the mutation rate of the concerning 
virus and on the nature of the target phenotype. Generally, the higher the 
mutation rate, the higher the probability is that beneficial mutations can be 
isolated within reasonable timeframes and in experiments of manageable size.
In this regard, riboviruses (i.e. all RNA viruses excluding the retroviruses) 
are well-known to exhibit the highest of viral mutation rates. The genomic 
mutation rates of riboviruses during their replication – by RNA-dependent 
RNA polymerases – have been estimated to be centered at around 0.76 
mutations per replication round (12). Considering the replication mechanism 
of these viruses (involving two replications per progeny genome) (12,13), 
this rate would translate to 1.5 mutations per genome per viral generation. 
Interestingly, with such high mutation rates, riboviruses are thought to exist 
close to an error-threshold, beyond which viral fitness would become ever 
lower due to degeneration (13,14). The answer to ‘why’ riboviruses evolved 
such high – and burdensome – mutation rates would lie in part in the 
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associated benefit of being able to rapidly evolve in the face of changing 
host conditions (13). Thus, the spontaneous mutation rates of riboviruses, but 
possibly also those of retro- and DNA viruses [which can be several orders 
of magnitudes lower (15,16)], may be exploitable to evolve viruses towards 
desired properties.
The concept of viral genetic adaptation under laboratory-controlled 
conditions has long been illustrated by the common observation that repeated 
passage of a pathogenic virus in tissue culture can lead to an attenuated 
phenotype in vivo. This makes that tissue culture-adapted strains are natural 
candidates for live-attenuated vaccines. For example, the repeated passage 
– at low temperature – of the respiratory syncytial virus (RSV), a ssRNA virus 
of the paramyxo family, yielded strains that, while remaining immunogenic, 
exhibited attenuated phenotypes in infants (17). This phenomenon of 
attenuation by repeated tissue culturing illustrates a very common process in 
evolution: prolonged subjection to a new set of conditions might result in a 
loss of ability to live under the old conditions.
However, the opposite of attenuation is also bound to occur: extensive 
viral growth on a particular cell type will enhance viral fitness on those cells. 
In this regard, because laboratory virus strains have mostly been propagated 
on transformed cells, their adaptation to these cells often led to a general 
enhanced ability to replicate in tumor cells. Below, we discuss several such 
cases of enhanced, and/or more selective, tumor cell killing by tissue culture-
adapted strains. Furthermore, examples are given of how viral adaptability has 
been exploited – purposely or coincidentally – to achieve other vectorological 
goals, such as altered protease specificity or receptor usage.
Riboviruses
Many studies illustrate the high adaptive potential of riboviruses. For example, 
pathogenic riboviruses have been reported to evolve escape mutants during 
anti-viral therapy (18-21). Furthermore, in laboratory experiments, different 
riboviruses have been found to readily adapt to new cell types (22,23), new 
host organisms (23-25), or altered growth conditions (26). In this regard, even 
under the relatively ‘constrained’ conditions imposed by alternated passaging 
on two highly divergent host cell types (i.e. from vertebrate and invertebrate 
origin), were several different riboviruses – i.e. sindbis virus, vesicular stomatitis 
virus, and Eastern equine encephalitis virus – able to evolve increased levels 
of fitness for either of the selective environments (27-29). 
Regarding the use of riboviruses as oncolytic agents, there are many 
reported cases of tissue culture-adapted strains having an enhanced and 
preferential ability to kill cancer cells. In fact, several of the most promising 
oncolytic riboviruses are attenuated lab strains or recombinant vectors 
derived from them (30). Examples of such attenuated oncolytic strains are 
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73-T (31) and HUJ (32) of Newcastle disease virus, Edmonston-B of measles 
virus (33,34), and A7(74) of semliki forest virus (35). All these strains were 
obtained after extensive viral passaging in vitro and/or in vivo, e.g. in tissue 
culture cell lines, tumor cells, chicken eggs, or mice.
The Edmonston-B strain of measles virus (MV-Edm), for example, was 
generated by subjection of a primary measles isolate to multiple passages 
(82 in total) in human embryonic kidney cells, human amnion cells, chick 
embryos, and chick embryo fibroblasts. This measles strain was observed to 
be low pathogenic while remaining immunogenic (36). Its derivatives have 
therefore successfully been used worldwide as live attenuated vaccines. 
Additionally, however, MV-Ed was coincidentally found to potently and 
selectively kill various tumor cell types (30) and, subsequently, to have efficacy 
as an oncolytic virus in animal models and in a phase I clinical trial (33,34,37). 
The enhanced oncolytic phenotype displayed by MV-Ed is thought to be due, 
at least in part, by altered receptor specificity (30). Owing to mutations in the 
viral attachment glycoprotein, the virus has an enhanced ability to interact 
with CD46 (38,39), a cancer-associated antigen expressed widely and highly 
on the cell surface of many tumor cells. 
The enhanced oncolytic phenotypes of the above strains were mostly 
obtained unintentionally, as the result of attenuation processes. More recently 
however, the high spontaneous mutation rates of riboviruses have been exploited 
more purposely to realize specific vectorological goals. Examples in this regard 
are directed evolution experiments – performed with rhinovirus, coxsackievirus, 
vesicular stomatitis virus, sindbis virus (VSV), tick-borne encephalitis virus, and 
avian influenza virus – to achieve enhanced growth on certain target cells and/or 
to achieve altered receptor or protease specificity (22,40-46). All these studies 
show that with proper selective conditions imposed, riboviruses can be readily 
forced to evolve towards desired new phenotypes.
An example of how the high adaptability of riboviruses can be exploited 
for vector engineering is given by a study that performed directed evolution 
to optimize a sub-optimally functional, transductionally retargeted VSV (40). A 
recombinant replicating VSV, engineered to express a chimaeric glycoprotein 
containing a single-chain antibody directed to human Her2/neu, exhibited a 
preferential ability to infect Her2/neu-expressing target cells over non-target 
cells. However, despite this, the virus grew very poorly on its target cells over 
multiple infection rounds. Therefore, to optimize this retargeted virus, it was 
serially passaged on the Her2/neu-expressing target cells, eventually yielding 
viruses – after fifteen passages – showing much better growth on these cells. 
Isolated infectivity-enhanced viruses were found to carry an improved version 
of the chimaeric glycoprotein (with two mutations in the single-chain antibody 
segment) that, putatively as a consequence of being more abundantly 
expressed on the viral surface, was better capable of promoting infection. 
Therefore, showing that a ‘suboptimally retargeted’ riboviruses can quickly be 
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adapted for improved functionality, this study provides an illustration of the 
power of combining rational and random engineering approaches.
Retroviruses
Retroviruses are RNA viruses that replicate through a host genome-integrated 
DNA intermediate, i.e. a ‘provirus’ (47). Per retrovirus infection cycle (from 
provirus to provirus), the viral genome undergoes three error-prone replication 
events (15). First, transcription from the provirus is carried out by a host RNA 
polymerase, generating an RNA viral genome that is packaged into the virus 
particle (along with a second genome). Then, in a newly infected cell, two 
replications by the virus-encoded reverse transcriptase convert the incoming 
RNA genome into double stranded DNA (dsDNA), which becomes integrated 
into the host genome. 
The fidelity of the above replication process has been found to be 
intermediate to that of riboviruses and DNA viruses (13,15,48). Mutation 
rates for retroviruses have been estimated at around 0.1 per genome per 
replication, thus corresponding to 0.3 per genome per round of cell infection 
(15). This spontaneous mutation level, although being lower than that found 
for riboviruses, provides the basis for the notoriously high adaptive potential 
of retroviruses in the face of the immune system or anti-viral drugs (49,50). 
Additionally, this inherent mutation level has been found to readily facilitate the 
directed evolution of retroviruses for vector engineering purposes. Indeed, it 
has become somewhat of a general approach to exploit retroviral adaptability 
for the improvement of sub-optimal recombinant retroviral vectors (51-55). 
Especially regarding env gene modifications, has forced evolution 
proven a useful tool for vector optimization. The env gene encodes for the 
precursor of the polypeptides that constitute Env, the envelope glycoprotein 
complex that mediates cellular receptor binding and membrane fusion. In 
general, modification of Env and Env-pseudotyping are powerful ways to 
endow retroviruses with new functionalities like altered cell tropisms (56,57). 
However, these targeted genetic interventions of Env are often associated with 
difficult-to-foresee functional defects that affect for instance viral infectivity or 
stability. Therefore, evolution-based strategies – in the context of replicating 
retroviruses – have been used to optimize the functionality of modified Env 
molecules.
Studies where env-modified viruses were subjected to forced evolution 
include those aiming to reengineer HIV-I Env as an effective vaccine antigen 
(51,52). In these studies, new Env variants – with impaired ability to mediate 
infection – were genetically incorporated in the context of a replication 
competent virus in order to allow for their functional optimization by evolution. 
This was done for example for variants lacking one or more of the variable 
loops of Env (51). These deletion mutants have improved immunogenic profiles 
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but are often, when non-optimized, problematic for production processes 
because of their relative structural instability. Importantly, forced evolution in 
the context of HIV-I to restore their functionality successfully yielded variable 
loop-deletion mutants exhibiting improved characteristics regarding the 
expression and secretion as stable multi-subunit Env complexes.
Other examples of using forced evolution to optimize env-modifed viruses 
are provided by studies on an avian retrovirus genetically pseudotyped 
with the amphotropic murine leukemia virus (MLV) Env protein (53,54). This 
chimaeric virus was optimized as a mammalian cell-gene delivery vehicle by 
two successive evolution steps. First, it was adapted to restore its ability to 
replicate on avian cells (this ability had been impaired by the env gene swap) 
(53). Then, to aid the establishment of stable producer cell lines, the virus 
was further adapted to be less toxic for avian cells (54). Interestingly, these 
two subsequent adaptations were respectively caused by two subsequent 
substitutions at a single amino acid position in Env.  
dna viruses 
With the exception of several ssDNA viruses, DNA-based viruses generally 
replicate with much lower spontaneous mutation rates than RNA viruses 
(13,15,16). For example, herpes simplex virus I (HSV-I), which carries a 
dsDNA genome of 152 kb, is estimated to have a genomic mutation rate of 
around 0.0027 per replication or 0.006 per infection cycle (this latter number 
corresponds to Drake and Hwang’s estimation of 1.36 × 10-4 mutations per 
1128-bp tk sequence per three infection cycles) (16,58). These rates are up to 
more than two orders of magnitudes lower those of riboviruses and retroviruses 
(see above). Still, despite their relative genetic stability, viruses from different 
dsDNA virus families – including the adeno-, herpes-, and poxviridae – have 
proven amenable, to some extent at least, to evolution-based engineering. 
adenoviruses. For adenovirus (Ad), for instance, it is long known that the 
genetic diversity obtained during normal virus propagation can be sufficient 
to isolate heat-stable or host range mutants from virus stocks (59,60). Recently, 
this was illustrated again in the context of a heat-liable Ad mutant deleted for 
the Ad core protein V (61). Subjection of a preparation of this virus to a simple 
incubation procedure (3 days at 37°C) demonstrated the a priori presence – 
within the virus stock – of thermostable viral mutants carrying compensatory 
mutations (within the precursor of the Ad core protein X/µ). Thus, these 
second-site mutations had occurred, and were presumably strongly selected 
for, during normal virus propagation rounds.
Another example demonstrative of Ad’s natural adaptability comes from 
early work from Harald zur Hausen’s lab (62,63). Human adenovirus type 12 
was serially passaged in two different tumor cells, yielding virus mutants with 
an enhanced growth potential. Interestingly, the isolated tumor-adapted 
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viruses all carried rearrangements at their genome termini, with a common 
feature of the right terminal alterations being a duplication of the inverted 
terminal repeat.
Finally, a recent special case of exploiting adenoviral mutability is one that 
employed Ad’s spontaneous recombination ability (64). Specifically, an array of 
Ad serotypes was used in a high MOI-infection to invite recombination among 
the different, co-infected viruses. The genetically diverse viral pools resulting 
from this procedure were subsequently adapted to growth on different tumor 
cell lines. Ultimately this led to the isolation of an oncolytic viral mutant – a 
complex Ad3/Ad11p chimaera – that showed efficacy in models for colon 
cancer treatment.
herpesviruses. Also herpesviruses have shown sufficiently high levels of 
genetic diversification to purposely isolate interesting new mutants in selection 
experiments. In this regard, several herpesviruses have been evolved towards 
envelope glycoprotein D-independent infection (65-67). In case of pseudorabies 
virus (PrV), glycoprotein D (gD) mediates a secondary cell attachment step that 
is essential for PrV cell entry. However, PrV-encoded gD is not required for 
the direct viral cell-to-cell spread of PrV. Therefore, a gD-deleted PrV, which is 
unable to infect cells by itself, can be propagated through the co-cultivation 
of infected and non-infected cells. In this regard, Schmidt et al. found that 
the repeated passage of a gD-deleted PrV, by the co-cultivation procedure, 
eventually led to the evolution of variants that had regained the ability to infect 
cells (65). These infective gD-deleted mutants carried putative compensatory 
mutations within the fusion effectors glycoproteins B (gB) and H (gH) (68).
In similar types of adaptation experiments, gD-independent infection has 
also been achieved for bovine herpesvirus (BHV) (66) and herpes simplex 
virus (HSV) (67), viruses for which gD normally is essential for viral cell entry 
as well as direct viral cell-to-cell spread. In case of HSV, the adapted, gD-
independent viruses contained a compensatory double mutation in the fusion 
effector gB (67). Interestingly, the gB mutant was found to be hyperactive, 
allowing for membrane fusion in the absence of the gD-receptor binding 
trigger. Interestingly, this hyperactive phenotype was found to be very 
beneficial in the context of a retargeted HSV; the combination of the gB 
mutant and a ligand-bearing gD was found to dramatically increase target-
specific infection.
Spontaneous mutation by herpesviruses has also been exploited for 
genetic selection in cancer cells to increase viral antitumor activity. In this 
regard, several passages of an attenuated, γ34.5 gene-deleted HSV-I variant 
in neoplastic cells resulted in the isolation of second-site ‘suppressor’ mutants 
exhibiting a regained ability to replicate in cancer cells (69). Surprisingly, while 
these mutants showed a much improved in vitro and in vivo oncolytic efficacy, 
they still exhibited the severely attenuated parental phenotype (69,70). The 
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common suppressor mutation seen in the isolated mutants – a discrete 583 
bp deletion – was found to cause a much earlier onset of expression of a 
viral inhibitor (Us11) of cellular PKR. Thus, suppressor viruses are thought to 
have overcome the PKR-induced shutoff of protein synthesis that occurs in 
the absence of the γ34.5 gene product. Similar results have been obtained in 
another adaptation study using γ34.5 mutant viruses (71). This study extended 
the above approach by performing the serial passage procedure in vivo (in 
tumor xenografts), and by additionally making use of a cytokine-armed virus 
(expressing murine interleukin-12 from γ34.5 gene loci) (71).   
poxviruses. Finally, also spontaneous mutation by poxviruses has proven 
to facilitate adaptation procedures. For example, a recent study showed that 
several tissue culture adapted strains of vaccinia virus have evolved, relatively 
to the parental strain, enhanced abilities to replicate in tumor cells (72). This 
ability is likely due to that these strains were adapted to growth, by continual 
passage, in transformed cells. One of the strains that proved exceptionally 
potent and tumor-selective (the WR strain) served in this study as the 
backbone for the development of a new recombinant oncolytic vaccinia virus. 
The resulting virus, JX-963, proved to have systemic efficacy against primary 
carcinomas and metastases in immunocompetent mouse and rabbit models. 
mUtagen-indUced mUtagenesis
Physical and chemical mutagens can be used to generate genetically 
diverse virus populations from which new phenotypes can be selected. Such 
mutagen-based random mutagenesis and selection procedures have logically 
mostly been applied to genetically stable DNA viruses – e.g. adenovirus, HSV, 
vaccinia virus, and polyomavirus – and much less to the faster mutating RNA 
viruses. Early forward genetics studies used mutagens to facilitate genetic 
screens for identifying and investigating viral functions. Recently, however, 
mutagen-induced mutagenesis has also been employed with the purpose of 
optimizing or generating new oncolytic viral vectors. Among the mutagens 
that have been used for viral mutagenesis are nitrous acid, hydroxylamine, 
nitrosoguanidine, ultraviolet radiation, and the nucleotide analog BrdU. 
Mutagenesis by mutagens is brought about through various different 
mechanisms, but is always ultimately dependent on cellular or viral functions 
like replication and DNA repair.
Mutagenesis by nitrous acid, the most-used mutagen to mutate viruses, 
involves deamination of adenines and cytosines and therewith the formation 
of respectively hypoxanthine and uracil. This reaction affects the base pairing 
potential of the concerning nucleosides: hypoxanthine prefers pairing with 
cytosine and uracil with adenine. Therefore, during viral replication, altered 
templating properties – of the affected nucleosides – will cause certain base 
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pair substitutions to occur, namely the transitions A:T to G:C, and C:G to T:A. 
However, besides deamimation of bases, nitrous acid also causes interstrand 
cross-links in duplex DNA (73). If left unrepaired, this type of lesion will block 
viral replication, thus causing virus inactivation. Additionally, if cross-links do 
get repaired – by the cellular repair mechanism – they are likely to leave behind 
deletions (73), which are generally much more deleterious than substitutions. 
Thus, nitrous acid has mutagenic properties – causative of substitutions and 
deletions – as well as direct inactivating effects (74). In general, it is thought 
that the greater part of the drop in virus viability seen after treatment with a 
mutagen is the consequence of such direct inactivating effects rather than of 
the biological effects of genetic alterations (75).
Theoretical considerations have been made as to how strong a mutagenic 
pulse should be for a maximized chance to select a desired phenotype 
(75). Exposure of a virus population to a mutagen will cause a level of virus 
inactivation (due to both the direct inactivating effects as well as lethal 
genetic mutations). This level of inactivation – or its reciprocal, the surviving 
fraction – is a parameter that can be set by the investigator to influence the 
chance of success in a mutagenesis and selection experiment. In this regard, 
Bull showed that in the context of a single-pulse mutagenic treatment, the 
theoretical optimum for the surviving fraction can be calculated by e-D, where 
D is the phenotype dimensionality, i.e. the number of mutations needed 
to create the phenotype (75). Thus, if a certain phenotype can be reached 
by 1 mutation, then a surviving fraction of 37% would give the highest 
chance of success. Likewise, for selection of a phenotype dependent on 2 
mutations, then 14% survival would be best. Interestingly, most studies that 
performed viral mutagenesis using mutagens mutated to survival levels that 
are considerably lower than the percentages above. 
As said, in classical experimental virology, mutagen-induced mutagenesis 
was used to facilitate the screening for new phenotypes, especially in case of 
the relatively genetically stable DNA viruses. Phenotypes that were commonly 
isolated in genetic screens are those for which appropriate selective conditions 
could be readily imposed. Such phenotypes included for example temperature 
sensitivity (76-81) and altered host range (60,82,83). Through recombination 
mapping and functional analysis (e.g. complementation assays), the selected 
phenotypic mutants subsequently aided the identification of new genes and 
functions. For example, temperature-sensitive (84) and host range mutants 
(83) of polyoma virus, a tumorigenic double stranded DNA virus, have proven 
useful in the elucidation of mechanism of neoplastic transformation (85,86). 
Recently, this forward genetics approach has been revisited to generate 
viruses with enhanced oncolytic properties (87-91). For example, Fu and 
Zhang sought to increase the tumor cell killing capacity of HSV G207, a 
well-studied, but sub-optimally potent oncolytic HSV exhibiting a tumor cell-
selective phenotype (as a consequence of an inactivated ICP6 gene) and a 
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non-virulent profile (by virtue of the deletion of its γ34.5 loci) (89). HSV G207 
was mutagenized by replication of the virus – for one infection round – in the 
presence of BrdU, a nucleoside analog of thymine that can cause mutations 
through mistemplating. Subsequently, from the mutagenized virus preparation, 
mutants were isolated that showed a syncytial phenotype in plaque assays. 
Characterization of one of the mutants – exhibiting a strong syncytial activity – 
demonstrated a significantly increased antitumor potency in vitro and in vivo. 
Thus this study showed that random mutagenesis can readily facilitate a non-
fusogenic HSV to acquire a strong membrane fusion capability.
Investigators have also sought to improve adenovirus as an oncolytic virus 
(87,88,91). Yan et al. mutated HAdV-5, using nitrous acid, and subsequently 
performed repeated passages on a tumor cell line to enrich for viral mutants 
with an acquired growth advantage (87). This ‘bioselection’ procedure yielded 
mutants displaying an enhanced cytotoxicity in different cancer cell lines but 
not on a number of primary human cell lines. The observed phenotype was 
associated with a mutation causing a C-terminal truncation of the i-leader 
protein, a protein with as yet no known function. Interestingly, another genetic 
screen (involving UV-induced viral mutagenesis), by Subramanian et al., 
yielded a similar i-leader-truncating mutation (91). This mutation was selected 
as a second-site suppressor mutation in the context of a small-plaque mutant 
of Ad (dl327, which lacks most of Ad’s E3 region). Thus, both studies implicate 
a stimulating role of the i-leader protein in viral spread.
Gros et al. extended the above oncolytic adenovirus bioselection strategy 
by performing several in vivo selection rounds in human tumor xenografts-
bearing mice (88). This approach led to the isolation of an oncolytic mutant 
showing a large-plaque, enhanced-spread phenotype in vitro and enhanced 
systemic efficacy in vivo. Intriguingly, the causative mutation was found to 
rid the E3/19K protein of its endoplasmic reticulum retention domain, thus 
relocating it to the plasma membrane. There, at the cell membrane, the 
mutant protein might exert a viroporin-like function: it might render the cell 
permeable to ions and destabilize the membrane, thereby promoting the 
observed enhanced viral release. With the identification of this unanticipated, 
putative gain-of-function mutation, this study illustrates the relevance and the 
feasibility of using the in vivo tumor environment as a selective pressure for 
the isolation of enhanced oncolytic viruses.
phage displaY-Based selection oF viRUs 
taRgeting moieties
Virus targeting – to specific receptors, cells, or tissues – is an all-important goal 
in viral gene therapy (2). Therefore, viral capsid or surface proteins have been 
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used as sites for the genetic incorporation of various targeting ligands (92,93). 
Additionally, viruses have been retargeted using bispecific adaptor molecules 
consisting of targeting ligands conjugated to virus-binding moieties (94-97). 
However, the natural repertoire of high-affinity, virus incorporable, target-
specific ligands is limited. Therefore, random peptide display on phage has 
been explored as a means to select peptides capable of binding specific 
cellular targets (98). 
Phage peptide display is the expression of a peptide library on the outside 
of bacteriophage particles (99). The peptides are expressed as fusions of a 
phage coat protein, e.g. minor coat protein pIII or the major coat protein 
(pVIII) of M13 filamentous phage. Importantly, each phage virion represents 
a physical linkage between a peptide variant and its genetic code. This 
phenotype-genotype connection is what makes phage library-based selection 
possible: selection for a certain peptide or protein variant will co-select for its 
encoding sequence (which is then simply recovered and identified by PCR and 
sequencing). The power of the phage display technology is that very large and 
complex libraries are readily made, allowing for instance virtually all possible 
variants of a 7-mer peptide to be represented in a single library (100). 
Phage display-based selection to obtain new virus targeting motifs can be 
performed both in vitro and in vivo. In vitro, selection has been performed 
to isolate peptides binding specific cell types as for example ciliated airway 
epithelial cells, vascular endothelial cells, and vascular smooth muscle cells 
(96,101-103). In vivo biopanning procedures selected for peptides that home 
to certain tissues, like organ-specific vasculatures (104-107), renal tubular 
epithelium and glomeruli (108), and tumor xenografts (109,110). After such 
selection procedures, the individual targeting peptides are genetically 
incorporated into predefined sites – known to be able to accommodate 
heterologous peptides – of for example the adenovirus fiber protein or the 
AAV capsid protein. These sites are respectively the HI loop and C-terminus 
of the Ad fiber (111-113), and amino acid 587 of AAV capsid (92). Additionally, 
isolated targeting ligands have been chemically coupled to Ad (101), or 
genetically fused to an adenovirus specific binding moiety such as antibody 
fragments (94,96) or the extracellular domain of the coxsackie and adenovirus 
receptor (95). 
Several studies successfully retargeted AAV and Ad by genetic incorporation 
of in vivo selected targeting peptides (106-108,114). Grifman et al. showed that 
AAV capsid-incorporation of a previously isolated tumor-targeting peptide, 
NGR (109), altered the tropism of the recombinant AAV vector, leading to 
preferential transduction of cells expressing the target of NGR, CD13 (114). 
Further, the group of Baker performed in vivo phage selection in rats to obtain 
peptides that home to the lung or brain (107). Incorporation of some of these 
peptides into the the AAV-2 capsid resulted in both independence from the 
natural receptor, heparan, and relative redirection of in vivo infection to the 
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vascular beds of the concerning targeted organs. Finally, two studies of the 
same lab incorporated in vivo selected targeting peptides into Ad (106,108). 
Cardiac and kidney vasculature-homing peptides were inserted into the HI 
loop of Ad19p serotype fiber in the context of an Ad5-based vector. The 
resulting vectors showed selective transduction of certain vascular cells of the 
respective targeted organs. 
An important issue of these strategies is whether the isolated targeting 
peptide will retain its cell-binding or tissue-homing functionality in the context 
of the virus particle. A targeting peptide selected in the context of a phage 
virion – and displayed as either a linear or cyclic epitopes – might lose its 
functional configuration when inserted in the virus capsid protein. Moreover, 
the functionality of the peptide might differ per location in the capsid protein 
or per exact insertional configuration. Also, certain peptide insertions may 
compromise virion integrity. Therefore, to avoid selecting peptides that could 
be non-functional out of the bacteriophage context, attempts have been 
made to select peptides immediately in the right context. The most rigorous 
approach is to perform selection in the complete viral context, thus to perform 
virus library-based selection. This approach has been well established for AAV 
and to a much lesser extent for Ad, as discussed in the next sections. However, 
a less rigorous but potentially useful approach is to perform context-specific 
phage display: the peptide library is displayed on phage in the context of the 
viral capsid protein or a portion of it.
For Ad retargeting, a number of context-specific phage display systems have 
been developed. The ‘contexts’ that were displayed on phage in these systems 
were either the complete fiber knob domain (115,116) or only the two β-sheets 
(H and I) that flank the HI loop  (117). Biopanning experiments using these 
context-specific systems identified peptides that, upon their incorporation in 
the complete virus, enhanced Ad’s ability to transduce the target cells (mouse 
fibroblasts and skeletal muscle cells) (116,117). Of note, an advantage of the 
approach displaying only the H and I sheets of fiber knob, as opposed to 
approach using the intact fiber knob, is that larger libraries can be generated.
Besides for peptide affinity biopanning, phage display has also been 
used for the engineering of protein domain-based affinity ligands (118-
121). In these cases, instead of a peptide library, a small protein domain 
with randomized protein binding site is displayed on phage. The advantage 
of using small protein domain scaffolds instead of peptides for obtaining 
affinity ligands is that target binding can occur in the context of a stable 
secondary structure, which potentially allows for better and more selective 
binding of targets. One type of affinity ligand that has been engineered in 
this way is the ‘affibody’ (121). Affibody libraries are made by randomization 
of a limited number of solvent-accessible surface residues of a staphylococcal 
protein A-derived alpha-helical bacterial receptor domain Z. Because of their 
relatively simple and stable structure that does not rely on disulfide bridges, 
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affibodies have potential as virus targeting ligands. This is especially the 
case for non-enveloped viruses, like adenovirus, for which genetic capsid 
incorporation of more complex, disulfide bridge-containing secretory ligands 
(e.g. antibody-derived ligands) has proven problematic (122-124). In this 
regard, affibodies directed against the tumor-associated antigen HER2/neu 
have been successfully incorporated into the adenovirus capsid with retention 
of target binding functionality (125-127).
viRal liBRaRY-Based selection
Owing to the availability of modern molecular cloning and diversification 
techniques and efficient viral library generation methods, various powerful 
viral library-based engineering strategies have been developed (128,129). 
These strategies have proven extremely useful to obtain viruses with desired 
traits, especially in the fields of retrovirus and AAV vectorology. Although 
diversification techniques and combinatorial selection strategies are evolving, 
these new random engineering approaches generally entail one or more 
rounds of the following steps: (a) in vitro diversification of a bacterially cloned 
viral gene or genome, (b) conversion of the resultant plasmid-based library 
into a viral library, and (c) viral library-based phenotypic selection. In vitro 
methods that have been used in the diversification step are transposon-
mediated mutagenesis, cloning of degenerated oligonucleotides, error-
prone PCR, and in vitro recombination. After the diversification step, the 
diversified cloned fragment or genome must be efficiently packaged (or 
‘rescued’) into virus particles to create a viral library. Importantly, for each viral 
particle within this library the genotype and the phenotype must correspond. 
Then, after phenotypical selection from the viral library (e.g. for functionality, 
target binding, target cell entry, temperature stability, neutralizaing antibody 
avoidance), the selected genotype can be recovered by PCR and be analyzed. 
Viral library-based selection strategies have been best established and proven 
most fruitful for AAV and retroviruses, viruses for which viral genome handling 
and/or viral library generation is relatively efficient compared to viruses like 
adenovirus and herpesvirus.
Random insertional mutagenesis
The concept of random insertional mutagenesis is the insertion of a known 
sequence at random positions into the viral genome or genome fragment. 
This can be achieved by in vitro transposition (in bacteria) of a transposable 
element into plasmids (or bacterial artificial chromosomes) carrying the viral 
sequences. This technique, originally used to identify essential and non-
essential genes in herpesvirus (130), has emerged as a general means to 
study viral functions. More recently, however, it has additionally become a 
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useful tool for vector engineering purposes, e.g. to identify new sites in viral 
genomes that can tolerate transgene or targeting peptide insertions.
Different studies used transposon-based scanning to find permissive 
insertion sites within the envelope proteins of MLV and VSV. For example, the 
bacteriophage Mu transposon system was employed by Rothenberg et al. to 
construct a library of 15-nucleotide insertion mutations within the env gene of 
MLV (131). Selection for virus viability subsequently resulted in identification 
of multiple sites within the Env glycoprotein that are permissive for five-
amino-acid insertions. Likewise, Yu and Schaffer used a similar retrovirus-
based strategy to scan the vesicular stomatitis virus glycoprotein (VSV-G) for 
sites that tolerate a six-histidine (His6) tag-containing 13-amino acid sequence 
(172). Repeated selection for retroviral replication ability and affinity for 
Ni-nitrilotriacetic (Ni-NTA) led to the identification of His6-tag insertion 
mutants of VSV-G that facilitated virus purification using Ni-NTA columns. 
Other vectorological goals achieved for retroviruses by random insertional 
mutagenesis include the isolation of MLV variants capable of infecting non-
dividing cells (132) and the selection of MLV mutants with altered host genome 
integration properties (133). These results were accomplished through the 
generation of respectively a nuclear localization signal (NLS) insertion library 
and a DNA-binding domain insertion library.
Random insertional mutagenesis has also proven useful for the generation 
of new adenoviral vectors. Two recent studies from Hermiston’s lab showed 
that a modified transposon Tn7-based system could be efficiently used to 
scan the Ad genome for identification of insertion sites compatible with viral 
replication. The first study identified several unique sites for the insertion 
of (promoter-based) transgene expression cassettes (134). The second study 
performed Ad genome scanning using a splice acceptor-containing reporter 
gene expression cassette (135). This study identified sites allowing Ad major 
late promoter-driven expression of inserted transgenes. Together these 
studies provided new rationales for the development of new oncolytic Ad 
vectors armed with therapeutic genes.
Random peptide display / targeted randomization
Targeted randomization in conjunction with viral library-based selection has 
emerged as an important and fruitful way of viral vector engineering. A major 
application of this approach is ‘viral peptide display’, which entails the display 
and selection of randomized polypeptides in the context of viral capsid or 
envelope proteins (136). This application, which is conceptually analogous 
to phage display, allows for example for the selection of peptides capable 
of mediating cell receptor-specific or cell protease-dependent viral cell 
entry. Importantly, the viral display procedure ensures that polypeptides are 
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selected directly for functionality in the relevant viral context, which is a major 
advantage over peptide selection in the heterologous context of phage. 
protease-dependent retroviral cell entry via protease activatable env. 
The first study demonstrating the feasibility of random peptide display on 
a virus was one that sought to achieve protease-dependent replication of 
a retroviral vector (136). A randomized seven-residue linker was inserted 
between a heterologous receptor-binding ligand and MLV Env. The 
concerning ligand, EGF, is known to have an inhibitory effect on cell entry 
because it directs EGF receptor (EGFR)-bound MLV to lysosome-mediated 
degradation (137). Screening of the viral library for the ability to transduce 
EGFR-overexpressing cells selected peptide linkers that served as substrates 
for furin-like proteases. Thus, this study provided proof-of-principle that viral 
peptide display strategies can be employed to render the MLV cell entry 
mechanism dependent on proteases. 
However, despite the fact that the above selection strategy involved 
serial passage on a tumor cell line, the selected peptide linker sequences 
were substrates for ubiquitously expressed proteases, not cancer-associated 
proteases (136). Therefore, attempting to achieve cancer selectivity, a 
subsequent study adapted the strategy by inserting instead of a completely 
random sequence, a matrix metalloprotease-2 (MMP-2) substrate motif semi-
randomized such to avoid the possibility for furin-sensitive substrate (138). 
Two cycles of diversification and screening on human fibrosarcoma cells led 
to substrate sequences that were specifically cleaved by a tumor-associated 
MMP-2. Thus, MLVs carrying the concerning Env-EGF fusions transduced EGFR-
overexpressing cells in an MMP-2-dependent manner. A subsequent strategy 
sought to achieve a mechanism of MMP-2-dependency of MLV transduction 
that did not require high levels of EGFR on the cell surface (139). This was done 
by using instead of EGF, another cell entry-blocking moiety, CD40L, which acts 
in a general way, not requiring cognate receptor binding on the cell surface. 
Viral peptide library screening using the new chimaeric Env configuration 
successfully yielded virus whose replication is restricted to MMP-positive cells.
selection of targeting peptides in context of retroviral env. Random 
peptide display on retroviruses has also been used to select targeting peptides 
in the context of the Env glycoprotein. Bupp and Roth explored the receptor 
specificity-determining variable region A (VRA) of feline leukemia virus (FeLV) 
as a locale for targeted randomization (140). In FeLV, the VRA of Env is the sole 
major determinant of cell surface receptor specificity; exchange of a defined 
VRA segment between different FeLV subgroups altered the viral host range 
(141). Viral libraries were made by randomizing a 10- or 11-amino acid stretch 
within the VRA of FeLV Env (140,142,143). Screening of these libraries for 
the ability to infect certain target cell lines yielded host-range mutants with 
altered receptor usage abilities. Importantly, one isolated Env protein proved 
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to mediate cell entry via a receptor protein not known to be used by any other 
retrovirus (143,144). Further, another isolated Env protein uses a receptor 
known to be utilized by an endogenous retrovirus from a distant species 
(145). Of note, this latter targeted receptor, a G-protein-coupled receptor 
that functions as the human gamma-hydroxybutyrate (GHB) receptor, is up-
regulated in different human malignancies and therefore may be a useful anti-
cancer target. Although the above studies clearly demonstrate the power of 
this method to target retroviruses to alternative receptors, they also implicate 
a limitation regarding the repertoire of targetable cell surface receptors. In 
this regard, an efficient retroviral receptor appears to be required to be a 
multipass transmembrane receptor capable of providing a specific facilitatory 
role (e.g. perhaps regarding membrane fusion or intracellular trafficking) (145).
selection of targeting peptides in context of the aav capsid. After 
random peptide display on viruses was first demonstrated for retroviruses, 
the principle was soon also applied with much success to AAV vectors 
(146-148). Amino acid position 587 of the AAV-2 capsid is located within a 
motif required for viral binding to heparan sulfate proteoglycan (149-151), 
the primary receptor of AAV-2 (152). This particular position in the AAV 
capsid, which had already been found to tolerate the insertion of targeting 
peptides (92), was successfully used by different groups as a locale for the 
display of random peptide libraries (146,147). Perabo et al. and Muller et 
al. independently generated 7-amino-acid peptide display libraries and 
performed multiple-round selections for the ability to infect non-permissive 
target cells. Importantly, selected mutants showed enhanced infection of the 
respective target cell lines (i.e. a human megakaryocytic and a B-cell chronic 
lymphocytic leukemia cell line, and human coronary artery endothelial cells).
Several studies expanded the utility of the AAV capsid display approach by 
performing in vivo biopanning. Grimm et al. displayed a peptide library in the 
context of a chimaeric AAV (which itself was obtained by DNA family shuffling 
and phenotypical selection as discussed below), and subsequently subjected 
the resultant viral library to a selection regime involving serial passaging in 
mouse lungs (153). The procedure led to retargeting of the chimaeric AAV 
to distinct alveolar cells. Another in vivo biopanning study (using an AAV-
displayed peptide library) conducted multiple rounds of intravenous injection 
and subsequent viral recovery from mammary tumor tissue (154). Recombinant 
vectors displaying the peptides selected by this procedure were found to 
mediate significantly enhanced reporter gene expression in the target tissue. 
However, increased reporter expression was also observed in other tissues, 
especially that of the heart. Thus, the procedure led to a general expansion of 
AAV tropism despite the putative ablation of heparin binding ability. Finally, 
Ying et al. performed in vivo screening of an AAV-2 display peptide library to 
select vectors specifically homing to heart tissue after systemic delivery (155). 
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Indeed, selected viral clones showed better specificity of gene transfer to the 
heart than control vectors.
selection of targeting peptides in context of the adenovirus fiber. Viable 
strategies for high-throughput random peptide display in the context of Ad 
particles have only recently begun to emerge (156-159). A general bottleneck 
for the development of such strategies for Ad has been that plasmid-based 
genomes are very inefficiently converted – upon transfection in cells – into 
packaged Ad virions. Furthermore, Ad’s relatively large genome size, in 
comparison to AAV and retrovirus, poses an additional efficiency bottleneck 
for Ad library generation. Two recent studies took very similar approaches 
to bypass these issues (156,157). Both studies exploited the ‘cre-lox’ site-
specific recombination system to achieve efficient transfer of a plasmid-based 
Ad fiber-peptide library directly into ‘live’, replicating Ad vectors. Benefits 
of this strategy are that initial fiber-peptide library generation and handling 
takes place on a small shuttle plasmid and, more importantly, that subsequent 
transition to a viral library does not entail virus ‘rescue’ from a plasmid-derived 
genome. Both methodologies used the HI loop of the Ad fiber knob domain 
as the site for peptide library insertion. Lupold et al. subsequently screened 
their CAR-binding ablated Ad peptide display library for replication ability 
on the standard Ad propagation cell line 293 (which expresses CAR)  (156). 
This led to the isolation of viruses exhibiting enhanced, CAR-independent 
infectivity on different cell lines. Similarly, Miura et al. screened their library 
on a glioma cell line, leading to the selection of variants showing enhanced 
gene transduction on the target cell line but not on many other cell lines 
(157). Thus, in parallel, these studies established a general methodology for 
relatively high-throughput selection of new Ad targeting peptides.
The potential of random peptide display on Ad in the context of the 
fiber knob was soon further exemplified by the same two groups (158,159). 
Nishimoto et al. performed screening on a human pancreatic cancer cell line, 
and subsequently inserted the selected targeting peptide in a replication-
competent, CAR-binding ablated (ΔCAR) Ad (158). Compared to the parental 
ΔCAR vector, the resulting retargeted vector showed enhanced cytolytic 
potency on the original target cell line as well as several other pancreatic 
cancer cell lines. Moreover, the new oncolytic vector showed enhanced 
efficacy in subcutaneous tumors after intratumoral injection without 
displaying increased ectopic liver gene transduction. Further, in a more recent 
study, Wu et al. significantly expanded the utility of their random peptide 
Ad display methodology by employing it to optimize the positioning of a 
fiber knob-incorporated Ad targeting ligand (159). The concerning ligand, 
a phage display-derived peptide with affinity for the prostate specific 
membrane antigen (PSMA), was incorporated in the HI loop of the Ad 
fiber protein and was flanked by random peptide sequences. The resulting 
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viral library was then screened against PSMA-expressing cell and tumors, 
leading to the selection of viruses displaying preferential infection of PSMA-
expressing cells via the incorporated targeting peptide. Additionally, these 
viruses infected human prostate adenocarcinoma cell-derived tumors after 
intravenous administration. The unique engineering approach exemplified in 
this study may be highly valuable for Ad retargeting purposes: it represents 
a general way to improve the suboptimal functionality seen often for Ad 
capsid-incorporated heterologous ligands. Thus, by using this approach, Ad 
targeting might better benefit from the repertoire of ligands generated by 
phage-display-based engineering [e.g. simple targeting peptides but also 
more complex polypeptides like affibodies (121) or designed ankyrin repeat 
proteins (118)].
viral genome segment diversification
Another concept of viral library-based engineering is that entailing in vitro 
diversification of a viral genome segment, for instance a viral gene or possibly 
the whole viral genome. Particularly powerful diversification methods that are 
used in this regard are error-prone PCR (5,6) and in vitro recombination (7-11). 
These techniques, which are widely used for protein engineering purposes, 
have recently been introduced into the realm of viral library-based vector 
engineering. While error-prone PCR introduces random (point) mutations 
within an amplified (viral) segment, in vitro recombination generates genetic 
diversity through homology-based recombination between homologous but 
distinct (viral) segments. These diversification methods, which can be used 
together or in combination, are especially useful in the context of multiple-
round genetic diversification and selection schemes. 
Retroviruses. In vitro recombination for viral library generation was first 
performed in the context of retroviruses (160,161). Soong et al. shuffled the 
Env sequences from six different MLV strains, which led to a diverse library of 
Env recombinants (161). This library was subsequently subjected to a selection 
procedure that selects for Chinese Hamster Ovary (CHOK1) cell infectivity. 
The procedure involved passaging the library on CHOK1 cells, which are 
non-permissive for the parental MLV strains, in the presence of a minority 
population of a cell line that is permissive for some of the parental strains. This 
setup allowed for the enrichment of a chimaeric viral clone with a tropism for 
CHOK1 cells. A subsequent study by the same group also reported screening 
using an env region-shuffled library of six MLV strains (160). This time, the 
library was subjected to a selection scheme involving several repetitions of 
the ‘harsh’ concentration step of the normal virus manufacturing procedure. 
This led to the isolation of complex chimaeras that were physically more 
stable than the parental viruses.
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Another example of in vitro recombination being applied to diversify 
retroviral sequences comes from a study that shuffled the gag-pol regions 
from several different HIV-I isolates (162). The diversified region was cloned 
in an HIV-I backbone (containing SIV-encoded nef) and the resulting library 
was subsequently successfully used for evolution of an HIV-I variant with 
enhanced ability to replicate in certain cells of the pig-tailed macaque. Unlike 
any of the parental HIV-I strains, the recombinant viruses that emerged were 
able to continuously replicate on the target cells. Interestingly, the genomes 
of the enhanced viruses, besides being modified for the gag-pol region, also 
carried putatively adaptive mutations outside the shuffled regions.
aav. Within the last few years, PCR-based mutagenesis and in vitro 
recombination techniques have been extensively explored for AAV vector 
engineering. In 2006, Maheshri et al. developed a platform for directed 
evolution of AAV vectors based on these two methods (163). Mutant AAV-2 
cap libraries with random point mutations were generated by performing 
error-prone PCR followed by in vitro recombination. The recombination 
step in this procedure is important for effective sequence space sampling: 
it lessens the chance that any beneficial mutations remain linked to any 
deleterious ones. Different selection processes were subsequently applied 
to mutant capsid libraries, leading to the isolation of mutants with altered 
affinities for heparin or with an ability to evade antibody neutralization. In the 
latter case, after the first selection phase (involving three infection rounds 
in the presence of escalating concentrations of neutralizing serum), the 
enriched virus population was used for a second round of mutagenesis and 
selection. These operations yielded numerous successful viral mutants, one 
of which showed a 96-fold improvement in gene delivery in the presence 
of the antiserum. Contemporary to this study, Perabo et al. also performed 
AAV library-based selection for evasion of neutralizing antibodies (164). In 
this case, env was diversified by one round of error-prone PCR, and selection 
against serum samples led to the isolation of mutants with up to 5.5-fold 
increased resistance to neutralization.
Instead of using error-prone PCR as a source of genetic diversity, several 
subsequent studies employed ‘family DNA shuffling’ to tap into the natural 
repository of AAV diversity (153,165,166). Such studies generated AAV cap 
gene libraries based on up to 9 different AAV serotypes. More recently, family 
DNA shuffling of AAV cap genes has been combined for the first time with 
PCR-based mutagenesis (167). In this case, a multiple-round mutagenesis 
and selection procedure on an organotypic human airway model yielded AAV 
vectors exhibiting highly efficient gene delivery to pulmonary cells. Other 
recent studies successfully used shuffled AAV cap libraries in similar directed 
evolution protocols to increase AAV transduction into human ciliated airway 
epithelium or glial cells (168,169). Finally, chimeric AAV cap libraries have also 
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been subjected to in vivo biopanning procedures. In the first study to report 
this, a library was successfully screened for muscle-homing AAV after tail vain 
injection of mice (170). Another study employing in vivo biopanning reported 
the selection of chimeric AAVs capable of crossing the seizure-compromised 
blood-brain barrier (171).
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Background: the adenovirus 14.3 kda hexon-associated protein IX (pIX) 
functions in the viral capsid as ‘cement’ and assembles the hexons in stable 
groups-of-nine (gons). Although viruses lacking pIX do not form gons, and 
are less heat-stable than wild-type (wt) viruses, they can be propagated with 
the same kinetics and yields as the wt viruses. to facilitate ‘pseudotyping’ of 
adenoviral vectors we have set up an efficient system for the generation of 
pIX-producing helper cell lines. 
methods: With a lentiviral pIX-expression cassette, monoclonal and 
polyclonal helper cell lines were generated, which express wt or modified 
pIX genes at levels equivalent to wt hAdv-5 infected cells. the incorporation 
efficiency into pIX gene deleted viruses was examined by Western analysis, 
immuno-affinity electron microscopy, and heat-stability assays. 
Results: Immuno-affinity electron microscopy on viruses lacking the pIX 
gene demonstrated that more than 96% of the particles contain pIX protein 
in their capsids after propagation on the pIX-expressing helper cell lines. In 
addition, the pIX level in the helper cells was sufficient to generate heat-
stable particles. finally, the ratio between pIX and fiber was equivalent 
to that found in wt particles. the pIX-producing cell lines are very stable, 
demonstrating that pIX is not toxic to cells. 
conclusion: these data demonstrate that lentivirus vectors can be used for 




The human adenoviruses (HAdVs) have been studied extensively as gene 
transfer vehicles for experimental gene therapy. The modification of the vector 
tropism to enhance the efficiency and cell-type specificity of gene transfer is 
an important topic in the adenovirus (Ad)-derived vector design. Successful 
transgene delivery with HAdV vectors is dependent on efficient transduction 
of target cells, with minimal transduction of non-target cells (1). One approach 
to enhance the efficiency and specificity relies on the coupling of targeting 
devices to the viruses after their production and purification. Such targeting 
devices could be single-chain antibodies, synthetic ligands, synthetic soluble 
receptors, etc. (2). Alternatively, the tropism of HAdV receptors can be 
changed by genetic modification of capsid components. Modification of the 
major capsid proteins II (hexon) (3–5), III (penton base) (6), and IV (fiber) (7–9) 
has been exploited for insertion of targeting ligands. More recently, the use 
of the minor capsid protein IX (pIX) of human and bovine Ad as an anchor for 
linking targeting ligands has been evaluated (10–13). Protein IX is a 14.3 kDa 
protein, of which 240 copies are present in the capsid. It arranges the hexons 
in stable assemblies consisting of groups-of-nine (GONs) (14,15). HAdVs 
deficient for pIX can be propagated with yields similar to wild-type (wt) Ads; 
however, such particles are heat-labile and rapidly inactivated at 48 °C (16). 
Image analyses have positioned pIX at a buried position, approximately 65 
Ångstroms lower than the tops of the hexons (17). In vitro transduction data 
and immuno-affinity electron microscopy techniques have demonstrated 
that the ligand accessibility is augmented by the insertion of an alpha-helical 
spacer between the carboxyl terminus of pIX and the targeting ligand. The 
lengths of the inserted spacers positively correlate with the accessibility of 
the ligands at the outer surface of the viral capsid (18). These data make pIX 
a promising candidate for the addition of foreign ligands (2). 
The modified pIX gene can be inserted into the vector backbone. 
Alternatively, helper cell lines can be used to provide the pIX in trans. 
The latter approach would lead to particles that do not carry the genetic 
information for the tropism-modifying capsid modification. Previous data 
showed that expression of the pIX gene had an adverse effect on cell viability 
(19). Nevertheless, monoclonal pIX-producing cell lines could be isolated that 
could restore the pIX deficiency (19–21). 
Here we describe a new efficient and robust technique for the generation 
of stable pIX-producing helper cell lines without the need for clonal selection. 
The resulting cell populations could effectively complement the pIX deficiency 
and, as a result, the heat stability of the pIX-gene deleted viruses was fully 
restored. The availability of a technique for the efficient generation of pIX 
trans-complementing helper cells will facilitate the use of ‘pseudotyping’, as 
opposed to genetic retargeting, as a strategy for modifying the tropism of 





The HAdV-5 E1-transformed cell lines 293 (22), PER.C6 (23), and 911 
(23,24) were maintained at 37 °C in a humidified atmosphere of 5% CO2 
in Dulbecco’s modified Eagle’s medium (DMEM; Gibco-BRL, Breda, The 
Netherlands) supplemented with 8% fetal bovine serum (FBS; Gibco-BRL) 
and 0.3% glucose (J.T. Baker, Deventer, The Netherlands). For PER.C6 cells 
this medium was supplemented with 10 mM MgCl2. The 911 cells were used 
to propagate and titer adenovirus vectors. Infections of the cells with HAdVs 
were carried out in infection medium containing 2% FBS. 293T cells were 
transfected with the calcium phosphate co-precipitation technique (25). 911 
cells were transfected with the calcium phosphate co-precipitation technique 
using pEGFPc1 (Clontech, BD Biosciences, The Netherlands). 
production of recombinant lentiviruses
The lentiviral vectors used in this study are so-called SIN vectors (26), and 
contain the Rev-responsive element sequence (27), the central polypurine tract 
(cPPT) (28–30), and the human hepatitis B virus-derived post-transcriptional 
regulatory element. All lentivirus vectors were derived from the plasmid pRRL-
cPPT-CMVeGFP- PREsense-SIN (31), here named pLV-CMV-eGFP. Plasmids 
pLV-CMV-IRES-eGFP, pLV-CMV-pIX-IRES-eGFP, pLV-CMV-pIX-IRES-NPTII, 
pLV-CMV-pIX.MYC-IRESNPTII, and pLV-CMV-pIX.flag.75.MYC-IRES-NPTII 
were constructed by standard cloning procedures. The encephalomyocarditis 
virus internal ribosomal entry site (IRES) was obtained from pTM3 (32) and the 
NPTII-coding region was isolated from pEGFP-N2 (Clontech, BD Biosciences, 
The Netherlands). The genes for pIX, pIX.MYC, and pIX.flag.75.MYC were 
obtained from the pCDNA3.1-based constructs pAd5pIX, pAd5pIX.MYC, and 
pAd5pIX.MYC.flag.75.MYC, respectively (18). A schematic outline of these 
vectors is provided in Figure 1. 
The lentiviral vectors were produced as described previously (33). Briefly, 
the three ‘helper’ plasmids encoding HIV-1 gag-pol, HIV-1 rev, and the 
VSV-G envelope were co-transfected together with the pLV construct into 
293T cells. After overnight incubation, the cells were washed and cultured 
in fresh medium. The medium was harvested 48 and 72 h post-transfection, 
passed through a 0.45-µm filter, and stored at −80 °C until use. The viruses 
were quantified by antigen-capture enzyme-linked immunosorbent assay 
(ELISA) measuring HIV p24 amounts (ZeptoMetrix Corp., New York, NY, USA) 
as described previously (34). Approximately 1 ng p24 is equal to 2 × 103 




For transduction the lentiviral supernatant was added to fresh medium 
supplemented with 8 µg/ml Polybrene (Sigma Aldrich, Zwijndrecht, The 
Netherlands). After overnight incubation the medium was replaced with fresh 
medium. Cells transduced with lentiviral vectors containing the neomycin 
selection gene were cultured in medium supplemented with 200 µg/ml G418 
(Invitrogen, Breda, The Netherlands). 
adenovirus vectors
The pTrackCMV-GFP/LUC is an E1-deleted HAdV-5- based shuttle plasmid that 
carries a green fluorescent protein (GFP) and a firefly luciferase (LUC) transgene, 
each under the control of the human cytomegalovirus (CMV) immediate-early 
promoter (35). The ∆pIX pTrack CMV.GFP/LUC plasmid was constructed as 
described previously for ∆pIX pTrackCMV-GFP (18). Replication-incompetent 
HAdV-5 vectors HAdV-5CMV.GFP/LUC and HAdV-5∆pIX.CMV.GFP/LUC were 
generated with the pAdEasy-1 system as described elsewhere (35). Wild-type 
(wt) HAdV-5 and HAdV-5-dl313 were obtained from the virus collection of 
the Department of Molecular Cell Biology of the Leiden University Medical 
Center. The HAdV-5-dl313 virus lacks 2307 bp of the E1 region including the 
5’ portion of the pIX gene. This mutant does not express detectable amounts 
of pIX (16). The infectious titer of the adenovirus vectors was determined by 
plaque assay (24). For heat-stability assays, 150-µl aliquots were incubated at 
45 °C for 0, 4, 6, 8, and 10 min and then quickly cooled on ice for 5 min. U2OS 
cells were infected with 100 µl virus suspension from each aliquot. After 24 h 
viral titers were determined by measuring the luciferase activity, as described 
previously (36). 
Figure 1. schematic representation of the lentiviral vectors. The vectors are derived 
from a self-inactivating, third-generation HIV-1-derived vector. Upon integration, the vector 
loses its capacity to produce RNA other than the mRNA from the transgene-expression 
cassette. The positions of the Rev-responsive element (RRE), the central polypurine 
tract (cPPT), and the posttranscriptional regulatory element (PRE) are indicated. The pIX 
transgenes were inserted upstream of the internal ribosome entry site (IRES) and the 





Cell lysates were made in RIPA lysis buffer (50 mMTris.Cl, pH 7.5, 150 mM 
NaCl, 0.1% SDS, 0.5% DOC and 1% NP40). Protein concentrations were 
measured with the BCA protein assay (Pierce, Perbio Science B.V., Etten- 
Leur, The Netherlands). Virus lysates were prepared by adding 5 × 109 virus 
particles [measured by a standard OD260 protocol (37)] directly to Western 
sample buffer. The Western blotting and detection procedures have been 
previously described (18). For detection of fiber the 4D2 antibody was used 
(1 : 2000; Abcam, Cambridge, UK). 
Facs analysis 
For fluorescence-activated cell sorting (FACS) analyses the cells were 
trypsinized and suspended in phosphate-buffered saline supplemented with 
1% FBS, and subsequently kept on ice. The samples were analyzed with a 
FACScan flow cytometer (Becton Dickinson), as described (18). Data analysis 
was performed using CellQuest 3.1 software (Becton Dickinson). For each 
sample, 10 000 events were collected. 
immuno-affinity electron microscopy 
The presence of the modified pIX molecules in the viral capsids was visualized 
with antisera and gold-labeled protein-A, as described (18). Subsequently, 
these samples were fixed in 1.5% glutaraldehyde in cacodylate buffer and 
negatively stained with 1% uranyl acetate for 15 min. The viruses were 
examined with a Philips EM 410-LS transmission electron microscope at 80 kV. 
ResUlts
It has been shown previously that pIX is an attractive candidate for use as 
anchor for polypeptide ligands (10–12,18,38–40). Since pIX is dispensable 
in the capsid, generation of helper cell lines that synthesize pIX may allow 
‘pseudotyping’ of HAdV vectors. Therefore, we designed and evaluated a 
lentivirus-based system for the generation of new pIX-complementing cell 
lines. To test the efficiency of a lentivirus-based system for generating E1- 
and pIX-complementing helper cell lines, 911 cells were transduced with 
LV-CMV-eGFP at 40 ng p24 per 105 cells. After 48 h the transduced cells 
were harvested and the number of eGFP-positive cells was determined by 
FACS analysis (Figure 2). The 911 cell line was efficiently transduced. Similar 
results were obtained when using the E1-complementing helper cell lines 
293 and PER.C6 (data not shown). Note that the expression of the transgene 
is generally higher and more homogenous than in cells transfected with the 
calcium phosphate co-precipitation technique (Figure 2).  
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To examine the pIX production after lentivirus-mediated pIX-gene 
transfer, 911 cells were exposed to LV-CMV-pIX-IRES-NPTII at 40 ng p24 per 
105 cells, and nine monoclonal G418-resistant cell lines were isolated after 
limiting dilution. Similar pIX amounts are detected in all 911-pIX cell lines 
(Figure 3A), which is consistent with the homogenous pIX signals observed 
by immunohistochemistry (data not shown). Therefore, in all subsequent 
experiments, polyclonal cultures of G418-resistant lentivirus-transduced cells 
were used. 
Next, pIX amounts were assessed during wt HAdV-5 replication in 911 cells. 
For this, 911 cells were infected with wt HAdV-5 at multiplicity of infection 
(MOI) of 5. HAdV-5-dl313, which lacks a functional pIX gene, was used as 
a control. At various time points the cells were collected in lysis buffer and 
the pIX amounts were determined by Western analysis (Figure 3B). The pIX 
amount peeked at 32 h post-infection. The peak amounts of pIX after HAdV-5 
infection were compared with the amounts of pIX in LV-CMV-pIX-IRES-NPTII-
transduced polyclonal cell populations established after transduction of 911 
cells with LV-CMV-pIX-IRES-NPTII at 40 ng (N1) and 200 ng (N5) p24 per 
105 cells. After 7 days in medium containing 200 µg/ml G418, cells were 
harvested and protein samples were analyzed by sodium dodecyl sulfate/
polyacrylamide gel electrophoresis (SDS-PAGE). Equivalent amounts of pIX 
were detected in the LV-CMVpIX- IRES-NPTII-transduced cells and in HAdV-
5-infected cells at 32 h post-infection. In the 911-pIX.N5 cells more pIX was 
present than in 911-pIX.N1 cells (Figure 3C). This probably reflects a higher 
copy number of integrated pIX vector in the 911-pIX.N5 cells. We noted such 
a strict copy-number dependency of reporter gene expression previously in 
differentiated adipocytes and 293T cells (33). 
To test the stability of these cell lines, the cells were passaged for 5 months 
on G418 selection. Only a moderate reduction in pIX amounts occurred over 
the course of this period, demonstrating that these cell lines are reasonably 
Figure 2. transduction-efficiency assay. GFP-positive cells were visualized by FACS 
analysis. (A) Negative control. (B) The helper cell line 911 transduced with LV-CMV-eGFP at 
40 ng p24 per 105 cells. (C) 911 cells transfected with the calcium phosphate co-precipitation 
technique using 10 μg pEGFP-C1 per semi-confluent 9-cm dish.
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Figure 3. Western blot analyses. (a) Comparison of pIX amounts of the monoclonal 911 
cell lines after lentivirus-mediated transfer of the pIX gene. The cell lines were generated 
after transduction of 911 cells with LV-CMV-pIX-IRES-NPTII. (B) Protein IX amounts during 
wt HAdV-5 and HAdV-5-dl313 infection. 911 cells were infected with HAdV-5 (MOI = 5). 
Cell lysates were prepared at 0, 8, 16, 24, 32, 40 and 48 h post-infection and a Western 
analysis was performed using anti-pIX serum. (c) pIX amounts of the 911-pIX.N1 and 
911-pIX.N5 cell lines. Equal amounts of lysates of the 911-pIX.N1, 911-pIX.N5, and as 
control 911 cells infected with HAdV-5 at 32 h post-infection, were assayed by Western 
analysis. (d) pIX amounts of the 911-pIX.N1 cell line 7 days (7 d) and 5 months (5 m) post-
transduction. (e) pIX amounts of the 911-pIX.G cells and 911-pIX.N1 cells 7 days (7 d) and 
3 months (3 m) post-transduction. (F) Complementation efficiency of the 911-pIX.N1 and 
911-pIX.N5 helper cell lines. To test the incorporation efficiency of pIX produced by the 
911-pIX.N1 and 911-pIX.N5 cells, HAdV-5∆pIX.CMV.GFP/LUC was propagated on the cell 
lines and purified by CsCl centrifugation, after which protein lysates of the purified viruses 
samples were made for Western analysis. The amounts of pIX in HAdV-5∆pIX.CMV.GFP/
LUC propagated on 911-pIX.N1 and 911-pIX.N5 cell lines were compared with wt HAdV-5, 
with anti-pIX serum and, as a virus-particle loading control, the 4D2 antibody directed 
against the fiber protein. (g) pIX.MYC and pIX.flag.75.MYC amounts in the complementing 
cell lines 911-pIX.MYC and 911-pIX.flag.75.MYC were compared with the pIX amounts in 
the 911-pIX.N1 cell line. Equal amounts of cell lysate were assayed as described above. (h) 
The incorporation efficiency of the pIX.MYC and pIX.flag.75.MYC variants produced by the 
helper. The HAdV-5∆pIX.CMV.GFP/LUC vector was propagated and purified as described 
above and pIX amounts were compared with the amount of pIX in wt HAdV-5 particles.
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stable (Figure 3D). To test the stability of pIX-producing cell lines without 
selection, 911 cells were transduced with LV-CMV-pIX-IRES-eGFP at 40 ng 
p24 per 105 cells (911-pIX.G). The pIX amounts in the unselected 911-pIX.G 
cells were compared with that in 911-pIX.N1 cells grown in parallel in medium 
containing G418 (Figure 3E). Only a slight reduction in pIX amounts was 
detected after 3 months without selection in the 911- pIX.G cells, while there 
was no decrease in pIX amounts in the 911-pIX.N1 cells. This demonstrates 
that pIX is not toxic  for 911 cells. For further experiments we used cells 
transduced with the lentiviral vectors harboring the NPTII selection gene.  
Next, we examined the incorporation of pIX into the capsid of the HAdV-5 
vector HAdV-5∆pIX.CMV.GFP/LUC. This vector lacks a functional pIX gene 
and carries the eGFP and the firefly luciferase reporter genes under control 
of two separate CMV promoters. HAdV- 5∆pIX.CMV.GFP/LUC viruses was 
propagated on the 911-pIX.N1 and 911-pIX.N5 cell lines, and harvested and 
purified via the conventional CsCl purification method. During purification, 
the particle-associated pIX is separated from the non-associated pIX since 
variants of pIX that cannot be incorporated into the capsid do not co-purify 
with the particles of CsCl gradients (18). To evaluate the amount of pIX in the 
particles, 5 × 109 CsCl-gradient purified particles from each virus preparation 
were analyzed by Western blot analysis (Figure 3F). The amounts of pIX in 
the pIX-loaded HAdV- 5∆pIX.CMV.GFP/LUC particles is similar to, or maybe 
even slightly higher than, the amounts in wt HAdV-5 particles, while the fiber 
contents are identical. The yield of the HAdV-5∆pIX.CMV.GFP/LUC vector in 
the pIX-complementing cells was similar to the yield routinely obtained on 
911 cells (data not shown).  
To further characterize the pIX loading in HAdV- 5∆pIX.CMV.GFP/LUC 
particles that were propagated on the pIX-complementing cells 911-pIX.N1 
and 911-pIX.N5, we tested these viruses for their heat-stability. The HAdV-
5∆pIX.CMV.GFP/LUC rapidly decreased in titer in response to incubation at 
45 °C, whereas the vector containing a wt pIX gene (HAdV-5.CMV.GFP/LUC) 
was thermostable (Figure 4A) (16). The HAdV-5∆pIX.CMV.GFP/ LUC particles 
that were loaded with pIX via propagation on complementing cell lines 
911-pIX.N1 and 911-pIX.N5 were as thermostable as HAdV-5.CMV.GFP/LUC. 
To verify that the majority of particles carried pIX upon propagation on 
the pIX-complementing cell lines, we used the two MYC-tagged pIX variants 
pIX.MYC and pIX.flag.75.MYC (18). New 911 cell lines were generated via 
transduction with LV-CMV-pIX.MYC-IRES-NPTII and LV-CMV-pIX.flag.75.MYC-
IRES-NPTII, resulting in the 911-pIX.MYC and 911-pIX.flag.75.MYC helper 
cell lines, respectively. To test the expression level in the newly produced 
cell lines, samples were taken and used for Western analysis (Figure 3G). The 
amounts of pIX.MYC and pIX.flag.75.MYC are similar to the pIX amount in 
the 911-pIX.N1 cell line. After propagation of HAdV- 5∆pIX.CMV.GFP/LUC 
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on the 911-pIX.MYC and 911- pIX.flag.75.MYC cell lines, the viruses were 
harvested and purified by CsCl banding. The MYC-tagged proteins efficiently 
incorporated (Figure 3H). The presence of the MYC-tagged pIX in the HAdV-
5∆pIX.CMV.GFP/LUC particles was visualized by immuno-affinity electron 
microscopy, with gold-labeled anti-MYC antibodies, as described previously 
(18). Of over 1000 particles counted, more than 96% of the particles bound 
the gold-labeled antibodies (Figure 5). There was no gold label present on 
HAdV-5∆pIX.CMV.GFP/LUC lacking the MYC tag.  
Subsequently, we examined the heat stability of the adenoviruses 
containing the MYC-tagged pIX molecules (Figure 4B). The HAdV-5∆pIX.
CMV.GFP/LUC loaded with pIX.MYC was as stable as HAdV-5.CMV.GFP/LUC. 
Whereas the virus loaded with pIX.flag.75.MYC was significantly stabilized 
compared to the pIX-deficient HAdV-5∆pIX.CMV.GFP/LUC particles, it was 
less stable than the particles loaded with either pIX or pIX-MYC.  
Figure 4. virus-stability assay. Thermostability of pIX gene-deleted HAdV vectors carrying 
pIX molecules produced by the trans-complementing helper cells and, as control, pIX gene-
containing HAdV vectors. Infectivity of HAdV-5∆pIX.CMV.GFP/LUC particles produced on 
pIX trans-complementing helper cells, and on 911 cells, as determined by their capacity 
to transfer the luciferase reporter gene to indicator cells. The results are presented as 
the percentage residual luciferase activity. Each bar represents the mean ± standard 
deviation (SD) of triplicate analyses. (a) Comparison of HAdV-5∆pIX.CMV.GFP/LUC viruses 
propagated on the 911-pIX.N1 (●) and 911-pIX.N5 (♦) with HAdV-5.CMV.GFP/LUC (■) 
and HAdV-5∆pIX.CMV.GFP/LUC (□) produced on 91 cells. (B) HAdV-5_pIX.CMV.GFP/LUC 
viruses produced on 911-pIX.MYC (▼) and 911-pIX.flag.75.MYC (▲) cells, compared with 
HAdV-5.CMV.GFP/LUC (■) and HAdV-5∆pIX.CMV.GFP/LUC (□) produced on 911 cells. The 




Here we describe the use of lentiviral vectors for the generation of pIX-
complementing helper cell lines. Lentiviruses are a versatile and efficient 
tool to transfer transgenes (33,41–44). We have used a third-generation 
nonreplicating HIV-1-derived vector. The VSV-G-pseudotyped lentiviral 
vectors can transduce a wide variety of cell types of different species (45). 
Also the conventional helper cells for adenovirus production can be efficiently 
transduced. The transduction of cells with lentiviral vectors results in modest 
changes in gene expression and cellular transcription (46). The propagation 
of HAdV-5 vectors on the transduced helper cells 911-pIX.N1 and 911-pIX.
N5 was not impaired. 
Previously, we evaluated the use of modification of pIX for retargeting of 
HAdV vectors (18). This system was based on transient expression of modified 
pIX genes in helper cells. The use of lentiviral vectors circumvents the need 
to sub-clone the stably modified clones after transduction. After lentiviral-
vector-mediated pIX gene transfer, the cells in a polyclonal cell population 
have homogenous pIX amounts as evident from immunohistochemistry and 
Western analyses. 
HAdV-5 lacking the pIX gene can be efficiently propagated on the pIX-
producing helper cell lines 911- pIX.N1 and 911-pIX.N5. Intriguingly, the 
amounts of pIX in the particles seem even slightly higher than in wt HAdV-5 
particles. Contamination of the purified virus with non-virus-associated 
Figure 5. immuno-affinity electron microscopic analysis of hadv-5∆piX.cmv.gFp/lUc 
particles loaded with piX.mYc and piX.flag.75.mYc. The fraction of particles loaded with 
the MYC-tagged pIX was assessed by detection of the MYC tag on the virions visualized 
by the presence of gold particles. There is no MYC tag detected on the HAdV-5∆pIX.CMV.




pIX protein can be excluded: a variant-pIX protein with a deletion in the 
N-terminus is not present in the purified virus preparation (18). There are 
two possible alternative explanations. Firstly, if the pIX-gene-deleted virions 
have lost their pentons (47), we could have loaded more particles, without 
increasing the fiber signal on the blots. Alternatively, the pIX-gene expression 
may be deregulated if a wt HAdV-5 virus is grown on helper cells. This could 
be the result of deregulation of the transcription of the E1B gene of the virus 
in the helper cells, and E1B transcription affects pIX-gene expression (48). 
However, the heat-inactivation data, the electron microscopy data, and our 
particle quantization data do not support these explanations. 
By propagation on the transduced cell line populations the heat-stable 
phenotype could be fully restored. Previous studies have demonstrated that 
pIX can be incorporated into the HAdV capsid upon heterologous expression 
in helper cell lines, after transient expression (18), and after generating stable 
cell lines using EBV replicons and plasmid vectors (20). In the latter studies 
selected stable cell lines could restore the heat-stable phenotype. Moreover, 
pIX-deficient HAdV vectors with a genome size larger than wt HAdV-5 could be 
efficiently packaged on the pIX-producing cell lines, but not on the parental, 
non-modified helper cells (20). However, the selection and characterization of 
monoclonal cell lines is a laborious and time-consuming process, making the 
efficient lentivirus-based system described here a valuable extension of this 
technology. 
To further exploit the possibility to examine pIX-fusion proteins via this 
system we tested two MYC-tagged pIX variants, i.e. pIX.MYC and pIX.flag.75.
MYC, which can be efficiently incorporated into the virus capsid (18). Here we 
showed that the two MYC-tagged pIX variants incorporate with efficiencies 
equivalent to that of wt HAdV-5. However, the variant with the flag.75.MYC 
extension exhibited moderately reduced heat stability. This suggests that 
the flag.75.MYC extension has an effect on the capsid-stabilizing function of 
pIX. This is unlikely to be due to inhibition of the pIX-trimer formation, since 
recent data demonstrated that trimer formation is required neither for pIX 
capsid incorporation, nor for the heat-stable phenotype (49). The addition 
of relatively large ligands has previously been shown to influence the capsid 
stability (38), suggesting that steric hindrance may hinder bona fide capsid 
stabilization. 
In conclusion, the use of lentiviral vectors for the generation of pIX-producing 
helper cell lines may allow development of systems for ‘pseudotyping’, rather 
than genetic retargeting, of HAdV-vectors. By pseudotyping, HAdV vectors 
are retargeted to a specific cell type or tissue by propagating them on the 
appropriate pIX-complementing helper cell line. So far few studies have been 
focused on HAdV peudotyping. Stable cell lines expressing the fiber gene 
have been described but it has proven difficult to achieve expression levels 
sufficiently high to fully load all particles (50,51). The availability of a robust 
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system for generating pIX-producing cell lines, together with the observation 
that trimer formation of pIX is not required for its incorporation into the capsid, 
makes modification of pIX a feasible approach for developing a system for 
development and generation of batches of ‘pseudotyped’ HAdV vectors. 
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AdenovIrus tArgetIng to 
hlA-A1/mAge-A1-posItIve tumor 
cells By fusIng A sIngle-chAIn 




Adenovirus vectors have great potential in cancer gene therapy. targeting 
of cancer-testis (ct) antigens, which are specifically presented at the 
surface of tumor cells by human leukocyte antigen (hlA) class I molecules, 
is an attractive option. In this study, a single-chain t-cell receptor (sctcr) 
directed against the ct antigen melanoma-associated antigen (mAge)-A1 
in complex with the hlA class I molecule of haplotype hlA-A1 is fused with 
the c terminus of the adenovirus minor capsid protein IX. propagation of a 
protein-IX (pIX)-gene-deleted human adenovirus 5 (hAdv-5) vector on cells 
that constitutively express the pIXsctcr fusion protein yielded viral particles 
with the pIXsctcr fusion protein incorporated in their capsid. generated 
particles specifically transduced melanoma cell lines expressing the hlA-A1/ 
mAge-A1 target complex with at least 10-fold higher efficiency than 
control viruses. Whereas loading of hlA-A1- positive cells with mAge-A1 
peptides leads to enhanced transduction of the cells, the efficiency of virus 
transduction is strongly reduced if the hlA-A1 molecules are not accessible 
at the target cell. taken together, these data provide proof of principle 
that pIXsctcr fusions can be used to target hAdv-5 vectors to tumor cells 
expressing intracellular ct antigens.  
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intRodUction  
Recombinant viral vectors hold great promise in the field of cancer gene 
therapy. Much effort is devoted to generating vectors that have the ability to 
specifically transduce tumor cells. In this respect it will be of major interest to 
develop vectors that are targeted to antigens that are specifically expressed 
at the surface of tumor cells to prevent transduction of noncancerous cells.  
 Intriguingly, in many cases cancer cells have been found to induce a tumor 
cell-specific response of the immune system. Cytotoxic T lymphocytes (CTLs) 
have been discovered that eradicate tumor cells via the recognition of tumor-
specific antigens, while leaving healthy tissue intact. Such tumor-specific 
antigens might belong to the group of so-called ‘cancer-testis’ (CT) antigens, 
which are presented at the tumor cell surface by major histocompatibility 
complex (MHC) class I molecules and are recognized by CTLs (1). CT antigens 
are expressed in a variety of cancerous tissues and are generally silent in 
normal tissues, except for the testis (2). To date, 89 CT genes or isoforms, 
which are organized into 44 families, have been described. From these, 19 
families are testis restricted, 11 show additional expression in one or two 
somatic tissues, 9 are expressed in three to six tissue types besides testis and 
5 are ubiquitously somatically expressed. With the exception of the testis-
restricted CT antigens, the others also show expression in the pancreas but at 
levels as much as 10 times lower than in the testis (2). Expression of CT antigens 
was first shown in melanoma and all the classic CT antigens are expressed in 
this type of tumor, but since the 1980s, expression in various other tumors has 
been recognized (2). The highly specific expression profiles of the CT antigens 
make them interesting target molecules for cancer therapies. Importantly, CT 
antigens belonging to the melanoma-associated antigen (MAGE) A, B and 
C family seem to be involved in oncogenesis, providing protection against 
apoptosis in tumor cells (3). The expression of other tumor antigens, such as 
‘overexpression’ antigens p53 and HER-2/neu, or ‘differentiation antigens’ 
gp100 and Mart-1, is less restricted to tumor cells and their use for cancer-
drug targeting may be associated with negative side effects.  
 The principle of targeting human MHC class I molecules (human leukocyte 
antigen, HLA class I), in complex with tumor-specific antigens, has been the 
subject of many studies on T-cell targeting to tumor cells (4). So far, HLA 
class I/peptide targeting of viral vectors has not been extensively explored. 
Promising results have been obtained by targeting measles virus particles to a 
specific HLA class I/peptide complex via fusion of a single-chain T-cell receptor 
(scTCR) to the attachment protein H of the virus (5). Recently, adenovirus has 
been also retargeted to CT antigens by replacing the knob domain of the 
fiber protein with a CT antigen-specific scTCR (6).
 Adenoviral vectors are among the most promising viral vectors for cancer 
gene therapy for several reasons. They can be produced in large quantities, 
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they do not lead to stable genetic modification of the transduced cells and 
they have a good safety profile (7). Genetic modification of adenoviral capsid 
proteins might lead to the development of vectors that are specifically 
targeted to tumor cells, thereby improving safety and efficacy. Cell binding 
of subgroup C-derived human adenovirus (HAdV) vectors (including HAdV-5 
and HAdV-2), which are widely used in gene therapy, involves two distinct 
steps. First, they bind with high affinity to the coxsackie virus and adenovirus 
receptor (CAR) at the cell surface. Second, interaction of penton base Arg-
Gly-Asp (RGD) motifs with cellular integrins, including αvβ3 and αvβ5 leads 
to endocytosis (8). Many tumor cells are relatively refractory to infection by 
subgroup C-derived HAdV vectors due to the paucity of CAR receptors (9). 
Development of genetically modified vectors that can infect CAR-negative 
cells has mainly focused on incorporation of heterologous ligands in the 
fiber knob, or on replacement of the entire knob domain by a heterologous 
ligand (7). The complexity of incorporating ligands into the adenovirus fiber 
locale has prompted the identification of other capsid proteins amendable for 
ligand incorporation. These approaches have the potential to incorporate an 
increased number of complex ligands per virion. To date, the capsid proteins 
hexon (10,11), penton base (12), minor capsid protein IX (pIX) (13-18), and 
protein pIIIa (19) have been explored as platforms for the incorporation of 
heterologous peptides [reviewed by Vellinga et al. (20)].  
We have been exploiting the adenovirus minor capsid pIX as an anchor 
to genetically incorporate large proteins (17,18). Protein IX is a small (14.3 
kDa) protein of unknown structure that acts as capsid cement, stabilizing the 
interactions between hexon trimers on each facet of the virion (21). Twelve 
molecules of pIX are associated with each facet of the icosahedron, with an 
overall stoichiometry of 240 pIX monomers per virion (22). Although the main 
mass of pIX is thought to be located in the cavities between the so-called 
group-of-nine hexon capsomers, the postulated position of pIX in the capsid 
is being challenged (23-26). 
Nevertheless, we have recently demonstrated efficient and functional 
incorporation of the hyperstable single-chain antibody fragment 13R4 that 
was fused with pIX via a 75-Ångstrom spacer (18). The 13R4 was functional 
in the capsid as was evidenced by its capacity to bind Escherichia coli 
β-galactosidase.  
Here we report the production of an adenoviral vector which is targeted to 
tumor cells presenting peptides of the CT antigen MAGE-A1 on HLA class I 
molecules of haplotype HLA-A1, via a scTCR (TCRA1M1) fused with adenovirus 
minor capsid pIX. To ensure enhanced protrusion of the scTCR at the virus 
surface, a 75-Ångstrom α-helical spacer was included between pIX and 
the TCR (17). We produced virus particles that were efficiently loaded with 
the pIX_TCRA1M1 fusion protein. The transduction efficiency of the HLA-A1/ 
MAGE-A1-positive melanoma cell lines MZ2-MEL3.0 and MZ2-MEL43 was 
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strongly increased upon incorporation of the fusion protein. These findings 
represent (a) the first demonstration of a pIXscTCR-mediated adenovirus 
targeting of a cell type that is normally refractory to HAdV-5, and (b) further 
proof-of-principle of targeting the highly tumor-specific CT antigen/HLA class 
I complexes at the surface of human tumor cell lines.  
ResUlts
establishment and characterization of the piX_tcRa1m1-producing 
helper cell line  
To establish a helper cell line stably expressing the pIX_TCRA1M1 fusion protein, 
911 cells were transduced with the recombinant lentivirus LV.pIX_TCRA1M1. A 
schematic overview of the pro-lentiviral DNA construct and the sequence 
eventually incorporated in the 911 genome is provided in Figure 1.  
RSV-U3 R U5 RRE cPPT CMV pIX_TCRA1M1 PRE U5R
U3TATA
STOPATG
pIX NeoRIRESF 75A V V C
LV.pIX_TCRA1M1
Co-transfection with packaging plasmids in 293T cells
Stable transduction 911 cells
R U5 RRE cPPT CMV pIX_TCRA1M1 PRE U5R
Figure 1. schematic representation of the lentivirus system used to establish the 911 
helper cell line stably expressing piX_tcRa1m1. The vector used in this study is a third-
generation, self-inactivating (SIN) vector, with a major part of the 3’ U3 region deleted, 
including the TATA box (27). The Rev-responsive element (RRE) (28), the central polypurine 
tract (cPPT) (29–31), and the human hepatitis B virus-derived posttranscriptional regulatory 
element  (PRE) are indicated. The encephalomyocardin virus internal ribosomal entry site 
(IRES) was obtained from pTM3 (32). The NPTII coding region (NeoR), which mediates 
resistance to G418, was isolated from pEGFP-N2 (Clontech, Leusden, the Netherlands).
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After growing the cells for several weeks in selection medium (containing 
200 µg/ml G418), western analysis on cell lysate was performed. This revealed 
pIX_TCRA1M1 protein amounts that were similar to the pIX level in 911 cells 
infected with HAdV-5.LUC virus (Figure 2A). The protein size of pIX_TCRA1M1 
was as expected (65.8 kDa). The percentage of pIX_TCRA1M1-positive cells was 
determined by immunohistochemistry analysis (Figure 2B). This showed more 
than 90% of the cells to be positive for pIX_TCRA1M1. The pIX fusion protein 
appeared to be located mainly in the cytoplasm. Surprisingly, visualizing 
pIX_TCRA1M1 protein in the cells by using a conformation-dependent antibody 
recognizing the variable domain of the scTCR (Vα12.1) was dependent 
on adenovirus infection of the cells (Figure 2C). At 24 h postinfection, a 
Vα12.1-mediated signal could be observed (cells were infected with the 
Figure 2. characterization of the 911/piX_tcRa1m1 helper cell line. (a) Western analysis 
on lysates of the 911/pIX_TCRA1M1 cells. Production of pIX_TCRA1M1 was compared to the 
production of wild-type (wt) pIX in 911 cells infected with HAdV-5. Used antibodies were α-pIX 
and horseradish peroxidase (HRP)-conjugated secondary antibody. The predicted size of 14.3 
kDa for wt pIX and 65.8 kDa for pIX_scTCRA1M1 was confirmed by the SDS–polyacrylamide 
gel electrophoresis (PAGE), as indicated in the figure. (B) Immunohistochemistry assay on 
911/pIX_TCRA1M1 cells. The pIX_TCRA1M1 was visualized by using α-pIX antibody. The nuclei 
were stained with propidium iodide. (c) Immunohistochemistry assays on 911/pIX_ TCRA1M1 
cells, infected with HAdV-5∆pIX. Fixation was performed at 24 h postinfection. The upper 
panel shows wide-field microscopy images of α-hexon and Vα12.1-stained cells. The lower 
panel shows confocal microscopy images of α-pIX-stained 911/pIX_TCRA1M1. Infected 911 
cells were included as negative control. To illustrate the presence of fluorescence signal in 
the nuclei more clearly, pseudocolor images of the cells are shown. Fluorescent intensities 
range from purple (low) to green (high).
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viral vector HAdV-5.CMVLUC∆E1∆E3∆pIX, see next paragraph). Detection 
of pIX_scTCRA1M1 by Vα12.1 antibody was absent at earlier time points of 
infection and in pIX_TCRA1M1-negative 911 cells (result not shown). Confocal 
laser scanning microscopy was used to analyze the subcellular localization 
of the pIX_scTCRA1M1 protein after virus infection (Figure 2C). Although the 
majority of the pIX_TCRA1M1 protein was observed in the cytoplasm, significant 
amounts were present in the nuclei of infected cells. In >90% of the infected 
cells the pIX_TCRA1M1 fusion protein was readily detectable in the nucleus.  
efficient incorporation of piX_tcRa1m1 in the virus capsid  
Next, we tested the incorporation of pIX_TCRA1M1 into the capsid of the 
vector HAdV-5.CMVLUC∆E1∆E3∆pIX. This vector lacks a functional pIX 
gene and carries the firefly luciferase reporter gene under control of the 
cytomegalovirus (CMV) promoter. After transduction of the 911/pIX_TCRA1M1 
cells with the ∆pIX virus, the offspring virus particles were harvested and 
purified via the conventional cesium chloride (CsCl) purification method. 
This resulted in the virus HAdV-5/ pIX_TCRA1M1. During purification, particle-
associated pIX molecules were separated from the nonassociated pIX 
molecules, as nonassociated variants do not co-purify with the virus particles 
in the CsCl gradient (17,33). A schematic representation of the pIX_TCRA1M1 
fusion protein, with its exposed single-chain TCRA1M1 positioned above the 
hexon capsomers, is depicted in Figure 3A.  
The presence of pIX_TCRA1M1 in the virus particles was detected by western 
assay (Figure 3B). The amount of pIX_TCRA1M1 in the HAdV-5/pIX_TCRA1M1 
particles is slightly lower than the amounts of pIX in wild-type (wt) HAdV-5 
particles. Loading was similar to the loading of pIX_13R4 in the previously 
produced virus HAdV-5/pIX_13R4 (18). The 13R4 is a single-chain antibody 
fragment directed against β-galactosidase, which is approximately 14 kDa 
smaller than the scTCRA1M1.  
Incorporation of pIX_TCRA1M1 in the virus capsid was also shown by 
spot-blot analyses (Figure 3C). Virus particles were spotted on a nitrocellulose 
membrane, followed by incubation with various antibodies. Upon spotting, 
the virus particles remain intact, indicated by the inability to detect the 
adenovirus core protein VII (pVII). Only after denaturation of the virus particles 
the pVII could be detected. From the appearance of the a-flag signal it can 
be concluded that flag epitopes of the pIX_TCRA1M1 fusion protein were 
accessible to immunoglobulins in the context of intact virus particles. For the 
α-flag and the α-pIX detection longer exposure times were used, resulting in 
increased background signals.  
To further investigate the accessibility of the single-chain TCRA1M1 at the 
surface of the virus particles we performed an immunoprecipitation assay, in 






















































































Figure 3. analysis of piX_tcRa1m1 incorporation in the virus capsid. (a) Schematic 
representation of the pIX_TCRA1M1 fusion protein exposing the single-chain TCRA1M1 above 
the hexon capsomers. A spacer of 75 Ångstrom is included to improve presentation of 
the single-chain T-cell receptor (scTCR). A flag tag is present in between the C terminus 
of pIX and the 75-Ångstrom spacer. Additional linkers flank the 75-Ångstrom spacer (with 
amino-acid sequence ‘ser-gly-gly-gly’) to enhance the flexibility of the scTCR. (B) Western 
analysis on virus lysates of cesium chloride (CsCl)-purified viruses to analyze incorporation 
of pIX_TCRA1M1 in the particles. To compare incorporation efficiencies, virus lysates of 
HAdV-5 and HAdV-5/pIX_13R4 were included. The α-hexon antibody was included as a 
virus particle loading control. The predicted size of 14.3 kDa for wild-type pIX and 65.8 kDa 
for pIX_scTCRA1M1 was confirmed by the SDS–polyacrylamide gel electrophoresis (PAGE), as 
indicated in the figure. (c) Spot-blot analysis to detect the presence of pIX_TCRA1M1 in intact 
virus particles. Virus was spotted onto a membrane followed by incubation with multiple 
antibodies. As a control to show integrity of the particles upon the spot-blot treatments, 
incubation with an antibody directed against the core protein VII (pVII) was included. Only 
after denaturation could pVII be detected. (d) Binding of pIX_TCRA1M1-loaded virus particles 
on beads containing α-TCR antibodies (Vα12.1 or Vβ1). After incubation of beads with the 
pIX_TCRA1M1-loaded virus (containing the luciferase reporter as a transgene) or a control 
virus (containing the Escherichia coli β-galactosidase gene as a transgene), the supernatant 
was applied to MEL2A cells. The ratio of luciferase to β-galactosidase expression in the 
cells was subsequently measured, and was normalized to the ratio obtained on mock beads 
(beads without antibody).
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beads was analyzed (Figure 3D). The pIX_TCRA1M1 virus was mixed with a control 
virus and subsequently incubated with Vα12.1 or Vβ1 antibody precoated 
beads. Both antibodies specifically recognize the variable (V) domain of the 
TCRA1M1. After incubation, supernatant fraction, containing virus particles that 
were not bound to the beads, was applied to MEL2a cells, and the infection 
ratio of pIX_TCRA1M1 virus (containing the luciferase transgene) to control 
virus (containing the β-galactosidase transgene) was determined. As a result, 
significantly lower ratio for the Vα12.1- or Vβ1-treated samples was observed 
when compared to the ratio obtained from the samples without antibody 
treatment. This shows the binding of intact pIX_TCRA1M1 virus particles to the 
Vα12.1 and Vβ1 antibodies. Thus, it can be concluded that the V domains of 
the TCRA1M1 at the surface of the virus particles are accessible, suggesting that 
the scTCR may be free to interact with the HLA-A1/MAGE-A1 complex at the 
cell surface.  
targeting of the piXsctcR-containing virus to hla-a1/ mage-a1-
positive mZ2-mel3.0 tumor cells  
To test the targeting potential of the HAdV-5/ pIX_TCRA1M1 virus to HLA-A1/
MAGE-A1-expressing cells, transduction of MZ2-MEL3.0 melanoma cells 
(CARneg, HLA-A1pos, MAGE-A1pos) was analyzed and compared to control virus 
transduction. The absence of CAR expression is an important aspect to test 
the targeting potential of the pIX_TCRA1M1-containing virus, since the virus 
is not ablated for its natural CAR-binding ability, which occurs via the fiber 
attachment protein. In parallel to the infection of MZ2-MEL3.0, the CAR-
positive melanoma cell line MEL2a (CARpos, HLA-A1pos, MAGE-A1neg) was 
infected with the viruses to analyze CAR-mediated transduction. Transduction 
efficiencies of the viruses were determined by measuring luciferase 
production 24 h after transduction. As represented in Figure 4, presence of 
the pIX_TCRA1M1 fusion protein in the virus capsid results in a highly increased 
transduction of the target cell line MZ2-MEL3.0. Whereas CAR-mediated 
transduction on the MEL2a cell line was highest for the pIXscTCR-lacking 
virus (indicated by a twofold higher luciferase activity), the opposite pattern 
was obtained for the target cell line MZ2-MEL3.0, which was approximately 
fourfold better transduced by the pIXscTCR-loaded virions. When setting 
the targeting ratio (MZ2-MEL3.0/MEL2a) for HAdV-5 at one, the normalized 
targeting effect for HAdV-5/ pIX_TCRA1M1 on the MZ2-MEL3.0 cell line is 9.5. 
The approximate 10-fold increase in transduction specificity on the target cell 
line did not significantly change by increasing (multiplicity of infection, MOI = 
10.000) or decreasing (MOI = 100) the MOI (results not shown).  
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downmodulation of hla-a1/mage-a1 availability results in de-
creased targeting by hadv-5/ piX_tcRa1m1 
To demonstrate that HAdV-5/ pIX_TCRA1M1 mediates transduction through 
binding to HLA molecules at the cell surface, MZ2-MEL3.0 cells were 
incubated with α-HLA-ABC antibodies, prior to adding the virus. This 
resulted in a significant decrease in transduction with the pIXscTCR virus, 
whereas no decrease was observed for the control virus (Figure 5A). This 
observation indicates that transduction of the MZ2-MEL3.0 cells is inhibited 
by immunoglobulins binding to HLA molecules.  
As an alternative blocking strategy, HLA class I presentation at the 
surface of MZ2-MEL3.0 was downmodulated by the expression of the human 
cytomegalovirus (HCMV) US11 protein. The US11 protein causes rapid 
degradation of newly synthesized HLA class I heavy chains by mediating their 
retrograde transport or ‘dislocation’ from the endoplasmic reticulum (ER) into 
the cytosol, where they are degraded by proteasomes (34). MZ2-MEL3.0 cells 
were transduced using retroviruses encoding US11 or a control vector and 
surface HLA class I levels were analyzed by flow cytometry (Figure 5B). The 
MZ2-MEL3.0 cells were efficiently transduced with the retroviruses, since the 
majority of the cells was positive for the vector-mediated green fluorescent 
protein (GFP) expression. The downshift of the US11-expressing cells in the 





















Transduction ratio     
MZ2 - MEL3.0 / MEL2a
Figure 4. targeting of hadv-5/piX_tcRa1m1 to hla-a1/mage-a1-presenting mZ2-
mel3.0 cells. The target cell line MZ2-MEL3.0 (HLA-A1pos/MAGE-A1pos, CARneg) was 
transduced with HAdV-5 and HAdV-5/pIX_TCRA1M1. In parallel, transduction of the MEL2a 
cell line was performed to determine fiber-coxsackie adenovirus receptor (CAR)-mediated 
transduction of both vectors. As transduction readout, luciferase production was determined 
24 h after transduction. Multiplicity of infection was 1000 virus particles per cell. The 
insert graph shows the ratio of MZ2-MEL3.0 to MEL2a transduction for the targeted virus 
HAdV-5/pIX_TCRA1M1, which is normalized to the ratio for the control virus. The presence of 
pIX_TCRA1M1 results in a 10-fold improved transduction of the MZ2-MEL3.0 cell line.
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luciferase production after HAdV-5/ pIX_TCRA1M1 and HAdV-5 transduction 
was measured in the cell lines MZ2-MEL3.0/US11.ires.GFP and MZ2- MEL3.0/
ires.GFP (Figure 5C). This revealed a decrease in pIX_TCRA1M1-mediated 
targeting for the US11-expressing cells. Complete blocking of targeting did 























































Figure 5. downmodulation of human leukocyte antigen (hla) availability results in 
decreased targeting. (a) Incubation of MZ2-MEL3.0 with α-HLA-ABC antibody results in 
significant decrease in HAdV-5/pIX_TCRA1M1 transduction. Transduction of the control virus 
is not downregulated after α-HLA-ABC loading. (B) Fluorescence-activated cell sorting 
(FACS) analysis shows downregulation of HLA class I presentation at the cell surface of 
MZ2-MEL3.0 cells after infection with the retroviral vector pLZRS.US11.ires.GFP or the 
control vector pLZRS.ires.GFP. The dot plots show for both transductions the presence 
of green fluorescent protein (GFP)-positive cells (shift to the right). The downshift in case 
of the pLZRS.US11.ires.GFP transduction indicates the downregulation of HLA class I 
presentation (detection via B9.12.1 antibody plus allophycocyanin (APC)-conjugated 
secondary antibody). (c) Decrease in HAdV-5/pIX_TCRA1M1 targeting after US11-mediated 
downregulation of HLA class I molecules. Compared to the control cell line, the ratio 
HAdV-5/pIX_TCRA1M1 to HAdV-5 transduction is lower for the US11-expressing cell line 
(ratios of respectively 13.2 and 5.2). Multiplicity of infection was 1000 virus particles per 
cell. Luciferase production was measured 24 h after transduction.
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Further analysis on different cell lines to confirm specificity of tar-
geting to hla-a1/mage-a1  
During the time course of our study, the cell line MZ2-MEL43 became available. 
This line is CARneg, HLA-A1pos and MAGE-A1pos. Since the level of HLA-A1 
expression appeared to be at least equal to the HLA-A1 level of the target cell 
line MZ2-MEL3.0 (Figure 6A), the targeting efficiency of HAdV-5/pIX_TCRA1M1 
to MZ2-MEL43 and MZ2-MEL3.0 was analyzed in parallel (Figure 6B). A third 
cell line, MZ2-MEL2.2, which is a derivative from MZ2-MEL3.0 but does not 
express MAGE-A1, was included as well. As expected, transduction with 
the pIXscTCR virus was enhanced in cell line MZ2-MEL43. Interestingly, the 
targeting efficiency was 45% higher to MZ2-MEL43 than to MZ2-MEL3.0. As 
expected, no targeting was obtained on the MAGE-A1-negative cell line MZ2-
MEL2.2, demonstrating the absolute requirement for MAGE-A1 presentation. 
The enhanced transduction in the two HLA-A1/MAGE-A1-positive cell lines was 
blocked by incubation of the pIXscTCR virus with the antibody Vα12.1 (Figure 
6B), confirming that the targeting is dependent on the scTCR in the capsid.  
To further analyze the specificity of targeting, MZ2- MEL2.2 cells (CARneg, 
HLA-A1pos, MAGE-A1neg) were loaded either with a control peptide (an irrelevant 
peptide derived from influenza virus A nucleoprotein), a MAGE-A1 peptide 
or were mock treated, and were subsequently exposed to the pIXscTCR virus 
(Figure 6C). Incubation of the cells with MAGE-A1 peptide, but not with the 
control peptide, resulted in a significant increase in transduction by HAdV-5/
pIX_TCRA1M1. This effect did not occur in HAdV-5 transduction, confirming the 
dependency of HAdV-5/pIX_TCRA1M1 transduction on the presentation of the 
MAGE-A1 on HLA-A1. Compared to the MZ2-MEL3.0 cell line, the targeting 
efficiency to MAGE-A1-loaded MZ2-MEL2.2 cells was rather low. This can be 
explained by the significantly lower number of HLA-A1 molecules at the cell 
surface (Figure 6D).  
discUssion
We demonstrate successful targeting of HAdV-5 vectors to HLA-A1/MAGE-A1-
presenting tumor cells using an scTCR incorporated in the capsid as a genetic 
fusion with pIX. The pIX_TCRA1M1-loaded virions transduced HLAA1/ MAGE-
A1-expressing cells and HLA-A1-expressing cells loaded with MAGE-A1 
peptides. These findings warrant further exploration of minor capsid pIX as 
an anchor for the insertion of targeting moieties.  
The fusion of targeting proteins to pIX has some potential advantages. The 
use of pIX allows the incorporation of larger numbers of targeting molecules 
since it is present in 240 copies whereas 36 fiber molecules are present per 
virion. Furthermore, incorporation of large targeting ligands in the fiber, such 
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as scTCRs or scFv’s, may lead to a reduced number of fiber molecules per 
virion (35). Intriguingly, pIX fusion proteins with sizes of up to 120 kDa can be 
accommodated in the capsid, although incorporation efficiency of the modified 
pIX (linked to an HSV1-TK/luciferase fusion protein) was slightly decreased.36 
However, this may be improved by the use of α-helical spacers (17).  
To produce our targeting virus, with pIX_TCRA1M1 incorporated in the capsid, 
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Figure 6. comparison of the targeting on multiple cell lines to further confirm hla-a1/
mage-a1 specificity. (a) Flow cytometry analysis of human leukocyte antigen (HLA)-A1 
expression at the surface of MZ2-MEL43 cells. The control plot represents incubation with 
secondary antibody only. (B) The targeting efficiency of the HAdV-5/pIX_TCRA1M1 virus on 
three different cell lines was determined, and normalized to the targeting on MZ2-MEL3.0 
cells equal to 100%. Enhanced transduction of the pIXscTCR virus compared to the control 
virus was observed for the cell line MZ2-MEL43. This cell line was more efficiently targeted 
than the MZ2-MEL3.0 cells. No specific targeting was obtained on the melanoma-associated 
antigen (MAGE)-A1-negative cell line MZ2-MEL2.2. A decrease in targeting was obtained 
after incubation of the pIXscTCR virus with Vα12.1 antibody. (c) Improved transduction of 
MZ2-MEL2.2 cells after loading with MAGE-A1 peptide. MAGE-A1 peptide or an irrelevant 
peptide derived from influenza virus A nucleoprotein antigen was added to the wells 2 h 
before transduction with HAdV-5/pIX_TCRA1M1. Luciferase production was measured 24 h 
after transduction and was normalized to transduction on non-peptide-loaded cells. (d) 
Flow cytometry analysis to compare the presentation of HLA-A1 and HLA-ABC at the cell 
surface of MZ2-MEL2.2 and MZ2-MEL3.0 cells. The control graphs represent incubation 
with secondary antibody only. The MZ2-MEL3.0 cell line had significantly more α-HLA-A1 




(37). By using this strategy of incorporation of pIX in a ∆pIX virus, the time-
consuming process of making viruses with pIX modifications in the genome 
can be avoided. Efficient incorporation of modified pIX, for example, linked 
to single-chain antibody fragments, can be obtained (18). After transduction 
of 911 helper cells that produce the pIX_TCRA1M1 protein, production of pIX_
TCRA1M1 in the cells was verified by immunohistochemistry. Infection of the 
transduced helper cells with ∆pIX virus resulted in the production of virus 
particles with close to wt level of the pIX_TCRA1M1 protein incorporated in 
their capsid, demonstrating the usefulness of this approach.  
Interestingly, pIX_TCRA1M1 was detected predominantly in the cytoplasm 
of the LV.pIX_TCRA1M1- transduced 911 helper cells. This is in contrast to the 
location of the wt pIX, which is mainly nuclear (38). As can be concluded from our 
results, the aberrant subcellular localization of pIX_TCRA1M1 does not hamper 
incorporation in the virus capsid. Since adenovirus particles are assembled 
in the nucleus, these results imply that a sufficient amount of pIX_TCRA1M1 
was present in the nuclei during formation of the HAdV-5/pIX_TCRA1M1 virus. 
Indeed, we could confirm by confocal microscopy that during the adenovirus 
infection significant amounts of pIX_TCRA1M1 are localized in the nucleus.  
The targeting specificity to tumor cells expressing the MAGE-A1-derived 
epitope in the context of HLA-A1 was demonstrated via different approaches. 
First, transduction of the HLA-A1/MAGE-A1-positive MZ2- MEL3.0 cells was 
increased up to 10-fold by the incorporation of pIX_TCRA1M1 in the virus 
capsid. The targeting efficiency in another HLA-A1/MAGE-A1-positive cell 
line, MZ2-MEL43, appeared to be higher. Specificity was also evident from 
experiments in which HLA-A1-positive/MAGE-A1-negative MZ2- MEL2.2 
cells were loaded with MAGE-A1 peptides. This resulted in a significant 
increase in transduction efficiency. The targeting specificity was lower than 
achieved on MZ2-MEL3.0 cells. This may be due to distinct presentation 
of synthetic peptides when compared to endogenously processed and 
presented peptides at the cell surface. Also, MZ2-MEL2.2 cells express fewer 
HLAA1 molecules at their cell surface than MZ2-MEL3.0 cells (Figure 6D). 
Furthermore, the targeting efficiency to MZ2-MEL3.0 could be reduced by 
blocking HLA, either via incubation of the cells with α-HLA-ABC antibody, or 
alternatively, via the expression of the HCMV US11 gene. The US11 causes 
degradation of newly synthesized MHC class I heavy chains by mediating their 
dislocation from the ER into the cytosol (34). For the antibody incubation, as 
well as the US11-mediated downregulation, the blocking of targeting was 
not 100%. Apparently, the incubation of cells with a-HLA-ABC antibody was 
not sufficient to block all HLA-A1 molecules. In case of the US11- mediated 
downmodulation, flow cytometry analysis showed that a small but detectable 
fraction of the cell population had not been transduced (GFP-negative), and 
thus did not downregulate HLA class I presentation, which probably explains 
the incomplete block of targeting.  
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We report successful targeting of HAdV-5 via fusion of a specific targeting 
moiety to capsid pIX. It has been speculated that targeting via pIX results 
in entrapment of the virions in the endosomes, caused by high-affinity 
interaction between the pIX fusion protein and the cellular receptor (16). 
However, binding of T-cell receptors to their target MHCI/peptide complex is 
known to have low affinity (39). This may allow the scTCR-containing virions 
to escape from the endosome. Alternatively, binding of the virus particles to 
the HLA-A1/MAGEA1 complex may have resulted in a distinct internalization, 
that is, differing from the normal HAdV-5 internalization via clathrin-coated 
vesicles. Cellular internalization mediated by binding to MHCI molecules is 
exploited by Simian virus 40, which enters the cell via a unique pathway that 
involves caveolae, rather than clathrin-coated pits (40). Interestingly, HLA 
class I has been suggested as an alternative receptor for HAdV-5 (41). 
The fact that the scTCR used in this study is biologically active at the 
surface of the adenovirus supports the feasibility of targeting adenovirus 
vectors by fusing complex polypeptide molecules, such as scTCRs or scFv 
fragments, to capsid pIX. Normally, such complex polypeptides are routed 
via the protein secretory pathway. This aspect might hamper functional 
incorporation in the capsid of adenovirus particles, which are assembled in 
the nucleus. The reducing environment in the cell prevents the formation 
of disulfide bridges, which may result in improper folding of these proteins 
(42). Another obstacle for the implementation of scTCRs in adenoviral vectors 
might be that the relatively large scTCRs hamper correct virion formation or 
might interfere with crucial processes necessary for virus propagation. Initial 
attempts to produce adenovirus vectors with an scTCR fragment genetically 
fused to a knobless fiber protein were unsuccessful (43). Incorrect folding 
and/or trimer formation of the fiber protein due to the presence of the scTCR 
fragment was reported to be the most likely explanation. The incorrect fiber 
formation might have caused the inability to rescue the virus, even though 
the mutated viral DNA was introduced into the target cell line. However, more 
recently the successful development of a scTCR-containing adenovirus has 
been reported (6). Our results, with a scTCR bound to the minor capsid pIX, 
emphasize the potential of scTCRs for obtaining transductional specificity in 
adenoviral vectors. The pIX_TCRA1M1 fusion protein was incorporated in the 
capsid with high efficiency. Although it remains to be established whether 
all scTCRs are functional if fused with pIX, our results clearly demonstrate 
the functionality of at least part of the scTCRs. The variable domains of the 
scTCR, which mediate binding to the HLA-A1/MAGE-A1 target complex, 
were accessible to antibodies in the context of intact virions, which was 
shown via immunoprecipitation of the virus on Vα12.1- or Vβ1-coated beads, 
and alternatively, via downregulation of transduction as a result of Vα12.1 
incubation. The presence of the 75-Ångstrom α-helical spacer (17) in between 
the scTCR and pIX domains might have been crucial to generate sufficient 
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flexibility for proper orientation of the scTCR at the capsid surface. Detailed 
studies on elucidating the process of scTCR folding during virus infection 
would be of great interest. Our immunohistochemistry analysis on the 911/
pIX_TCRA1M1 cell line yielded staining with the conformation-dependent 
antibody Vα12.1, only after adenovirus infection. It is tempting to speculate 
that the scTCR only adopts its proper conformation upon change of the 
intracellular milieu upon induction of adenovirus-induced cell death.  
The pIXscTCR-containing virus used in this study was not de-targeted, 
as the CAR-binding elements, the heparan sulfate proteoglycans-binding 
elements and the plasma protein-binding elements are still present in the 
capsid. For the final aim of in vivo tumor therapy via delivery of an HAdV-5 
vector, these elements should be abolished. Also, it would be interesting to 
test whether shortening of the fiber shaft or complete removal of the fiber 
improves targeting efficiency, for instance by reducing steric hindrance of the 
pIXscTCR molecules by the protruding fiber proteins. Currently, pIXscTCR 
targeting in the context of fiber mutations is under investigation.  
Our approach as described here utilizes the targeting of CT antigen 
epitopes that are presented at the cell surface of tumor cells by HLA class 
I molecules. This principle differs from previously reported retargeting 
approaches of adenovirus-based vectors, which encompass the targeting of 
‘overexpression’ receptors like Her2/neu (44) or the epidermal growth factor 
receptor (45). The expression profile of the CT antigens is generally much 
more specific compared to the expression profile of the ‘more conventional’ 
target molecules such as the overexpressed receptors. The fact that HLA 
class I/CT antigen complexes can elicit a highly specific response of the 
immune system has prompted many studies on immune cell modifications 
with the aim to direct the modified cells toward tumor cells (4). However, 
tumor therapies via such approaches may not be feasible since the process 
of isolating, modifying and expansion of patient immune cells is likely to be 
difficult and time consuming. Viral vector-based cancer gene therapy might 
be a more suitable strategy. Genetic modification of adenoviral vectors, which 
are the most widely used virus vectors in clinical tumor gene therapy studies, 
is relatively easy. Besides, adenoviruses have a good safety profile and can be 
produced with high titers.  
Our results show that HAdV-5 vectors can be genetically modified to 
mediate greatly enhanced gene delivery into tumor cells by targeting HLA 
class I/CT antigen complexes. The successful combination of two aspects 
with great potential in cancer gene therapy, adenovirus as a vector and CT 
antigens as a target, clearly warrants further exploration. Follow-up studies 
are under way, and especially the fusion of other scTCRs to pIX (directed 
against other HLA class I/CT antigen complexes), and the evaluation of in vivo 
performance of the modified HAdV-5 vectors will be of great interest.  
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mateRials and methods
dna constructs  
The lentiviral vectors used in this study were described in earlier studies 
(37). Plasmid pLV.CMV.pIXflag75AscTCRA1M1.bc.neo, abbreviated as pLV.pIX_
TCRA1M1, was constructed by standard cloning procedures. The pLV plasmid 
contained a G418 resistance gene (neo) downstream of the pIX_TCRA1M1 
sequence, separated by an internal ribosome entry site (bc). In between 
the pIX and scTCR sequence, sequences are present that encode a flag 
tag and a 75-Ångstrom spacer. Insertion of this spacer has been shown to 
greatly enhance presentation of pIX-fused proteins at the virus capsid (17). 
The gene for pIXflag75 was obtained from the pcDNA3.1-based construct 
pAd5pIXflag75MYC (17). The gene encoding scTCRA1M1 was subcloned from 
the retroviral vector pBullet. VαVβCβ (46). The scTCRA1M1 sequence of pBullet. 
VαVβCβ was originally constructed from the Vα, Vβ and Cβ sequences from 
an HLA-A1/MAGE-A1-specific CTL clone MZ2-82/30 of patient MZ2 (47).  
cells  
All cell lines were maintained at 37 °C in a humidified atmosphere of 5% 
CO2 in Dulbecco’s modified Eagle’s medium (DMEM, Gibco-BRL, Breda, 
the Netherlands) supplemented with 8% fetal bovine serum (FBS, Gibco- 
BRL) and penicillin-streptomycin mixture. Cell lines used for the adenovirus 
targeting experiments were the melanoma cell lines MEL2a, MZ2-MEL2.2, 
MZ2-MEL3.0 and MZ2-MEL43. Expression status of the CAR and HLA-A1/
MAGE-A1 has been described before for the cell lines MEL2a (CARpos/
HLA-A1pos/MAGE-A1neg), MZ2-MEL2.2 (CARneg/HLA-A1pos/MAGE-A1neg) and 
MZ2-MEL3.0 (CARneg/HLA-A1pos/MAGE-A1pos) (6). The status of the previously 
uncharacterized cell line MZ2- MEL43 is CARneg/HLA-A1pos/MAGE-A1pos, as 
determined by flow cytometry analysis and shown in Figure 6A in this paper. 
The HAdV-5 E1-transformed cell line 911 was used to propagate and titer 
adenovirus vectors (48). 
lentiviral and retroviral transductions  
The recombinant lentivirus LV.pIX_TCRA1M1 was produced as described 
elsewhere (37). The lentivirus titer was determined by p24 enzyme-linked 
immunosorbent assay, assuming that 1 ng p24 equals 2.5 ×103 transducing 
units (49). To establish a helper cell line stably expressing pIX_TCRA1M1, 911 
cells were transduced with the recombinant lentivirus, resulting in the cell 
line 911/pIX_TCRA1M1. Infection was done with five transducing units per 
cell. To select for stably transduced cells, the cell line 911/pIX_TCRA1M1 was 
cultured in medium supplemented with 200 mg l-1 G418 (Invitrogen, Breda, 
the Netherlands).  
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The retroviral vector pLZRS-US11-IRES-EGFP was made by subcloning 
the HCMV US11 cDNA fragment into the pLZRS-IRES-EGFP vector (50). This 
construct was used, together with the wt enhanced green fluorescent protein 
(EGFP)-expressing retroviral vector, to produce amphotropic retrovirus by 
transfection of the Phoenix cell line with the calcium phosphate method 
(www.stanford.edu/group/nolan/retroviral_systems/retsys.html). Transfected 
cells were grown under puromycin selection (2 µg ml-1), which was removed 
24 h before collecting the virus. MZ2-MEL3.0 cells, grown on retronectin- 
coated dishes (Takara, Japan), were transduced with the recombinant viruses 
to create cells stably expressing US11 and the control construct.  
adenovirus vectors  
The 911/pIX_TCRA1M1 helper cell line was transduced with the replication-
deficient adenoviral vector HAdV- 5.CMVLUC∆E1∆E3∆pIX. Production and 
characteristics of this vector are described elsewhere (17). The vector carries a 
firefly luciferase transgene under control of the human CMV immediate-early 
promoter. In this vector the pIX gene had been deleted from the genome. 
Three days after transduction, the offspring virus was harvested and purified 
by CsCl banding, resulting in the virus HAdV-5.CMVLUC∆E1∆E3∆pIX+pIX_
TCRA1M1 (indicated in this paper as HAdV-5/pIX_TCRA1M1). Adenovirus particle 
titers were determined by measuring optical density at 260 nm, using a 
standard protocol (51). The control virus used in all retargeting experiments 
was HAdV-5.CMVLUC∆E1∆E3 (indicated as HAdV-5).  
immunohistochemistry  
Immunohistochemistry was performed on the helper cell line 911/pIX_TCRA1M1, 
with or without HAdV- 5.CMVLUC∆E1∆E3∆pIX infection. Infection was 
performed with 1000 virus particles per cell, 24 h before fixation. After washing 
with phosphate-buffered saline (PBS), the cells were fixed in acetone/methanol 
(1:1) for 10 min at room temperature. Staining was performed with the antibodies 
α-pIX (rabbit polyclonal (1:500), kindly provided by Dr Keith Leppard, University 
of Warwick, UK) (52), Vα12.1 (Pierce-Endogen Biotechnology, Rockford, IL, USA) 
and α-hexon (clone BOD604, fluorescein isothiocyanate (FITC)-conjugated, 
Biodesign International, Saco, ME, USA). FITC-labeled antibodies (Jackson 
ImmunoResearch, France) were used as secondary antibody. Upon analysis of 
the uninfected cells, the nuclei were stained using propidium iodide. Exact 
detection procedure has been described previously (18).  
Wide-field microscopy was performed with a Leica DM-IRBE microscope. 
Confocal laser scanning microscopy was performed on a confocal microscope 
system (model TCS/SP2; Leica). Z-series images (slice spacing 0.45 µm) were 
acquired with a 63_ NA 1.4 plan Apo objective and were analyzed with Leica 
confocal software.  
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immunoblotting procedures  
Western analysis was performed to analyze production of pIX_TCRA1M1 in 
the helper cells and to analyze incorporation efficiency of pIX_TCRA1M1 in the 
virus capsid. Cell lysates were made in radioimmunoprecipitation assay lysis 
buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 0.1% SDS, 0.5% DOC, 1% NP40). 
Protein concentrations were measured with the bicinchoninic acid protein 
assay (Pierce Biotechnology, Perbio Science BV, Etten-Leur, the Netherlands). 
Virus lysates were prepared by adding 5×109 virus particles directly to western 
sample buffer. The pIX variants were visualized with rabbit polyclonal α-pIX 
serum (1:2000) (52). Goat polyclonal α-hexon (1:1000) (Abcam, Cambridge, 
UK) was used as a virus particle loading control. Secondary antibodies were 
horseradish peroxidase (HRP)-conjugated goat-α-rabbit and rabbit-α-mouse 
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The western blotting 
and detection procedures have been previously described (17,37).
A spot-blot type analysis was used to detect viral capsid proteins in 
intact virus particles. Immobilon membrane (Millipore, Etten-Leur, The 
Netherlands) was activated with methanol, washed for 10 min with PBS and 
virus (3×109 particles) was spotted onto the membrane. Virus was spotted 
as intact particles (untreated) or as virus lysate (denatured through adding 
western sample buffer plus 5 min incubation at 98 °C). This was followed up 
by blocking for 1 h in Soja milk (Alpro soja, Breda, The Netherlands), and 
washing twice for 10 min with 0.2% Tween20 in PBS. Thereafter, probing of 
capsid proteins was performed according to the same protocol as applied for 
the western analysis. The primary antibodies used were mouse monoclonal 
α-fiber knob (1D6.14, 1:1000) (53), goat polyclonal α-hexon (1:2000; Abcam), 
α-flag (1:500) (α-flag M2 Affinity Gel Freezer-Safe; Sigma-Aldrich Chemie, 
Zwijndrecht, the Netherlands), rabbit polyclonal α-pIX (1:2000) (52) and α-pVII 
antibody (1:500) (kindly provided by Saw See Hong, Laboratoire de Virologie 
et Pathoge´ne`se Virale, Lyon, France). Secondary antibodies used were HRP-
conjugated goat-α-rabbit and rabbit-α-mouse (Santa Cruz Biotechnology).  
Binding of virus particles to anti-tcR-coated beads  
The ability of the pIX_TCRA1M1 virus to bind to anti-TCR-coated beads was 
investigated through an immunoprecipitation assay. Protein G Sepharose 
beads (30 µl; Pierce Biotechnology) were incubated with 1 µg of antibody 
(Vα12.1 or Vβ1), for 2 h at 4 °C in 600 µl cold PBS. Antibody-coupled beads 
were added to 1 ml DMEM without serum, containing two types of virus; 
HAdV-5.CMVLUC∆E1∆E3∆pIX (5 ×1010 particles), and HAdV-5.CMVLacZ∆E1 
(5 ×1010 particles). Control samples were incubated with beads only. After 
incubation for 12 h at 4 °C, 50 µl of the supernatant was added to 450 µl 
DMEM (containing 8% FBS), which was subsequently applied on MEL2a cells 
in a 24-well plate. After 24 h, the expression levels of intracellular luciferase 
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and β-galactosidase were determined. To this end, the cells were washed 
once with PBS, and lysed in 100 µl LUC-lysis mix (25 mM Tris-phosphate (pH 
7.8), 2 mM CDTA, 2 mM DTT, 10% glycerol and 1% Triton-X in PBS). After 
shaking for 15 min at room temperature, lysates were centrifuged (10000 
g, 10 min). Luciferase production was determined with Promega Luciferase 
Assay, and β-galactosidase production was determined with the Tropix 
Galacto-Light reporter gene assay (Applied Biosystems, Bedford, MA, USA). 
Light intensity measurement was performed in a Victor Wallac 2 microplate 
reader (PerkinElmer, Inc., Waltham, MA, USA).  
virus transduction assays  
Transduction efficiencies with HAdV-5/pIX_TCRA1M1 and HAdV-5 were 
analyzed by measuring luciferase production. For all virus transduction assays, 
transduction was performed in 24-well plate, with 1000 viral particles per cell, 
in 500 µl DMEM/8% FBS. After 24 h, luciferase production was measured as 
described above (25 µl luciferase assay reagent was added to 10 µl lysate).  
Incubation of cells with α-HLA-ABC antibody (ascites) was performed to 
test downmodulation of targeting. The cells were incubated for 12 h with 20 
µg ml-1 α-HLA-ABC (in medium), which was removed from the cells before 
adding the virus. TCR blocking analysis was performed by incubating the 
virus (108 particles) for 12 h (4 °C) with 150 ng Vα12.1 antibody in 100 µl PBS 
supplemented with 2% horse serum. After adding 400 µl medium, the virus 
was added to 105 cells (resulting in a titer of 1000 particles per cell).  
For peptide loading of the MZ2-MEL2.2 cells, 500 ng MAGE-A1 peptide, 
or 500 ng of an irrelevant peptide derived from influenza virus A nucleoprotein 
antigen (54) was added per well 2 h prior to adding the virus.  
Flow cytometry  
To perform flow cytometry analysis on the different cell lines, the cells were 
trypsinized, resuspended in PBS (containing 0.5% bovine serum albumin and 
0.02% sodium azide), and were incubated with antibodies. The cells were 
incubated with saturating conditions of α-CAR antibody (55), α-HLA-ABC 
antibody (W6/32, Cedarlane, ON, Canada) or α-HLA-A1 antibody (One 
Lambda, CA, USA) for 30 min on ice, followed by incubation with phycoerythrin 
(PE)-labeled secondary antibody (Caltac Laboratories, Burlingame, CA, USA) 
for 30 min on ice. The status of HLA-ABCGE expression at the cell surface 
of the US11-expressing MZ2-MEL3.0 cell line and the control lines was 
performed by using α-HLA-ABCGE (B9.12.1, Immunotech, Marseille, France) 
as primary antibody and allophycocyanin (APC)-conjugated goat-α-mouse 
immunoglobulin G (Jackson ImmunoResearch) as secondary antibody. Flow 
cytometry data were analyzed with CellQuest software (Becton Dickinson).  
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A lentIvIrAl vector-BAsed 
AdenovIrus fIBer-pseudotypIng 
ApproAch for eXpedIted 
functIonAl Assessment of 
cAndIdAte retArgeted fIBers
aBstRact
Background: many studies aimed at retargeting adenovirus (Ad) rationally 
focus on genetic modification of fiber, which is the primary receptor-binding 
protein of Ad. retargeted fibers ultimately require functional validation in 
the viral context.
methods: lentiviral vectors (lv) were used to express fiber variants in cells. 
Infections with a fiber gene-deleted Ad vector yielded fiber-pseudotyped 
viruses. An enzyme-linked immunosorbent assay and slot blot-based assays 
probed target binding-ability of retargeted fibers. differential treatments 
with an alkylating agent prior to western blot analysis allowed for examination 
of intra- and extracellular redox states of fibers.
Results: In the present study, lv-based fiber-pseudotyping of Ad is presented 
as an accelerated means to test new fibers. lv-mediated gene transfer 
yielded stable and uniform populations of fiber variant-expressing cells. 
these populations were found to effectively support fiber-pseudotyping 
of Ad. As a secondary objective of the study, we functionally assessed a 
chimeric fiber harboring a tumor antigen-directed single-chain antibody 
fragment (scfv). this fiber was shown to trimerize and achieve a degree of 
binding to its antigenic target. however, its capsid incorporation ability was 
impaired and, moreover, it was unable to confer a detectable level of target 
binding upon Ad. Importantly, subsequent analyses of this fiber revealed the 
improper folding of its scfv constituent.
conclusions: lv-based fiber-pseudotyping was established as a convenient 
method for testing modified fibers for functionality within Ad particles. 
furthermore, a new chimeric fiber was found to be inadequate for Ad 
retargeting. the folding difficulties encountered for this particular fiber might 
be generally inherent to the use (i.e. for genetic Ad capsid incorporation) of 
complex, disulfide bridge-containing natural ligands.
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intRodUction   
Aiming to improve safety and efficacy of systemic Ad-mediated gene 
therapy, diverse genetic capsid modification strategies are being employed 
to retarget Ad, which involves restricting the broad infectivity profile of Ad 
and, simultaneously, redirecting Ad infection to specific target cells (1,2). In 
this regard, because the canonical infection route of HAdV-5 entails a primary 
docking step that involves Ad fiber protein binding to cellular coxsackievirus 
and adenovirus receptor (CAR) (3), many genetic strategies for Ad retargeting 
rationally focus on modification of the fiber (4,5). These efforts typically seek 
to generate new fiber variants that are ablated for interaction with CAR and 
additionally incorporate heterologous ligands for alternative, target cell-
specific receptors. Similarly, other capsid proteins are being genetically 
modified to ablate native viral interactions with cell or blood components 
and/or to incorporate targeting ligands (6–10). In this respect, with the recent 
recognition that hexon-to-FX binding is largely responsible for the hepatic 
tropism of Ad, new prospects have opened up for genetic capsid modification 
strategies aiming to detarget the liver.   
Genetic strategies aimed at altering Ad tropism through modification of 
fiber have been numerous (1,2,4,5). One method to endow HAdV-5-based 
vectors with novel tropism involves swapping of the fiber, or the fiber knob 
domain, with that of other Ad serotypes with distinct cellular receptors (11–13). 
Other fiber modification approaches focus on the insertion of targeting 
ligands at specific sites found to be accommodating for this purpose, such 
as the C-terminus and the so-called HI-loop (14–17). Furthermore, several 
studies have combined the above approaches by inserting peptide ligands 
into the knob domains of non-HAdV-5 serotype fibers (18–20). Finally, more 
rigorous strategies involve the complete deletion of the fiber knob domain 
(by which both CAR-binding and trimerization functionalities of the fiber are 
removed) and its functional replacement by an extrinsic trimerization domain 
and a targeting ligand (21–24). This approach would allow for the insertion 
of more complex ligands, which otherwise, in the knob-incorporated context, 
would be incompatible with correct fiber folding.   
New fiber designs drawn up to achieve Ad retargeting ultimately require 
experimental validation by functional testing of the new fibermodels in the 
context of Ad virions. Presently, this is mostly achieved by genetic incorporation 
of the new fiber construct into the Ad genome by means of homologous 
recombination in Escherichia coli, subsequent virus rescuing followed by 
upscaling in a suitable cell line, and, finally, functional assessment of the new 
fiber in its capsid-incorporated context. Although extensively proven to be 
functional, this scheme does have a significant drawback in that it is rather 
time-consuming.   
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An alternative fiber-testing system is represented by transient fiber-
pseudotyping of Ad. This approach, as first established by von Seggern et 
al. (25), involves the use of Ad packaging cells expressing the fiber variant 
of interest. Infection of these cells with a fiber gene-deleted (ΔF) Ad vector 
allows for the generation of virus particles carrying the modified fiber. Such 
transiently fiber-pseudotyped viruses can then be used for functional testing 
of the incorporated new fiber. In previous manifestations of this approach, 
the fiber variant-expressing cell populations used for the pseudotyping 
infection were either generated by means of transient transfection or by 
clonal selection and expansion of stably transfected cells (18,25,26). In this 
regard, the ‘transient transfection/infection’ procedure first described by 
Jakubczak et al. (26) comprises a major advancement in terms of time and 
labour expended on testing new fibers.   
In the present study, as a first objective, we established the feasibility of 
a fiber-pseudotyping system that makes use lentiviral vectors (LVs) for the 
generation of fiber variant-expressing cells. Importantly, this lentivirus-based 
system brings together two distinct benefits associated with previously 
described fiber-pseudotyping approaches. First, analogous to the transient 
transfection-based protocol (26), the lentivirus-based method is a procedurally 
quick way to test new fibers. Second, akin to the approach relying on stably 
transfected cell clones (25), the lentivirus-based procedure ensures that the 
cell population used for fiber-pseudotyping expresses the fiber of interest in 
a stable and uniform fashion. Thus, with its relative procedural speediness 
and its practical robustness, the system described in the present study 
is considered to represent a useful toolbox addition for testing candidate 
retargeted fibers.   
A secondary objective of the present study was to use this newly-established 
fiber-pseudotyping system for the functional assessment of a chimeric 
fiber harboring a scFv directed to an important tumor-associated antigen. 
Importantly, the scFv used in the present study was previously found to be 
capable of functional folding in a reducing environment, a finding suggestive 
of potential compatibility with the nuclear process of Ad particle assembly. 
The results obtained in the present study with this new scFv-fiber chimera are 
considered to be relevant to genetic adenovirus targeting strategies aiming 
to exploit complex ligands whose natural biosynthetic routes are distinct from 




cells   
The HAdV-5 E1-transformed cell line 911 has been described previously 
(27). Fiber-expressing cell lines 633 and 293-Fb were, respectively, obtained 
from Dan von Seggern (The Scripps Research Institute, La Jolla, CA, USA) 
and Monika Lusky (Transgene SA, Strasbourg, France) (25,28). 293HER2/
neu cells were described previously (29). All cell lines were grown at 37°C in 
Dulbecco’s modified Eagle’s medium (Gibco BRL, Breda, The Netherlands) 
supplemented with 8% fetal bovine serum (Gibco BRL) in a humidified 
atmosphere with 5% CO2.
adenovirus vectors   
HAdV-5 was obtained from the virus collection of the Department of 
Molecular Cell Biology of the Leiden University Medical Center. Ad.ZH is an 
HAdV- 5-based vector genetically modified to possess a previously described 
recombinant fiber termed FibΔCAR-HI-Link-ZHZH (29), which incorporates, 
in its HI-loop, a head-to-tail dimer of ZH, a Her2/neu targeted affibody (30). 
This virus was generated using previously described procedures based on 
homologous recombination and cosmid cloning (24), and subsequent virus 
rescuing by transfection of the PacI-digested recombinant genome into 
293HER2/neu. AdGLΔF/F and its fiber-pseudotyped versions AdGLΔF/
R7Knob and AdGLΔF/800E6 Fb were generated as detailed below. All viruses 
were purified by centrifugation on CsCl gradients by standard protocols. 
The physical particle titers were determined spectrophotometrically by the 
method of Maizel et al. (31), using a conversion factor of 1.1 × 1012 viral 
particles per absorbance unit at 260 nm.   
construction of a fiber gene-deleted ad vector genome plasmid   
A series of genetic manipulations led to the generation of pAdGLΔF, a 
plasmid containing an E1- and E3-deleted HAdV-5 genome further deleted 
for HAdV-5 nucleotides 31042–32699, which correspond to all but the last 
85 nucleotides of the fiber gene open reading frame. First, an intermediate 
‘fiber shuttle’ plasmid, pFS, was constructed by self-ligation of the fiber gene-
containing, 9.6-kbp EcoRI fragment of pAdEasy-I, an adenoviral genome 
plasmid lacking the left-end (including the E1 genes) and most of the E3 
region of the HAdV-5 genome (32). Then, pΔFS, a pFS derivative containing 
the above mentioned 1658-bp fiber gene deletion, was made by inversed 
polymerase chain reaction (PCR) on pFS using oligonucleotides FIB-Ct-SwaI-s 
and FIB-Nt-as (Table 1) and subsequent self-ligation of the resulting 8.0-kbp 
PCR product. Subsequently, within pΔFS, the pAdEasy-I derived Ad genome 
sequence upstream of the fiber gene deletion was extended by ligation of the 
116
4
SpeI site-containing, 1.3-kbp MfeI-EcoRI pAdEasy-I fragment into the unique 
EcoRI site of pΔFS, yielding pΔFS2. Finally, pAdGLΔF was generated by 
homologous recombination (in E. coli BJ5183) (33,34) between the 5.7-kbp 
BglI-fragment of pΔFS2 and SpeI-linearized pAdGL, a plasmid that itself is the 
product of homologous recombination between pAdEasy-I and pAdTrack-
CMV.Luc. The latter plasmid was constructed by insertion of a firefly luciferase 
gene into the multiple cloning site of pAdTrack-CMV, a shuttle vector of the 
AdEasy system (32).   
generation of a fiber gene-deleted ad vector and fiber-pseudo-
typed vector stocks
A fiber gene-deleted Ad vector was generated by transfection of PacI-
digested pAdGLΔF into the wildtype fiber-complementing cell line 293-Fb. 
The resulting rescued virus was propagated further on 293-Fb cells and 
purified as described above, giving AdGLΔF/F (293-Fb). This virus was 
subsequently used for the generation of purified preparations of AdGLΔF/F 
(633), AdGLΔF/R7Knob, and AdGLΔF/800E6 Fb through large-scale infection 
of 633, 911.R7Knob, and 911.800E6 cells, respectively. The latter two of these 
fiber-complementing cell types were made in the present study by means of 
lentiviral transduction (see below).   
construction of lv plasmids   
The LV plasmids used in the present study are based on pLV.CMV.IRES.
GFP and pLV.CMV.IRES.NPTII, which both originally stem from pRRL-cPPT-
CMV-XPRE- SIN (35) through multiple genetic manipulations that effectively 
resulted into insertion (between the BstZ17I and NsiI sites of the original 












aRestriction sites referred to in the Ma
terials and Methods are underlined.
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plasmid) of an internal ribosomal entry site (IRES) sequence followed by a 
green fluorescent protein (GFP) gene or a neomycin phosphotransferase II 
(NPTII) gene, respectively. Furthermore, within these plasmids, the original 
multiple cloning site (MCS) had been extended by sequential insertions of 
additional polylinker sequences. A third basal LV plasmid, pLV.CMV.IRES.
PURO, was generated for the present study by the replacement of the GFP 
gene of pLV.CMV.IRES.GFP with a puromycin resistance gene obtained by 
PCR from plasmid pBABEpuro (36).   
Plasmids pLV.CMV.Fiber.IRES.NPTII, pLV.CMV.Fiber.IRES.GFP, and pLV.
CMV.R7Knob.IRES.NPTII were constructed by PCR-amplification of the genes 
for wild-type HAdV-5 fiber and R7Knob fiber (37) using primers Fib-FWD-
PstI and Fib-REV-XhoI (Table 1), digestion of the PCR products with PstI and 
XhoI, and ligation of the resulting fragments in between the PstI and XhoI 
sites of pLV.CMV.IRES.NPTII or pLV.CMV.IRES.GFP. Of note, the resulting 
cloned fiber genes lack the poly A signal that normally overlaps the HAdV-5 
fiber stop codon. To construct wild-type and R7Knob fiber genes fused to an 
upstream tripartite leader (TPL) sequence, PCR-mediated splicing by overlap 
extension (SOE) was employed. First, the TPL sequence was amplified from 
pMad5 (38) using primers TPL-PstI-s and TPL-FIB-as, whereas the fiber genes 
were amplified from pLV.CMV.Fiber.IRES.NEO and pLV.CMV.R7Knob.IRES. 
NEO using primers TPL-FIB-s and F-BsrGI-as (Table 1). Then, mixing of TPL 
and fiber PCR products and subsequent amplification using only the ‘outer’ 
primers (TPL-PstI-s and F-BsrGI-as) resulted in the generation of the desired 
fusion products.   
These TPL-fiber fusion products were subsequently cloned into pLV.
CMV.IRES.NEO using PstI and BsrGI restriction sites, yielding pLV.CMV.TPL.
Fiber.IRES.NEO and pLV.CMV.TPL.R7Knob.IRES.NEO. Furthermore, pLV. 
CMV.TPL.Fiber.IRES.GFP was made by replacing the fiber gene-containing 
PstI-PmlI fragment of pLV.CMV.Fiber. IRES.GFP with that of pLV.CMV.TPL.
Fiber.IRES.NEO.   
The generation of an 800E6 fiber-expressing LV vector plasmid involved 
several cloning steps, which, in effect, amount to the following. The coding 
sequence for scFv800E6 was PCR-amplified from pIVEX 2.4d-His(6x)-ad-N-
ScFv800E6 (39) using primers 800E6-NcoI-MluI-F and 800E6-BsrGI-R (Table 1). 
Subsequently, employing the introduced NcoI site, the obtained scFv800E6 
sequence was ligated at its 5’ end to a chimeric gene fragment (made by 
PCR-mediated SOE) encoding the tail and first shaft repeat of the HAdV-5 
fiber protein followed by the coiled coil segment 13 and foldon domain of the 
bacteriophage T4 fibritin protein. Next, the resulting 800E6 fiber gene was 
fused (by virtue of the BshTI site existing within the fiber tail sequence) to the 
TPL sequence present in pLV.CMV.TPL.Fiber.IRES.NEO. Finally, the TPL-800E6 
fiber fusion sequence obtained was introduced as a PstI-BsrGI fragment into 
pLV.CMV.IRES.PURO, yielding pLV.CMV.TPL.800E6-Fb.IRES.PURO.   
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production of lv vectors   
LVs were produced by a previously described procedure involving transient 
cotransfection of a LV vector plasmid (expressing the transgene of interest) 
together with ‘helper’ plasmids encoding HIV-1 gag-pol, HIV-1 rev, and the 
VSV-G envelope (40). For quantification of virus yield in the harvested medium, 
p24 antigen levels were determined using a HIV-1 p24 antigen enzyme-linked 
immunosorbent assay (ELISA) kit (ZeptoMetrix Corp., New York, NY, USA).   
transient fiber expression   
911 cells seeded in six-well plate wells were grown to 70% confluency 
and subsequently transfected with plasmids pLV.CMV.Fiber.IRES.GFP, pLV.
CMV.TPL.Fiber.IRES.GFP, and pLV.CMV.TPL.Fiber.IRES.NPTII by the calcium 
phosphate coprecipitation technique (41). An equal molar amount of each 
plasmid was separately transfected (approximately 1 µg per well). Twenty-four 
hours after transfection, the cells were washed and cultured in fresh growth 
medium. The cells were harvested for western blot analysis after another 24 h. 
lentiviral transductions   
911 cells seeded in wells of six-well plates and grown, in 1 day, to a confluency 
of 50% (approximately half a million cells) were transduced with LV vectors 
(diluted in fresh growth medium) at 200 ng of p24 per well for 24 h in the 
presence of 8 µg/ml polybrene. After transduction, the virus containing 
medium was replaced by fresh growth medium and the transduced cells 
were passaged 1 day later. Selection for antibiotic resistance was initiated 
at the first passage. Cells transduced with LV.CMV.TPL.R7Knob.IRES.NPTII 
were grown in medium containing 400 µg/ml G418 (Invitrogen, Breda, The 
Netherlands), whereas those transduced with LV.CMV.TPL.800E6-Fb.IRES.
PURO were grown in the presence of 0.6 µg/ml puromycin (MP Biomedicals, 
Amsterdam, The Netherlands). The antibiotic-resistant cell populations 
obtained were, respectively, termed 911.R7Knob and 911.800E6.   
Western analysis   
Except otherwise specified, cell lysates were made in RIPA lysis buffer (50 
mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% DOC, and 1% NP40) 
supplemented with protease inhibitors. Protein concentrations were 
determined with a BCA protein assay (Pierce, Etten-Leur, The Netherlands) 
with bovine serum albumin (BSA) as the standard. Typically, cell lysate samples 
for western analysis were prepared by boiling of 20 µg of total protein in 
reducing sample buffer (final composition: 33 mM Tris-Cl, pH 6.7, 9% glycerol, 
2% SDS, and 2.2% β-mercaptoethanol, and 2.2% from a 1 : 20 dilution of a 
saturated bromophenol blue solution) for 5–10 min at 100°C. Virus samples 
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for western analysis were prepared by adding purified viruses directly to the 
reducing sample buffer, followed by boiling.   
For assessment of the intracellular redox state of expressed fibers, cells 
were lysed in the presence of either 10 mM dithiothreitol (DTT) or 10 mM 
N-ethylmaleimide (NEM), or in the absence of either of these agents. In the 
case of the DTT-treated lysates, Western samples were subsequently prepared 
using the reducing sample buffer, whereas, for the other two treatments, a 
nonreducing sample buffer was used (e.i. without β-mercaptoethanol). For 
assessment of the post-lysis redox state of 800E6 fiber, cells were lysed by 
freeze-thawing and subsequently treatedwith NEM (final concentration of 10 
mM). Western samples were then prepared using nonreducing sample buffer. 
All samples were subjugated to standard sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), with 8% polyacrylamide 
running gels, and subsequent protein transfer to poly (vinylidene fluoride) 
(PVDF) membranes (Immobilon-P transfer membrane; Millipore, Amsterdam, 
The Netherlands) by electroblotting. After immunological probing of the 
blots, horse radish peroxidase (HRP)-conjugated antibodies were detected 
by enhanced chemiluminescence (ECL). Primary antibodies used were mouse 
monoclonal anti-actin (1 : 5000, clone C4; Millipore), goat polyclonal anti-
hexon (1 : 2000, ab19998; Abcam, Cambridge, UK), rabbit polyclonal anti-
penton base (1 : 2000; laboratory made), and mouse monoclonal anti-fiber 
tail (1 : 5000, 4D2; Abcam) (42).   
For 800E6 fiber incorporation analysis, chemiluminescence- exposed X-ray 
films were scanned and the specific signals were quantified by a digital image 
analysis program (ImageJ, version 1.40g; http://rsb.info.nih.gov/ij/).   
immunofluorescence analysis   
For analysis of fiber variant expression in LV-transduced cells, 911.R7Knob 
or 911.800E6 cells were grown on glass coverslips in six-well plates, fixed 
and permeabilized with methanol, and probed with the mouse anti-fiber tail 
primary antibody 4D2 (1 : 1000; Abcam) and a fluorescein isothiocyanate 
(FITC)-conjugated goat anti-mouse IgG antibody. Nuclei were visualized 
by either propidium iodide or 4’,6-diamidino-2-phenylindole (DAPI). Cells 
were mounted in Dabco-glycerol (glycerol, 0.02M Tris-Cl, pH 8.0, and 2.3% 
1,4-diazabicyclo-[2.2.2]- octane) and viewed under a fluorescence microscope. 
elisa-based heR2-ecd binding assays   
To assess the binding of lentivirally expressed 800E6 fiber to HER2-ECD, an 
ELISA was employed. Her2/neu extracellular domain (HER2-ECD; Fox Chase 
Cancer Centre, Philedelphia, PA, USA) (43) or, as a control, BSA was diluted 
in 50 mM carbonate/bicarbonate buffer (pH 9.6) to a concentration of 5 µg/
ml. Subsequently, 100-µl aliquots were added to wells of 96-well Nunc F96 
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Maxisorp plates (Nunc/Sanbio, Uden, The Netherlands). After overnight 
incubation at 4°C, the wells were emptied and blocked with blocking buffer 
[2% BSA, 0.05% Tween 20 in phosphate-buffered saline (PBS)] for 1 h at room 
temperature, and subsequently washed with washing buffer (0.05% Tween 20 
in PBS). Per confluent 10- cm dish, 911 and 911.800E6 cells were resuspended 
in 1.4 ml of PBS and subsequently lysed by freeze-thawing. These freeze-thaw 
cell lysates were serially diluted by first making a one- to two-fold dilution 
in 2 × binding buffer (1% BSA, 0.1% Tween 20 in PBS) and subsequently, 
from this dilution, serial four-fold dilutions in 1 × binding buffer (0.5% BSA, 
0.05% Tween 20 in PBS). The binding buffers were supplemented with 
protease inhibitors. One hundred microliter aliquots of these dilutions were 
then added to the coated wells and left to incubate at room temperature 
for 1 h, after which the wells were washed with washing buffer. The wells 
were subsequently probed with mouse anti-fiber tail antibody (4D2; Abcam) 
diluted 1 : 2000 in 1 × binding buffer. After incubation for 1 h, the wells were 
washed and then incubated for 1 h with HRP-conjugated goat anti-mouse IgG 
antibody diluted 1 : 5000 in 1 × binding buffer. After a final wash, the plates 
were developed with the tetramethylbenzidine (TMB) substrate solution from 
a HIV-1 p24 antigen ELISA kit (ZeptoMetrix Corp) as recommended by the 
manufacturer.   
Another ELISA-based protocol was used to assess the binding of purified 
Ad virions to HER2-ECD. HAdV-5, Ad.ZH, and AdGLΔF/800E6 Fb were serially 
diluted in PBS and 100-µl aliquots of the virus dilutions were added to wells of 
Nunc Maxisorp plates. After overnight coating at 4°C, the wells were washed 
with PBS and blocked with 2.5% BSA, 2.5% protifar (Nutricia, Zoetermeer, 
The Netherlands) in PBS. The wells were then washed with 0.025% Tween 20 
in PBS. Subsequently, wells were incubated with 100-µl aliquots of a 1 ng/µl 
HER2-ECD dilution in 1.25% BSA, 1.25% protifar, 0.025% Tween 20 in PBS. 
Control wells were incubated with mouse monoclonal anti-fiber knob 1D6.14 
antibody (44) (1 : 100; obtained from V. van Beusechem, VU University Medical 
Center, Amsterdam, The Netherlands) or goat polyclonal anti-hexon (1 : 1000, 
ab19998; Abcam). Incubation was overnight at 4°C, after which the plates 
were washed with 0.025% Tween 20 in PBS. The bound primary reagents were 
then probed with corresponding HRP-conjugated secondary reagents, which, 
in the case of primary reagent HER2-ECD, was a goat polyclonal anti-six 
histidine (His-tag) antibody (ab1269; Abcam).   
Slot blot-based HER2-ECD binding Assay  Binding of purified Ad virions to 
HER2-ECD was assessed by a slot blot-based protocol that was adapted from 
a soluble CAR virus-binding assay described by Roelvink et al. (45). Purified 
Ad virions were diluted in PBS and blotted onto a PVDF membrane (Millipore) 
using a slot blot apparatus. After blocking with 2.5% BSA, 2.5% protifar in 
PBS for 2 h, blots were immunologically probed using the same primary and 
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secondary reagents as used in the ELISA-based virus binding assay above. 
Briefly, blots were incubated overnight at 4°C with either HER2-ECD (300 
ng/ml), 1D6.14 (1 : 250), or antihexon antibody (1 : 5000) diluted in PBS 
with 1.25% BSA, 1.25% protifar, and 0.025% Tween 20. Then, after washing, 
incubation followed with the respective HRPconjugates, which, after washing 
again, were detected by ECL.   
ResUlts
Feasibility of a lentiviral vector-based adenovirus fiber-pseudotyp-
ing approach   
Newly-designed, candidate fibers for adenovirus retargeting require 
assessment for their functionality in terms of capsid incorporation capacity, 
target molecule binding, and, ultimately, the ability to mediate target 
cellspecific transduction. For the rapid analysis of modified fiber proteins in 
the context of the viral particle, Jakubczak et al. (26) previously established 
a transient fiber-pseudotyping system based on transient transfection of a 
fiber-expression plasmid followed by infection with a fiber gene-deleted (ΔF) 
Ad vector. In the present study, we explored the practical feasibility of an 
adapted transient fiber-pseudotyping system that relies on lentiviral vector 
transduction, rather than transient transfection, for the expression of novel 
fiber variants in cells (Figure 1). In this approach, expansion of the lentivirally 
transduced cell population and its subsequent large-scale transduction with a 
ΔF Ad vector allows for the derivation of a purified virus preparation suitable 
for the functional testing (in the virus particle context) of newly-designed fibers. 
To establish the feasibility of such a LV vectorbased fiber-pseudotyping 
system we make use of a previously described recombinant fiber termed 
‘R7Knob’ (37). R7Knob is a variant of the HAdV-5 fiber containing only the 
first seven of the 22 shaft repeats. Additionally, in between its shaft and knob 
domains, it harbors a heterologous trimerization domain. Previously shown to 
be capsid incorporable, this fiber variant can serve here to provide proof of 
principle as to whether LV vectors can be used for the generation of stable, 
modified fiber-producing cells that, upon infection with a ΔF vector, will 
sustain production of fiber-pseudotyped progeny virus.   
For the generation of cells stably expressing fiber variants, we made use 
of LV vectors that are based on the self-inactivating, third-generation HIV-1-
derived vectors originally developed by the Trono group and Cell Genesys 
(46,47). These LV vectors (Figure 2A), which are devoid of any HIV-1 coding 
sequences and are thus produced by co-transfection with helper plasmids, 
are self-inactivating by virtue of a deletion of most of the 3’ U3 region. This 
deletion is designed to preclude, upon host cell genome integration of the 
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vector, the production of any RNA other than that promoted by the transgene 
expression cassette (Figure 2A).   
First, prior to transduction experiments with LV vectors, we performed 
DNA transfections with lentiviral vector plasmids for the evaluation of 
different fiber expression cassette configurations (Figure 2B). In normal Ad 
infection, three noncoding exons are spliced to the 5’ end of messenger 
RNAs from the major late transcription unit. This so-called TPL plays a role 
in ensuring viral protein production when general host cell protein synthesis 
is shut down (48,49). Furthermore, TPLcontaining transcripts have also been 
shown to exhibit enhanced translation in the absence of Ad infection (50). 
Therefore, analogous to a previous study by von Seggern et al. (51), we 
included the TPL sequence at the 5’ end of the fiber gene in our expression 
cassettes. Specifically, the complete TPL sequence was inserted immediately 
upstream of the fiber start codon, exactly mirroring the configuration of viral 
late transcripts. Additionally, as shown in Figure 2B, the expression cassettes 
were furnished with an internal ribosomal entry site downstream of the 
fiber gene followed by either genes encoding GFP or NPTII. Evaluation of 
fiber production in cells transfected with these constructs indeed showed 
enhanced expression for the TPL-containing cassettes compared to the TPL-
lacking construct (Figure 2B).   
Next, LV vectors were used to generate cells stably expressing the R7Knob 
fiber variant. With this intent, the E1-complementing cell line 911 (27) was 
transduced with a LV vector containing the TPL-R7Knob-IRES-NPTII cassette 
(Figure 2C). The transduced cell population, termed 911.R7Knob, was first 
passaged at 48 h and subsequently after every four or five days. Selection for 
G418 resistance, conferred to the cells by the NPTII gene, was initiated after 
the first passage. Western blot analysis of samples from different time points 
after transduction demonstrated that, once NPTII-positive cells had been 
selected for, R7Knob levels were sustained over time. By immune fluorescence, 
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Figure 1. a lentiviral vector-based adenovirus fiber-pseudotyping system for rapid 
testing of new fiber variants in the virus particle context. Cells stably expressing a 
recombinant fiber of interest are generated by a small scale transduction with a lentiviral 
vector (LV.recF). Expansion of these cells followed by a large-scale infection with a fiber 
gene-deleted Ad vector equipped with wild-type fibers (Ad∆F/wt F) allows for the derivation 
























































































Figure 2. Usage of lentiviral vectors for the generation of packaging cells employable 
for fiber-pseudotyping of ad. (a) Schematic outline of the lentiviral vector system. 
The lentiviral vectors employed are based on self-inactivating, third-generation HIV-I-
derived vectors (46,47) and are further optimized for enhanced integration capacity and 
transgene expression (35). RSV, Rous sarcoma virus promoter; ∆U3, deletion of (most of) 
the U3 region; RRE, HIV-I Rev responsive element; cPPT, HIV-I central polypurine tract; 
CMV, human cytomegalovirus promoter; PRE, human hepatitis B virus post-transcriptional 
regulatory element; wavy arrows, RNA transcripts; y, packaging signal. (B) Effect of TPL 
sequence inclusion in fiber expression cassettes. Western blot analysis was conducted on 
cells transfected with lentiviral vector plasmids with transgenic configurations as depicted. 
TPL, tripartite leader; IRES, internal ribosomal entry site; GFP, green fluorescent protein; 
NPTII, neomycin phosphotransferase II. (c) Western blot analysis of lentiviral vector-
mediated R7Knob expression at different time points post-infection. 911.R7Knob cells 
were generated by transduction with a lentiviral vector with the indicated transgenic 
configuration and were maintained under G418 selection pressure from day 2 post-infection 
onward. (d) Immunofluorescence analysis of lentiviral vector-mediated R7Knob expression. 
Cells were probed with anti-fiber tail antibody followed by a FITC-conjugated secondary 
antibody (top). Nuclei were visualized by staining with propidium iodide (bottom). 911.
R7Knob cells had been selected for G418 resistance prior to the analysis. (e) Comparison, 
by western blot analysis, of the R7Knob expression levels achieved in 911.R7Knob with 
fiber expression levels found in established fiber-complementing cell lines 293-Fb (28) and 
633 (25), and 911 cells at 32 h post-infection with HAdV-5. (F) Western analysis on purified 
virus particles demonstrating capsid incorporation of R7Knob. Per lane, 4 × 109 particles 
were loaded of HAdV-5 or of viruses obtained by trans-complementation of a fiber-gene 
deleted Ad vector by final amplification in 293-Fb, 633, or 911.R7Knob.
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it was further shown that almost all G418 resistant cells were positive for the 
R7Knob fiber, that cell-to-cell variability in expression levelwas minimal, and, 
importantly for adenovirus packaging purposes, that sub-cellular localization 
of the fiber variant was nuclear (Figure 2D).   
To further evaluate the feasibility of a LV vector-based fiber-pseudotyping 
system, we subsequently compared the level of R7Knob expression achieved 
by LV transduction with the levels of fiber expression obtained in the previously 
described fiber-expressing cell lines 293-Fb and 633, both of which have been 
successfully used in the past for fiber-complementation experiments (25,28). 
A western blot analysis featuring 911.R7Knob set side by side with these 
fiber-expressing cell lines and, as additional reference, 911 cells infected with 
HAdV-5, showed that expression of the R7Knob fiber was of an intermediate, 
but substantial level (Figure 2E). This result, together with the data above, 
demonstrates that lentiviral vectors can be used for the generation of a 
homogenous population of cells constitutively expressing a fiber variant, with 
the fiber expression level being within a range suitable for the purpose of 
fiber-complementation.   
Final validation of this LV-based approach was sought to be provided by a 
fiber-pseudotyping experiment that entails infection of the 911.R7Knob cells 
by a fiber gene-deleted Ad vector. For this purpose, an E1-, E3-, and fiber 
gene-deleted HAdV-5-based vector, AdGLΔF/F, was generated. This vector, 
having been produced on wild-type fiber expressing cells, was transiently 
loaded with normal fibers (hence the additional ‘F’ in its designation), 
enabling it to infect cells via interaction with CAR. Von Seggern et al. (25,52) 
previously showed that a vector carrying an essentially similar fiber gene-
deletion served well in the context of fiber-pseudotyping experiments. For 
the generation of a large-scale R7Knob-pseudotyped virus preparation, 911.
R7Knob cells were expanded, readily, to obtain 20 semi-confluent 175-cm2 
flasks that were subsequently used for infection with AdGLΔF/F. After 72 h, 
virus progeny was harvested and purified by a standard CsCl gradient-based 
protocol, yielding a purified AdGLΔF/R7Knob preparation. Subsequently, 
to evaluate capsid incorporation capacity of the R7Knob fiber supplied by 
the complementing cells, AdGLΔF/R7Knob was subjected to western blot 
analysis alongside with HAdV-5 and two AdGLΔF/F preparations (Figure 
2F). The results clearly show that the R7Knob fiber was incorporated into 
the AdGLΔF/R7Knob viral particles and, moreover, indicate that the level of 
R7Knob incorporation was considerable in relation to the fiber content of 
the wildtype fiber-bearing viruses. Thus, these findings demonstrate a case 
of successful fiber-pseudotyping of Ad involving lentiviral vectors for the 
generation of fibervariant producing cells.   
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design, expression, and functional characterization of a novel 
liganded fiber chimera incorporating an intrinsically stable, tumor 
antigen-directed scFv   
With the fiber-pseudotyping system described above in place, we subsequently 
used it for the functional assessment of a new candidate retargeted fiber. In 
this regard, we sought to functionally test a chimeric fiber molecule harboring 
a scFv directed against tumor antigen HER2/neu (39,53,54). Importantly, this 
particular single chain antibody, named scFv800E6, was specifically chosen 
for its intrinsic capability to fold efficiently and functionally in a reducing 
environment, a recognized prerequisite for bona fide assembly into the Ad 
capsid as part of a genetic capsid protein fusion (37,55–57).   
In the design of the fiber chimera harboring scFv800E6, we paralleled a 
genetic fiber modification strategy implemented previously by us and others 
in which the fiber knob domain is removed and its intrinsic functions (i.e. 
trimerization and receptor binding) uncoupled and, respectively, restored by 
the introduction of a heterologous trimerization motif and a ligand domain 
(21,24,37,55). Specifically, the ‘800E6 fiber’ constructed for the present study 
was a genetic fusion of the tail and first shaft repeat of the HAdV-5 fiber 
protein, the coiled coil segment 13 and the trimerization domain ‘foldon’ 
of the bacteriophage T4 fibritin protein, and, separated by a spacer, the 
scFv800E6 moiety (Figure 3A).   
In our scheme to test this new fiber for Ad targeting capability, we first set 
out to generate and characterize cells stably expressing this new, liganded 
fiber chimera. With this objective, 911 cells were transduced with a LV vector 
containing an 800E6 fiber expression cassette functionally arranged in the 
same way as that successfully used before to express the R7Knob fiber (Figure 
3A). Subsequent probing for the fiber tail by immune fluorescence showed 
that, before initiation of selection with puromycin, the LV-transduced cell 
population (911.800E6) was almost 100% positive for 800E6 fiber expression 
and exhibited minimal cell-tocell variability (Figure 3B). With respect to 
localization, however, expression appeared to be somewhat aberrant because 
the 800E6 fiberwas found both in the nucleus and the cytoplasm (whereas 
wild-type fiber normally localizes only to the nucleus).   
Subsequently, the lentivirally expressed 800E6 fiber was characterized 
with respect to its ability to trimerize, which is considered a key functional 
requirement for insertion into the capsid. In this regard, the T4 fibritin foldon 
domain had previously been shown to be successful in conferring trimerization 
ability to knobless, chimeric fiber-fibritin proteins (23). Although outfitted with 
this same foldon domain, the 800E6 fiber is not entirely structurally similar to 
these fiber-fibritin molecules and therefore its capacity to trimerize had yet 
to be determined. To this end, boiled and nonboiled lysates of 911.800E6 
and the wild-type fiber-expressing 633 cells were analysed, under reducing 
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conditions, by SDS-PAGE and immunoblotting (Figure 3C). For both fiber 
types, the nonboiled samples exhibited fiber tail-specific detection of proteins 
that were three times the predicted size of the respective fiber monomers, 
indicating the presence of fiber trimers. Furthermore, when the samples were 
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Figure 3. design, lv-mediated expression, and functional characterization of 800e6 
fiber. (a) Transgene construct configuration for lentiviral vector-mediated expression 
of 800E6 fiber. The components of the 800E6 fiber gene are depicted to scale. PURO, 
puromycin resistance gene; tail, fiber tail domain (44 amino acids); R, fiber shaft first repeat 
(15 amino acids) followed by residues Gly and Met; S13, fibritin coiled coil segment 13 
(39 amino acids); fld, fibritin foldon domain (30 amino acids); x, spacer (25 amino acids), 
VH and VL, variable fragments of monoclonal antibody 800E6 (53) heavy and light chain, 
respectively; y, (G4S)3 flexible linker; z, additional C-terminal residues (10 amino acids). 
(B) Immunofluorescence analysis of lentiviral vector-mediated 800E6 fiber expression. 
Cells were probed with anti-fiber tail antibody followed by a FITC-conjugated secondary 
antibody (top). Nuclei were visualized by staining with DAPI (bottom). 911.800E6 cells had 
not been selected for puromycin resistance prior to the analysis. (c) Western analysis of the 
lentivirally expressed 800E6 fiber protein. Reduced nonboiled (nb) and boiled (b) samples 
of 911.800E6 and, as a wild-type fiber control, 633 cell lysates were loaded for SDS-PAGE. 
Western blots were probed by anti-fiber tail antibody. (d) Binding experiment to assess the 
antigen recognition capability of 800E6 fiber. HER2-ECD or an irrelevant protein control 
(BSA) were immobilized in the wells of an ELISA plate and subsequently incubated with 
dilution ranges of freeze-thaw cell lysates of either 911.800E6 or control cells. Bound 
800E6 fiber was detected by immunological probing using anti-fiber tail antibody and a 
HRP-conjugated secondary antibody followed by development with TMB substrate and 
absorbance reading at 450 nm.
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to their respective fiber monomers. Thus, the results obtained show that the 
800E6 fiber, similar to the control wild-type fiber, was able to form detergent 
and reducing agent-resistant, heat-liable trimers.   
In these preliminary characterizations of the 800E6 fiber, an all-important 
query was whether the scFv constituent had preserved its functionality with 
respect to antigen binding. To answer this question, we conducted an ELISA 
experiment that employed the extracellular domain of Her2/neu (HER2-ECD) 
(Figure 3D). Immobilized HER2-ECD and, separately, an irrelevant protein (BSA) 
were incubated with freeze-thaw cell lysates of the 800E6 fiber expressing 
cells, 911.800E6, or 911. With subsequent probing for the fiber tail, this assay 
demonstrated that the 800E6 fiber was able to bind to HER2-ECD, whereas 
no affinity for BSA could be detected.   
Taken together, these experiments demonstrate that the 800E6 fiber 
maintains the important properties of trimerization capability and antigen 
recognition, suggesting the suitability of this chimeric fiber for Ad capsid 
incorporation and vector targeting.   
Functional assessment of the liganded fiber chimera in the context 
of fiber-pseudotyped ad particles   
The essential step in testing this new scFv-harboring chimeric fiber was to 
evaluate it for capsid incorporation efficiency and for functionality in the 
capsid-incorporated context. For this purpose, we put into service the fiber 
pseudotyping system established in the present study to generate, via large-
scale infection of 911.800E6 cells with AdGLΔF/F, a CsCl purified stock of 
‘AdGLΔF/800E6 Fb’, a fiber gene-deleted Ad vector transiently loaded with 
the 800E6 fiber.   
The chimeric fiber loadwas investigated by western blot analysis of 
purified AdGLΔF/800E6 Fb and, as a control, wild-type HAdV-5 virions (Figure 
4A). Qualitatively, this experiment demonstrated that AdGLΔF/800E6 Fb 
incorporates the full-size 800E6 fiber. However, quantification of fiber content 
by normalization to hexon shows that the chimeric fiber load in AdGLΔF/800E6 
Fb is considerably lower than that of wild-type fiber in HAdV-5. Digital image 
analysis of chemiluminescence-exposed film scans showed an 800E6 fiber 
incorporation level of approximately 12%. This analysis therefore revealed 
gravely impaired capsid incorporability of the 800E6 fiber.   
Because the 800E6 fiber was shown to be present, albeit at a sub-
stoichiomeric level, in the fiber-pseudotyped vector particles, it could, in 
principle, serve to mediate vector binding to its target antigen, Her2/neu. 
Therefore, we investigated the functionality of the capsid-incorporated 800E6 
fiber by performing a slot blot-based, HER2-ECD binding assay (Figure 4B). 
Specifically, membrane immobilized virus particles were incubated with 
HER2-ECD, after which (virus-) bound HER2-ECD was detected by virtue of a 
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fused histidine-tag. In this assay, negative and positive control viruses were 
represented, respectively, by HAdV-5 and Ad.ZH, the latter of which bears a 
recombinant fiber that genetically incorporates, in the HI loop of the knob 
domain, two copies of a Her2/neu specific ‘affibody’ termed ZH (29). This 
affibody-containing fiber had previously been shown to mediate Ad vector 
binding to HER2-ECD and therefore appropriately serves as a positive control 
in the present study for binding functionality in the capsid-incorporated 
context. The results of this slot-blot experiment indeed demonstrate Ad.ZH 
binding to HER2-ECD. However, no binding of AdGLΔF/800E6 Fb to this 
target could be detected.   
We subsequently sought to confirm the negative outcome for HER2-ECD 
binding obtained above by employing another technique. Accordingly, we 










































Figure 4. Functional assessment of the 800e6 fiber in the context of fiber-pseudotyped 
ad particles. (a) Western analysis on purified virus particles to assess the capsid 
incorporation capacity of 800E6 fiber. Of HAdV-5 and AdGL∆F/800E6 Fb, 2 × 1010 and 
4.6 × 1010 CsCl-purfied particles were loaded, respectively. The depicted incorporation 
level of 800E6 fiber in AdGL∆F/800E6 Fb (in relation to wild-type fiber load in HAdV-5) 
was calculated using digitally quantified hexon- and fiber-specific signals. (B) Slot-blot-
based binding experiment to assess the antigen binding capacity of 800E6 fiber in the 
capsid-incorporated context. CsCl-purified HAdV-5, Ad.ZH, and AdGL∆F/800E6 Fb were 
blotted to a PVDF membrane (2 × 109 viral particles per slot) and subsequently incubated 
with either HER2-ECD, anti-fiber knob antibody, or anti-hexon antibody. Bound primary 
reagents were detected using appropriate HRP-conjugated antibodies, which were 
subsequently detected by ECL. Serving as negative and positive controls in this experiment 
are, respectively, HAdV-5 and Ad.ZH, the latter of which genetically incorporates a fiber 
carrying HER2-ECD-specific affibody ligands in its knob domain (29).
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wells with the viruses under investigation, subsequent incubation with 
HER2-ECD, and, finally, detection of bound HER2-ECD using an anti-His 
tag antibody (Figure 5). The assay showed that, although Ad.ZH is clearly 
positive for binding, there is no indication that AdGLΔF/800E6 Fb can bind to 
HER2-ECD. These results thus corroborate those achieved with the slot-blot 
based method.   
In conclusion, the 800E6 fiber, although proven to exhibit target binding 
functionality when produced in cells (Figure 3D), was found unable to 
achieve (detectable) target binding in the Ad capsid-incorporated context 
(Figures 4B and 5).   
analysis of intra- and extracellular redox states reveals aberrant 
folding of the liganded fiber chimera   
The encountered impediments to functional capsid incorporation of 800E6 
fiber could point towards folding and/or solubility issues, especially in light 
of the fact that cellular localization of this fiber appeared to be aberrant 
(Figure 3B). Therefore, to obtain more clues with respect to the ability of 
800E6 fiber (and in particular its scFv constituent) to fold properly, we sought 
to investigate its redox state. On this topic, scFv800E6 had previously been 
found to be functionally folded when produced within a reducing environment 
(39,53,54), a property on which the candidacy for being part of a capsid 
incorporable fiber chimera was based. This preserved functionality suggests 
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Figure 5. elisa-based binding experiment to assess antigen binding capacity of 
capsid-incorporated 800e6 fiber. CsCl-purified HAdV-5 (negative control), Ad.ZH 
(positive control), and AdGL∆F/800E6 Fb were immobilized on an ELISA plate and probed 
with either anti-hexon antibody (left graph), anti-fiber knob antibody (middle graph), or 
HER2-ECD (right graph). Bound primary reagents were detected using appropriate HRP-
conjugated antibodies, followed by development with TMB substrate and absorbance 
reading at 450 nm.
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superfamily canonical intradomain disulfide bridges, of which this scFv has 
the potential to form two per polypeptide.   
We initially set out to demonstrate that, as expected, the intracellular 
800E6 fibers are devoid of disulfide bridges. To address this, a western blot 
experiment was conducted with samples representing the intracellular (or 
‘pre-lysis’) redox state of 633 and 911.800E6 cells (Figure 6A, left panel). 
These samples were obtained by lysing cells in nonreducing conditions in 
the presence of NEM, an alkylating agent that nonreversibly modifies non-
oxidized cysteine residues, and thereby precludes the formation of new 
disulfide bonds, at the same time as leaving intact those already formed. 
As a reference, non-NEM treated cells were also analysed, both under 
nonreducing and reducing conditions (Figure 6A, middle and right panels, 
respectively). Analysis of the protein samples representing the intracellular 
state of 911.800E6 cells gave bands corresponding to the reduced-state 
monomer and trimer sizes of 800E6 fiber, indicating that, within the cell, 
800E6 fiber is indeed present in a reduced state.   
The analyses further revealed, however, that, in the non-NEM treated, 
nonreduced protein samples, the 800E6 fiber is present (even when boiled) in 
much-larger-than- trimer-sized multimers (Figure 6A, middle panel), indicating 
a high occurrence of interpolypeptide (and probably intertrimer) disulfide 
linkages. By contrast, such large covalent meshes were not observed for the 
control samples with wild-type fiber.   
These observations may implicate that many of the fiber-incorporated 
scFv moieties are actually improperly folded; a misfolded state would allow 
for the formation of noncanonical, intermolecule disulfide bridges upon 
entrance to an oxidative milieu. To determine whether this implication 
holds true, we checked whether the observed intermolecule meshes arose 
immediately upon cell lysis and not artifactually at a later stage in the western 
blot procedure. To this end, a nonreducing Western blot was conducted with 
samples representing the post-lysis redox state of 911.800E6 cells (Figure 6B). 
In this case, the cells were first lysed by freeze-thawing and then immediately 
treated with NEM to fix their redox state (i.e. to prevent the occurrence of any 
disulfide bridges at a later stage). The analysis shows, for both the nonboiled 
and the boiled ‘post-lysis’ sample, that the majority of the 800E6 fibers are 
in the ‘aggregated’ state, indicating that the formation of intermolecular 
disulfide bridges already occurs quickly after, or during, cell lysis.   
Thus, collectively, the results obtained in the present study demonstrate 
that the 800E6 fiber, although intracellularly present in a completely reduced 
state, has a strong propensity to form intermolecule disulfide bridges upon 
encountering a shift to an oxidative environment. This tendency to form 
intermolecule bonds rather than the canonical intradomain disulfide bridges 
indicates that at least a sub-population of the scFv moieties within 800E6 




A long-standing goal in adenovirus-mediated gene therapy is the 
development of systemically deliverable genetically retargeted Ad vectors. 
In this regard, many previous efforts rationally focused on modification of 
the Ad fiber protein in order to achieve abrogation of native interactions of 
the fiber with cellular receptors and, furthermore, to realize the introduction 
of novel cell specificities. With the recent elucidation of the mechanisms 
responsible for liver entrapment of systemically-administered HAdV-5 vectors 
and the consequent opening of new genetic and pharmacological avenues 
to improve Ad bioavailability (58,59), genetic modification of the fiber holds 
all the more promise for the achievement of selective transduction of target 
cells in an in vivo context. Therefore, efficient means are required to assess 
















Figure 6. Western blot analysis to assess the redox state of 800e6 fiber before and 
after cell lysis. (a) Analysis of the pre-lysis redox states of 800E6 fiber and wild-type fiber. 
Nonreduced samples representing the pre-lysis redox states (left panel) of 800E6 fiber-
expressing (911.800E6) and wild-type fiber-expressing (633) cells were made by cell lysis 
in the presence of NEM. Additionally, nonreduced (middle panel) and reduced samples 
(right) were included, with the latter providing a reference to the molecular weights of the 
reduced-state monomers and trimers of 800E6 and wild-type fiber. Of all these samples, 
both nonboiled (nb) and boiled (b) aliquots were loaded for SDS-PAGE. Western blots 
were probed with anti-fiber tail antibody. Of note, to allow for the detection of excessively 
high-molecular-weight proteins (aggregates), the stacking gel had not been removed prior 
to the electroblotting. The portion of the blots containing proteins transferred from the 
stacking gel is indicated by an asterisk. (B) Post-lysis redox state. Nonreduced samples 
representing the post-lysis redox state of 800E6 fiber-expressing cells (911.800E6) were 
made by treatment with NEM after cells were lysed by freeze-thawing. Western blotting 
procedures were performed as in the above experiment.
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properties to Ad vectors. However, the conventional method of testing a new 
fiber is a rather time-consuming process, involving the generation of a fiber-
modified Ad genome and the subsequent rescuing of the fiber-modified virus. 
In the present study, a new, lentiviral vector-based adenovirus fiber-
pseudotyping system is presented as a means for expedited functional 
screening of new fiber variants designed to retarget Ad. This system entails 
the use of lentiviral vectors to generate ‘packaging cells’ stably expressing 
fibers of interest. Infection of these cells with a fiber gene-deleted adenovirus 
vector subsequently allows for the incorporation of the new fibers into the 
capsids of progeny virus. This fiber-pseudotyping approach enables new fiber 
variants to be rapidly tested (without the need for genomically modifying Ad) 
for capsid incorporation efficiency and for functionality (with respect to target 
binding and, ultimately, the capability to mediate specific transduction) in the 
context of Ad viral particles.   
Our system elaborates on a previous endeavor by Jakubczak et al. (26) that 
involves large-scale transient transfection with fiber expression constructs and 
subsequent coordinated infection of the transfected cells with an ΔF Ad vector 
(18,26). Similar to this transient transfection/infection system, the LV-based 
system described in the present study is a significantly quicker and less labour-
consuming way to evaluate modified fibers compared to the conventional 
method involving the rescue of viruses genomically incorporating the new 
fiber. However, because this new system entails an additional step (i.e. the 
generation of lentiviral vectors), it is evident that it does not fully match the 
transfection-based method in this respect. Nonetheless, for a number of 
reasons, the lentivirus-based system is considered to be a valuable addition 
to the repertoire of tools at the disposal of investigators seeking to test new 
fibers. First, in contrast to the transfection-based method, the lentivirus-
based system allows for cell manipulations (i.e. for achieving fiber expression) 
to be carried out at a small scale and without the need for close coordination 
with the subsequent fiber-pseudotyping infection. Second, fiber variant-
expression by means of lentiviruses proves to be associated with low cell-
to-cell variability, is stable over multiple passages, and can be selected for. 
Therefore, taken together, the lentivirus-based system provides a relatively 
facile and robust procedure for reliably generating a homogenous population 
of cells suitable for large-scale fiber-pseudotyping.   
In our demonstration of the lentiviral vector-based Ad fiber-pseudotyping 
system, we made use of R7Knob, a seven-shaft repeat-containing Ad5-based 
fiber. This fiber served to establish that lentiviral vectors can be used to 
generate fiber-variant producing cells and, furthermore, that such cells can 
achieve transient fiber-pseudotyping of Ad. However, because R7Knob is a 
non-retargeted fiber, it could not serve to illustrate directly the concept of 
using transiently fiber-pseudotyped vector stocks for the functional evaluation 
of candidate de- and/or retargeted fibers. The feasibility of this concept, 
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however, has already been demonstrated previously in several studies by 
others. First, Seggern et al. (25) reported that fiber-pseudotyping with a 
chimeric fiber (i.e. consisting of the Ad5 fiber tail and shaft fused to the Ad3 
fiber knob) resulted in infection being directed away from CAR and redirected 
to the Ad3 receptor. Furthermore, Jakubczak et al. (26) identified putative 
CAR-binding ablating mutations by assessment of transduction abilities of 
transiently fiber-pseudotyped vectors. Finally, in two recent studies, which 
both adopted the ‘transient transfection/infection’ system of Jakubczak et al. 
(26), pseudotyping with different types of liganded fibers was shown to result 
in accordant changes in vector tropism (18,55).
In the second part of the present study, the newly established LV-based fiber-
pseudotyping system was employed to evaluate a new fiber variant harboring 
a scFv as targeting ligand. In this regard, for endowing viral vectors with new 
target cell specificity, scFvs represent an important class of ligands. This is 
especially the case in the field of enveloped viral vector-retargeting, in which 
genetic fusion of scFvs to viral envelope proteins has, in multiple instances, 
resulted in the successful generation of viruses with modified cell specificities 
(60–63). However, because of the distinct natural biosynthetic routes of Ad 
capsid proteins and antibody fragments, scFvs are not considered as the 
optimal type of targeting moiety when it comes to adenovirus retargeting 
through genetic capsid modifications (37,55). As the assembly of Ad particles 
takes place in the nucleus, scFv-based ligands genetically fused to Ad capsid 
proteins are forced to fold in an unnatural environment in which secondary 
modifications associated with the secretory route (e.g. intra-domain disulfide 
bridges) are excluded. This could lead to improper or unstable folding of the 
scFv moiety and, consequently, to further complications as loss of antigen 
recognition capacity, aggregation, and disturbance of the capsid assembly 
process. On this matter, in a previous study, attempts to retarget Ad by 
genetically fusing a scFv or other disulfide bridge-containing ligands to the 
Ad fiber protein were unsuccessful and identified problems with respect to 
solubility, folding, and incorporation efficiency (37).   
To overcome the difficulties associated with the genetic Ad capsid 
incorporation of antibody-based ligands, recent focus in the field has been 
on the use of a class of particularly stably structured scFvs (56,57). These 
scFvs, termed intrabodies or hyper-stable scFvs, have been selected for their 
solubility and stability under the reducing conditions of the cytosol (64–68) 
and therefore are considered as promising candidates for functional and 
stable folding as part of a genetic Ad capsid protein fusion. Indeed, two 
such stabilized scFvs were successfully displayed on Ad particles by genetic 
anchorage to, respectively, fiber and pIX (56,57). Importantly, these capsid-
incorporated scFvs were shown to have retained their functionality with 
respect to specific antigen binding.   
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In view of the favorable results obtained with stabilized scFvs, we 
hypothesized that scFv800E6 (39,53,54), an intrinsically stable scFv directed 
to the important tumor associated antigen Her2/neu (69), would also be suited 
for the purpose of genetic Ad capsid incorporation. This scFv was previously 
found to possess, by nature, a structural framework of particular robustness, 
and it was observed to functionally fold in a reducing environment in a variety 
of expression platforms (39,53,54). Thus, for reasons of both therapeutic 
relevance and technical feasibility, scFv800E6 represents an interesting moiety 
to test for functionality as a targeting ligand genetically displayed on an Ad 
capsid protein. Therefore, analogous to previously established genetic fiber 
modification strategies (21,23,24), we chose to genetically insert scFv800E6 
into a de-knobbed, extrinsic trimerization domain-containing fiber scaffold.   
Functional assessment of lentivirally expressed 800E6 fiber demonstrated 
that this new chimeric fiber was capable of exerting two important functions 
that are considered as a key utility in genetic Ad targeting, namely trimerization 
and target binding. The intactness of these functionalities suggests that the 
respective responsible functional domains, fibritin foldon and scFv800E6, can 
both fold correctly in the context of this particular chimeric fiber configuration. 
The indication that scFv800E6 is able to acquire a functional fold as part 
of an Ad capsid fusion protein would further illustrate the stability and 
versatility previously reported for this scFv (39,53,54). Thus, these preliminary 
characterizations suggested the suitability of the 800E6 fiber for Ad capsid 
incorporation and vector targeting.   
However, functional assessment of the 800E6 fiber in Ad particles revealed 
that this fiber is significantly impaired in its capsid incorporation ability 
(Figure 4A). Moreover, in two independent binding experiments, 800E6 fiber-
pseudotyped Ad particles failed to detectably bind HER2-ECD (Figures 4B and 
5). These negative outcomes, which we suspected to indicate the improper 
folding of the scFv constituent of the 800E6 fibers, prompted analysis of the 
pre- and post-lysis redox states of the 800E6 fiber (Figure 6). This led to the 
observation that 800E6 fiber molecules have the tendency, when subjected 
to an oxidative environment, to form large covalent aggregates. We found 
that 800E6 fibers, although in a completely reduced state in the intracellular 
environment, immediately form intermolecular disulfide bridges upon a shift, 
by cell lysis, to the extracellular (oxidative) milieu. This finding suggests the 
poor formation of the canonical intra-domain disulfide bridges after cell lysis, 
which would be indicative of improper, unstable folding of the scFv moiety in 
the context of the 800E6 fiber. Taking all this into consideration, we are led to 
speculate that, in the HER2-ECD-binding experiment with loose 800E6 fibers 
(Figure 3D), it was only a subpopulation of functionally folded scFvs (amid 
perhaps a majority population of misfolded domains) that accounted for the 
observed target binding capacity.   
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It is suspected that the observed impairment in capsid incorporation 
ability of the 800E6 fiber is, to a large extent, directly consequential to the 
solubility and folding issues identified above. However, other factors most 
likely contribute to the observed low level of 800E6 fiber loading. For 
example, the structure of the fiber scaffold itself and/or its combination with 
the incorporated scFv could be a limitation to optimal display on the capsid. 
Furthermore, the observed low 800E6 fiber content in viral particles might 
also be partially attributable to a loss of incorporated fibers as a result of the 
physical strains imposed by post-lysis association (via disulfide bonds) with 
other viral particles, loose fibers, or other proteins with accessible cysteines.  
With respect to the failure of 800E6 fiber-pseudotyped Ad particles to 
detectably bind HER2-ECD, we recognize two chief causal factors. The first is 
the much-lower-than-stoichiometric presence of 800E6 fiber in the capsid and 
the second is the suspected nonfunctional folding of a considerable fraction 
of the scFv domains.   
The folding issues identified in the present study for the fiber-incorporated 
scFv800E6 appear to be representative of generic problems considered to 
be inherent to the use (as Ad targeting ligands) of complex proteins that 
contain disulfide bridges under natural conditions (37,55). Thus, in relation 
to the two artificially stabilized scFvs that have recently been reported to be 
functionally displayable on Ad (56,57), scFv800E6 appears a less favorable 
ligand for the purpose of genetic Ad targeting. Of relevance, in contrast to 
those successfully incorporated scFvs, scFv800E6 had not been specifically 
engineered for intracellular stability but was found to be particularly robust by 
nature (39,53,54). Therefore, considering this difference in origin, it is possible 
that the relatively unfavorable results obtained for 800E6 fiber are, after all, 
a result of a lesser stable structure of scFv800E6 compared to artificially 
stabilized scFv frameworks.   
In conclusion, in the present study, we establish a new LV vector-based 
transient adenovirus fiber-pseudotyping system that provides a convenient 
method for testing newly-designed retargeted fibers. Using this fiber testing 
system, a particular combination of a fiber scaffold with an incorporated 
antibody-based ligand was found not to be suited for Ad retargeting. 
Furthermore, as a result of being confronted with problems associated with 
solubility, folding, and functional capsid display of the new liganded chimeric 
fiber, the present study provides support for the existing doubts on the 
usefulness (i.e. in the context of genetic Ad targeting) of naturally occurring 
ligands that depend on disulfide bridges for stability and functionality. In this 
respect, the employment of a means to artificially optimize scFvs for stability 
in a reducing milieu comprises a very rational and promising approach to 
overcome fundamental incompatibilities between the natural biosynthetic 
routes of antibodies and adenovirus capsid proteins (64–68). However, 
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possibly the most suitable candidates for genetic Ad capsid incorporation are 
the new classes of non-immunoglobulin, artificial ligands (e.g. affibodies and 
designed ankyrin repeat proteins) made from existing protein scaffolds by 
randomization at selected amino acid positions, followed by selection against 
desired targets (30,70,71). Because of their biosynthetic compatibility with 
Ad capsid components and their low structural complexity, these molecules 
represent likely candidates for serving as genetic Ad capsid incorporable 
ligands, as already exemplified for affibodies in a number of previous studies 
(29,55,72).   
acKnoWledgements
We thank Jurgen Seppen for providing plasmids of the lentiviral vector 
system, Ralph Willemsen for a fiber-fibritin fusion construct, Dan von Seggern 
formaking the 633 cell line available, Monika Lusky for the 293-Fb cell line, 
Victor van Beusechem for the 1D6.14 antibody, Patrizia Galeffi for helpful 
suggestions during the preparation of the manuscript, and Kaori Suzuki for 
critically reading the manuscript. This work was supported in part by the 
European Union through the 6th Framework Program GIANT (contract no. 
512087).
ReFeRences
1. Glasgow, J.N., Everts, M. and Curiel, 
D.T. (2006) Transductional targeting of 
adenovirus vectors for gene therapy. 
Cancer Gene Ther., 13, 830-844.
2. Legrand, V., Leissner, P., Winter, A., Me-
htali, M. and Lusky, M. (2002) Transduc-
tional targeting with recombinant ad-
enovirus vectors. Curr.Gene Ther., 2, 
323-339.
3. Bergelson, J.M., Cunningham, J.A., 
Droguett, G., Kurt-Jones, E.A., Krithiv-
as, A., Hong, J.S., Horwitz, M.S., Crow-
ell, R.L. and Finberg, R.W. (1997) Iso-
lation of a common receptor for Cox-
sackie B viruses and adenoviruses 2 
and 5. Science, 275, 1320-1323.
4. Nicklin, S.A., Wu, E., Nemerow, G.R. 
and Baker, A.H. (2005) The influence of 
adenovirus fiber structure and function 
on vector development for gene thera-
py. Mol.Ther., 12, 384-393.
5. Wu, H. and Curiel, D.T. (2008) Fiber-
modified adenoviruses for targeted 
gene therapy. Methods Mol.Biol., 434, 
113-132.
6. Vellinga, J., Rabelink, M.J., Cramer, 
S.J., Van den Wollenberg, D.J., Van 
der, M.H., Leppard, K.N., Fallaux, F.J. 
and Hoeben, R.C. (2004) Spacers in-
crease the accessibility of peptide lig-
ands linked to the carboxyl terminus 
of adenovirus minor capsid protein IX. 
J.Virol., 78, 3470-3479.
7. de Vrij, J., Uil, T.G., van den Hengel, 
S.K., Cramer, S.J., Koppers-Lalic, D., 
Verweij, M.C., Wiertz, E.J., Vellinga, 
J., Willemsen, R.A. and Hoeben, R.C. 
(2008) Adenovirus targeting to HLA-
A1/MAGE-A1-positive tumor cells by 
fusing a single-chain T-cell receptor 
with minor capsid protein IX. Gene 
Ther..
8. Dmitriev, I.P., Kashentseva, E.A. and 
Curiel, D.T. (2002) Engineering of ad-
137AdenovIrus fIber-pseudotypIng
4
enovirus vectors containing heterolo-
gous peptide sequences in the C ter-
minus of capsid protein IX. J.Virol., 76, 
6893-6899.
9. Wu, H., Han, T., Belousova, N., Kras-
nykh, V., Kashentseva, E., Dmitriev, I., 
Kataram, M., Mahasreshti, P.J. and Cu-
riel, D.T. (2005) Identification of sites in 
adenovirus hexon for foreign peptide 
incorporation. J.Virol., 79, 3382-3390.
10. Hedley, S.J., Chen, J., Mountz, J.D., Li, 
J., Curiel, D.T., Korokhov, N. and Ko-
vesdi, I. (2006) Targeted and shielded 
adenovectors for cancer therapy. Can-
cer Immunol.Immunother., 55, 1412-
1419.
11. Krasnykh, V.N., Mikheeva, G.V., Doug-
las, J.T. and Curiel, D.T. (1996) Genera-
tion of recombinant adenovirus vectors 
with modified fibers for altering viral 
tropism. J.Virol., 70, 6839-6846.
12. Stevenson, S.C., Rollence, M., Mar-
shall-Neff, J. and McClelland, A. (1997) 
Selective targeting of human cells by a 
chimeric adenovirus vector containing 
a modified fiber protein. J.Virol., 71, 
4782-4790.
13. Gall, J., Kass-Eisler, A., Leinwand, L. 
and Falck-Pedersen, E. (1996) Adeno-
virus type 5 and 7 capsid chimera: fiber 
replacement alters receptor tropism 
without affecting primary immune neu-
tralization epitopes. J.Virol., 70, 2116-
2123.
14. Wickham, T.J., Roelvink, P.W., Brough, 
D.E. and Kovesdi, I. (1996) Adenovirus 
targeted to heparan-containing recep-
tors increases its gene delivery efficien-
cy to multiple cell types. Nat.Biotech-
nol., 14, 1570-1573.
15. Wickham, T.J., Tzeng, E., Shears, 
L.L., Roelvink, P.W., Li, Y., Lee, G.M., 
Brough, D.E., Lizonova, A. and Koves-
di, I. (1997) Increased in vitro and in 
vivo gene transfer by adenovirus vec-
tors containing chimeric fiber proteins. 
J.Virol., 71, 8221-8229.
16. Dmitriev, I., Krasnykh, V., Miller, C.R., 
Wang, M., Kashentseva, E., Mikhee-
va, G., Belousova, N. and Curiel, D.T. 
(1998) An adenovirus vector with ge-
netically modified fibers demonstrates 
expanded tropism via utilization of a 
coxsackievirus and adenovirus recep-
tor-independent cell entry mechanism. 
J.Virol., 72, 9706-9713.
17. Krasnykh, V., Dmitriev, I., Mikheeva, G., 
Miller, C.R., Belousova, N. and Curiel, 
D.T. (1998) Characterization of an ad-
enovirus vector containing a heterolo-
gous peptide epitope in the HI loop of 
the fiber knob. J.Virol., 72, 1844-1852.
18. Hesse, A., Kosmides, D., Kontermann, 
R.E. and Nettelbeck, D.M. (2007) Tro-
pism modification of adenovirus vec-
tors by peptide ligand insertion into 
various positions of the adenovirus 
serotype 41 short-fiber knob domain. 
J.Virol., 81, 2688-2699.
19. Uil, T.G., Seki, T., Dmitriev, I., Kashent-
seva, E., Douglas, J.T., Rots, M.G., Mid-
deldorp, J.M. and Curiel, D.T. (2003) 
Generation of an adenoviral vector 
containing an addition of a heterolo-
gous ligand to the serotype 3 fiber 
knob. Cancer Gene Ther., 10, 121-124.
20. Nakamura, T., Sato, K. and Hamada, H. 
(2003) Reduction of natural adenovirus 
tropism to the liver by both ablation of 
fiber-coxsackievirus and adenovirus re-
ceptor interaction and use of replace-
able short fiber. J.Virol., 77, 2512-2521.
21. van Beusechem, V.W., van Rijswijk, 
A.L., van Es, H.H., Haisma, H.J., Pine-
do, H.M. and Gerritsen, W.R. (2000) 
Recombinant adenovirus vectors with 
knobless fibers for targeted gene trans-
fer. Gene Ther., 7, 1940-1946.
22. Schagen, F.H., Wensveen, F.M., 
Carette, J.E., Dermody, T.S., Gerritsen, 
W.R. and van Beusechem, V.W. (2006) 
Genetic targeting of adenovirus vec-
tors using a reovirus sigma1-based at-
tachment protein. Mol.Ther., 13, 997-
1005.
23. Krasnykh, V., Belousova, N., Korokhov, 
N., Mikheeva, G. and Curiel, D.T. (2001) 
Genetic targeting of an adenovirus 
vector via replacement of the fiber pro-
tein with the phage T4 fibritin. J.Virol., 
75, 4176-4183.
24. Magnusson, M.K., Hong, S.S., Boul-
anger, P. and Lindholm, L. (2001) Ge-
netic retargeting of adenovirus: novel 
strategy employing “deknobbing” of 
the fiber. J.Virol., 75, 7280-7289.
25. Von Seggern, D.J., Huang, S., Fleck, 
S.K., Stevenson, S.C. and Nemerow, 
G.R. (2000) Adenovirus vector pseu-
dotyping in fiber-expressing cell lines: 
improved transduction of Epstein-Barr 
virus-transformed B cells. J.Virol., 74, 
354-362.
26. Jakubczak, J.L., Rollence, M.L., Stew-
art, D.A., Jafari, J.D., Von Seggern, 
D.J., Nemerow, G.R., Stevenson, S.C. 
138
4
and Hallenbeck, P.L. (2001) Adenovirus 
type 5 viral particles pseudotyped with 
mutagenized fiber proteins show di-
minished infectivity of coxsackie B-ade-
novirus receptor-bearing cells. J.Virol., 
75, 2972-2981.
27. Fallaux, F.J., Kranenburg, O., Cram-
er, S.J., Houweling, A., van Ormondt, 
H., Hoeben, R.C. and van der Eb, A.J. 
(1996) Characterization of 911: a new 
helper cell line for the titration and 
propagation of early region 1-deleted 
adenoviral vectors. Hum.Gene Ther., 7, 
215-222.
28. Legrand, V., Spehner, D., Schlesinger, 
Y., Settelen, N., Pavirani, A. and Me-
htali, M. (1999) Fiberless recombinant 
adenoviruses: virus maturation and in-
fectivity in the absence of fiber. J.Virol., 
73, 907-919.
29. Magnusson, M.K., Henning, P., Myhre, 
S., Wikman, M., Uil, T.G., Friedman, M., 
Andersson, K.M., Hong, S.S., Hoeben, 
R.C., Habib, N.A. et al. (2007) Adenovi-
rus 5 vector genetically re-targeted by 
an Affibody molecule with specificity 
for tumor antigen HER2/neu. Cancer 
Gene Ther., 14, 468-479.
30. Wikman, M., Steffen, A.C., Gunnerius-
son, E., Tolmachev, V., Adams, G.P., 
Carlsson, J. and Stahl, S. (2004) Selec-
tion and characterization of HER2/neu-
binding affibody ligands. Protein Eng 
Des Sel, 17, 455-462.
31. Maizel, J.V., Jr., White, D.O. and 
Scharff, M.D. (1968) The polypeptides 
of adenovirus. I. Evidence for multiple 
protein components in the virion and a 
comparison of types 2, 7A, and 12. Vi-
rology, 36, 115-125.
32. He, T.C., Zhou, S., da Costa, L.T., Yu, J., 
Kinzler, K.W. and Vogelstein, B. (1998) 
A simplified system for generating re-
combinant adenoviruses. Proc.Natl.
Acad.Sci.U.S.A, 95, 2509-2514.
33. Hanahan, D. (1983) Studies on trans-
formation of Escherichia coli with plas-
mids. J.Mol.Biol., 166, 557-580.
34. Chartier, C., Degryse, E., Gantzer, M., 
Dieterle, A., Pavirani, A. and Mehtali, 
M. (1996) Efficient generation of re-
combinant adenovirus vectors by ho-
mologous recombination in Escherichia 
coli. J.Virol., 70, 4805-4810.
35. Barry, S.C., Harder, B., Brzezinski, M., 
Flint, L.Y., Seppen, J. and Osborne, 
W.R. (2001) Lentivirus vectors encoding 
both central polypurine tract and post-
transcriptional regulatory element pro-
vide enhanced transduction and trans-
gene expression. Hum.Gene Ther., 12, 
1103-1108.
36. Morgenstern, J.P. and Land, H. (1990) 
Advanced mammalian gene transfer: 
high titre retroviral vectors with multi-
ple drug selection markers and a com-
plementary helper-free packaging cell 
line. Nucleic Acids Res., 18, 3587-3596.
37. Magnusson, M.K., Hong, S.S., Hen-
ning, P., Boulanger, P. and Lindholm, 
L. (2002) Genetic retargeting of adeno-
virus vectors: functionality of targeting 
ligands and their influence on virus vi-
ability. J.Gene Med., 4, 356-370.
38. Toes, R.E., Hoeben, R.C., van der Voort, 
E.I., Ressing, M.E., van der Eb, A.J., 
Melief, C.J. and Offringa, R. (1997) Pro-
tective anti-tumor immunity induced by 
vaccination with recombinant adenovi-
ruses encoding multiple tumor-associ-
ated cytotoxic T lymphocyte epitopes 
in a string-of-beads fashion. Proc.Natl.
Acad.Sci.U.S.A, 94, 14660-14665.
39. Galeffi, P., Lombardi, A., Pietraforte, I., 
Novelli, F., Di Donato, M., Sperandei, 
M., Tornambe, A., Fraioli, R., Martayan, 
A., Natali, P.G. et al. (2006) Functional 
expression of a single-chain antibody 
to ErbB-2 in plants and cell-free sys-
tems. J.Transl.Med., 4, 39.
40. Carlotti, F., Bazuine, M., Kekarainen, 
T., Seppen, J., Pognonec, P., Maassen, 
J.A. and Hoeben, R.C. (2004) Lentiviral 
vectors efficiently transduce quiescent 
mature 3T3-L1 adipocytes. Mol.Ther., 
9, 209-217.
41. Graham, F.L. and van der Eb, A.J. 
(1973) A new technique for the assay of 
infectivity of human adenovirus 5 DNA. 
Virology, 52, 456-467.
42. Hong, J.S. and Engler, J.A. (1991) The 
amino terminus of the adenovirus fiber 
protein encodes the nuclear localiza-
tion signal. Virology, 185, 758-767.
43. Adams, G.P., Schier, R., McCall, A.M., 
Simmons, H.H., Horak, E.M., Alpaugh, 
R.K., Marks, J.D. and Weiner, L.M. 
(2001) High affinity restricts the locali-
zation and tumor penetration of single-
chain fv antibody molecules. Cancer 
Res., 61, 4750-4755.
44. Douglas, J.T., Rogers, B.E., Rosenfeld, 
M.E., Michael, S.I., Feng, M. and Cu-
riel, D.T. (1996) Targeted gene delivery 
by tropism-modified adenoviral vec-
tors. Nat.Biotechnol., 14, 1574-1578.
139AdenovIrus fIber-pseudotypIng
4
45. Roelvink, P.W., Lizonova, A., Lee, J.G., 
Li, Y., Bergelson, J.M., Finberg, R.W., 
Brough, D.E., Kovesdi, I. and Wickham, 
T.J. (1998) The coxsackievirus-adenovi-
rus receptor protein can function as a 
cellular attachment protein for adeno-
virus serotypes from subgroups A, C, 
D, E, and F. J.Virol., 72, 7909-7915.
46. Dull, T., Zufferey, R., Kelly, M., Mandel, 
R.J., Nguyen, M., Trono, D. and Naldi-
ni, L. (1998) A third-generation lentivi-
rus vector with a conditional packaging 
system. J.Virol., 72, 8463-8471.
47. Zufferey, R., Dull, T., Mandel, R.J., Bu-
kovsky, A., Quiroz, D., Naldini, L. and 
Trono, D. (1998) Self-inactivating lenti-
virus vector for safe and efficient in vivo 
gene delivery. J.Virol., 72, 9873-9880.
48. Zhang, Y., Feigenblum, D. and Schnei-
der, R.J. (1994) A late adenovirus fac-
tor induces eIF-4E dephosphorylation 
and inhibition of cell protein synthesis. 
J.Virol., 68, 7040-7050.
49. Logan, J. and Shenk, T. (1984) Aden-
ovirus tripartite leader sequence en-
hances translation of mRNAs late after 
infection. Proc.Natl.Acad.Sci.U.S.A, 81, 
3655-3659.
50. Sheay, W., Nelson, S., Martinez, I., Chu, 
T.H., Bhatia, S. and Dornburg, R. (1993) 
Downstream insertion of the adenovi-
rus tripartite leader sequence enhanc-
es expression in universal eukaryotic 
vectors. Biotechniques, 15, 856-862.
51. Von Seggern, D.J., Kehler, J., Endo, 
R.I. and Nemerow, G.R. (1998) Comple-
mentation of a fibre mutant adenovirus 
by packaging cell lines stably express-
ing the adenovirus type 5 fibre protein. 
J.Gen.Virol., 79 ( Pt 6), 1461-1468.
52. Von Seggern, D.J., Chiu, C.Y., Fleck, 
S.K., Stewart, P.L. and Nemerow, G.R. 
(1999) A helper-independent adenovi-
rus vector with E1, E3, and fiber delet-
ed: structure and infectivity of fiberless 
particles. J.Virol., 73, 1601-1608.
53. Galeffi, P., Lombardi, A., Donato, M.D., 
Latini, A., Sperandei, M., Cantale, C. 
and Giacomini, P. (2005) Expression of 
single-chain antibodies in transgenic 
plants. Vaccine, 23, 1823-1827.
54. Lombardi, A., Sperandei, M., Cantale, 
C., Giacomini, P. and Galeffi, P. (2005) 
Functional expression of a single-chain 
antibody specific for the HER2 human 
oncogene in a bacterial reducing envi-
ronment. Protein Expr.Purif., 44, 10-15.
55. Belousova, N., Mikheeva, G., Gelovani, 
J. and Krasnykh, V. (2008) Modification 
of adenovirus capsid with a designed 
protein ligand yields a gene vector tar-
geted to a major molecular marker of 
cancer. J.Virol., 82, 630-637.
56. Hedley, S.J., Auf der, M.A., Hohn, S., 
Escher, D., Barberis, A., Glasgow, J.N., 
Douglas, J.T., Korokhov, N. and Curiel, 
D.T. (2006) An adenovirus vector with a 
chimeric fiber incorporating stabilized 
single chain antibody achieves target-
ed gene delivery. Gene Ther., 13, 88-
94.
57. Vellinga, J., de Vrij, J., Myhre, S., Uil, 
T., Martineau, P., Lindholm, L. and Hoe-
ben, R.C. (2007) Efficient incorpora-
tion of a functional hyper-stable sin-
gle-chain antibody fragment protein-IX 
fusion in the adenovirus capsid. Gene 
Ther., 14, 664-670.
58. Waddington, S.N., McVey, J.H., Bhel-
la, D., Parker, A.L., Barker, K., Atoda, 
H., Pink, R., Buckley, S.M., Greig, J.A., 
Denby, L. et al. (2008) Adenovirus se-
rotype 5 hexon mediates liver gene 
transfer. Cell, 132, 397-409.
59. Kalyuzhniy, O., Di Paolo, N.C., Sil-
vestry, M., Hofherr, S.E., Barry, M.A., 
Stewart, P.L. and Shayakhmetov, D.M. 
(2008) Adenovirus serotype 5 hexon 
is critical for virus infection of hepato-
cytes in vivo. Proc.Natl.Acad.Sci.U.S.A, 
105, 5483-5488.
60. Russell, S.J., Hawkins, R.E. and Winter, 
G. (1993) Retroviral vectors displaying 
functional antibody fragments. Nucleic 
Acids Res., 21, 1081-1085.
61. Menotti, L., Cerretani, A., Hengel, H. 
and Campadelli-Fiume, G. (2008) Con-
struction of a fully retargeted herpes 
simplex virus 1 recombinant capable of 
entering cells solely via human epider-
mal growth factor receptor 2. J.Virol., 
82, 10153-10161.
62. Conner, J., Braidwood, L. and Brown, 
S.M. (2008) A strategy for systemic 
delivery of the oncolytic herpes virus 
HSV1716: redirected tropism by anti-
body-binding sites incorporated on the 
virion surface as a glycoprotein D fu-
sion protein. Gene Ther..
63. Somia, N.V., Zoppe, M. and Verma, I.M. 
(1995) Generation of targeted retroviral 
vectors by using single-chain variable 
fragment: an approach to in vivo gene 




64. Martineau, P., Jones, P. and Winter, G. 
(1998) Expression of an antibody frag-
ment at high levels in the bacterial cy-
toplasm. J.Mol.Biol., 280, 117-127.
65. Proba, K., Worn, A., Honegger, A. and 
Pluckthun, A. (1998) Antibody scFv 
fragments without disulfide bonds 
made by molecular evolution. J.Mol.
Biol., 275, 245-253.
66. Worn, A. and Pluckthun, A. (1999) Dif-
ferent equilibrium stability behavior of 
ScFv fragments: identification, classi-
fication, and improvement by protein 
engineering. Biochemistry, 38, 8739-
8750.
67. Visintin, M., Settanni, G., Maritan, A., 
Graziosi, S., Marks, J.D. and Cattaneo, 
A. (2002) The intracellular antibody 
capture technology (IACT): towards a 
consensus sequence for intracellular 
antibodies. J.Mol.Biol., 317, 73-83.
68. Auf der Maur, A., Escher, D. and Bar-
beris, A. (2001) Antigen-independent 
selection of stable intracellular single-
chain antibodies. FEBS Lett., 508, 407-
412.
69. Menard, S., Pupa, S.M., Campiglio, M. 
and Tagliabue, E. (2003) Biologic and 
therapeutic role of HER2 in cancer. On-
cogene, 22, 6570-6578.
70. Zahnd, C., Wyler, E., Schwenk, J.M., 
Steiner, D., Lawrence, M.C., McKern, 
N.M., Pecorari, F., Ward, C.W., Joos, 
T.O. and Pluckthun, A. (2007) A de-
signed ankyrin repeat protein evolved 
to picomolar affinity to Her2. J.Mol.
Biol., 369, 1015-1028.
71. Binz, H.K., Amstutz, P. and Pluckthun, 
A. (2005) Engineering novel binding 
proteins from nonimmunoglobulin do-
mains. Nat.Biotechnol., 23, 1257-1268.
72. Myhre, S., Henning, P., Friedman, M., 
Stahl, S., Lindholm, L. and Magnusson, 
M.K. (2008) Re-targeted adenovirus 
vectors with dual specificity; binding 
specificities conferred by two different 




dIrected AdenovIrus evolutIon 
usIng engIneered mutAtor 
vIrAl polymerAses
aBstRact
Adenoviruses (Ads) are the most frequently used viruses for oncolytic and 
gene therapy purposes. most Ad-based vectors have been generated through 
rational design. Although this led to significant vector improvements, it is 
often hampered by an insufficient understanding of Ad’s intricate functions 
and interactions. here, to evade this issue, we adopted a novel, mutator 
Ad polymerase-based, ‘accelerated-evolution’ approach that can serve 
as general method to generate or optimize adenoviral vectors. first, we 
site-specifically substituted Ad polymerase residues located in either the 
nucleotide binding pocket or the exonuclease domain. this yielded several 
polymerase mutants that, while fully supportive of viral replication, increased 
Ad’s intrinsic mutation rate. mutator activities of these mutants were revealed 
by performing deep sequencing on pools of replicated viruses. the strongest 
identified mutators carried replacements of residues implicated in ssdnA 
binding at the exonuclease active site. next, we exploited these mutators to 
generate the genetic diversity required for directed Ad evolution. using this 
new forward genetics approach, we isolated viral mutants with improved 
cytolytic activity. these mutants revealed a common mutation in a splice 
acceptor site preceding the gene for the adenovirus death protein (Adp). 
Accordingly, the isolated viruses showed high and untimely expression of 
Adp, correlating with a severe deregulation of e3 transcript splicing.
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intRodUction
Viruses with life cycles involving lytic disruption of host cells are being 
explored for their use as oncolytic agents (1). Oncolytic viruses are unique 
anticancer agents owing to their ability to amplify their cell-lytic effect through 
replication and viral spread. This ability, combined with the promise of tumor 
selectiveness (2), fosters the hope that ‘oncolytic virotherapy’ could ultimately 
be more efficient and cause less side effects than existing therapies.
Adenovirus (Ad) is one of the most-studied viruses for oncolytic virotherapy 
and its potential has been demonstrated by promising preclinical studies and 
clinical trials (2,3). So far, however, the clinical efficacy of Ad-based virotherapy 
has not been spectacular; only when viral treatment was combined with more 
conventional therapies were the results unequivocally positive (4,5). Therefore, 
many seek to develop improved oncolytic Ads endowed with enhanced tumor 
cell killing abilities (2,3,6–11). In this regard, in addition to strategies based 
on rational design, ‘bioselection’- or ‘directed evolution’-type processes—i.e. 
methods based on genetic diversification and phenotypic selection—have 
proven useful to generate new oncolytic Ads (12–15). In studies that took 
such approaches, whole-genome genetic diversification was achieved either 
by chemical mutagens, by ultraviolet radiation or by recombination among 
co-infected Ad serotypes.
Here, we describe the development and validation of a new directed Ad 
evolution approach that is based on the high mutation rates achieved by 
engineered mutator Ad polymerases. This ‘accelerated evolution’ approach 
is distinct, conceptually and practically, from classical procedures employing 
chemical or physical mutagens. First, the use of mutator viral polymerases 
avoids the direct virus inactivating effects normally associated with mutagens 
(i.e. damage to the virus particle and irresolvable DNA lesions) (16,17). Second, 
and relatedly, our approach is inherently capable of bringing about genetic 
diversity over repeated viral infection rounds. Importantly, this property 
allows for multistep viral adaptation processes to occur, i.e. a virus may 
successively acquire multiple beneficial mutations. Thus, owing to the above 
aspects, this Ad engineering approach resembles not so much the classical 
genetic screens, but rather the adaptation processes by which the rapidly 
mutating RNA viruses—and their recombinant derivatives—can be readily 
altered or optimized (18–28). In this regard, many such RNA virus adaptation 
procedures have already led to potency-enhanced oncolytic viruses and/or 
optimized recombinant vectors.
First, to set up this system, we modified the Ad-encoded polymerase (Ad 
pol), a protein-primed family B DNA polymerase with proofreading function 
(29,30). Any mutator activities of the new Ad pol mutants were revealed by a 
deep-sequencing strategy allowing direct assessment of mutational buildups 
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in replicated viruses. Then, to validate our approach, several of the identified 
mutator polymerases were used in a directed evolution scheme aimed at 
increasing Ad’s oncolytic potency. Interestingly, this procedure isolated 
viruses with a common mutation causing untimely expression—due to altered 
splicing—of the adenovirus death protein (ADP) (31,32).
Thus, our data demonstrate that mutator mutants of a viral DNA polymerase 
can serve to provide the genetic diversity needed for efficient directed 
evolution of a normally genetically very stable DNA virus. The methodology 
outlined in our study may represent a general strategy to generate or optimize 
Ad-based gene delivery vehicles and oncolytic vectors.
mateRials and methods
cell culture
HAdV-5 E1-transformed human embryonic retinoblast cell line 911 and human 
untransformed diploid foreskin fibroblast cell line VH10 were described 
previously (33,34). Human ovarian (SKOV-3), breast (SKBR-3) and prostate 
(PC-3) adenocarcinoma cell lines were obtained from American Type Culture 
Collection (ATCC). All cell lines were grown at 37°C in DMEM (Gibco BRL, 
Breda, The Netherlands) supplemented with 8% fetal bovine serum (Gibco 
BRL) in a humidified atmosphere with 5% CO2. Cells transduced with lentivirus 
LV.PP were grown in the presence of 0.7 μg/ml puromycin (MP Biomedicals, 
Amsterdam, The Netherlands). Cells stably transduced with lentiviruses 
were named after their parental constituents. For example, an SKOV-3 cell 
population transduced with lentivirus LV.PP is designated as SKOV-3.PP.
lentiviral vectors
All lentivirus (LV) plasmids were based on pRRL-cPPT-CMV-X-PRE-SIN (35) or 
its derivative pLV.CMV.IRES.PURO (36), the latter of which carries an internal 
ribosomal entry site (IRES) followed by a puromycin resistance gene. LV 
vectors generated for this study were LV.AdPol, LV.PP and LV.pol-HA, which 
respectively encode for Ad5 pol, Ad5 pol bicistronically with puromycin 
and ‘pol-HA’, a C-terminally HA-tagged version of Ad5 pol. Furthermore, 
we developed a panel of 23 LV vectors, each encoding a single amino acid 
substitution mutant of pol-HA. Lentivirus stocks were titrated using a HIV-1 
p24 antigen enzyme-linked immunosorbent assay kit (ZeptoMetrix Corp., 
New York, NY, USA). For the rationale for selecting the Ad pol residues to 
be mutated, and for further details on vector generation, see Supplementary 
Data. 
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lentivirus-mediated expression of ad pol variants
Cells seeded in 3-cm wells and grown, in one day, to a confluency of 50–70% 
were lentivirally transduced overnight in a 2-ml volume in the presence of 
8 µg/ml polybrene. Transductions with LV.AdPol, LV.pol-HA and LVs encoding 
the Ad pol mutants were performed at 50 ng/ml p24 for 911 cells and 150 ng/
ml p24 for SKOV-3 cells. Transductions with LV.PP were at 50 ng/ml p24 for 
SKOV-3 and VH10 cells and at 200 ng/ml p24 for SKBR-3 and PC-3 cells. For 
immunofluorescence detection of Ad pol variants’ expression in transduced 
cell populations, cells were grown on glass coverslips, fixed and permeabilized 
with methanol, probed successively with an anti-HA tag and a fluorescien 
isothiocyanate (FITC)-conjugated antibody, and mounted in Dabco-glycerol 
for viewing under a fluorescence microscope.
ad vectors
Two polymerase-defective Ad vectors, AdGLΔPOL (E1- and E3-deleted; 
reporter genes in place of E1) and HAdV-5ΔPOL (wildtype in sequence apart 
from the polymerase gene-affecting deletion), were generated as described 
in  Supplementary Data. Viruses were purified by centrifugation on CsCl 
gradients by standard protocols. The physical viral particle titers (VP/ml) were 
determined using the fluorescent dye PicoGreen as described by Murakami 
and McCaman (37).
ad pol trans-complementation assays
For all assays, semiconfluent parallel cultures of 911 cells stably expressing 
Ad pol variants were incubated with AdGLΔPOL at a multiplicity of infection 
(MOI) of 0.15 pfu/cell for 1.5–3.5 h. For assays with luciferase-based readout, 
the infected cells were lysed in lysis mix [25 mM Tris-phosphate (pH 7.8), 2 mM 
CDTA, 2 mM DTT, 10% glycerol and 1% Triton-X in PBS] and stored at −80°C 
until luciferase activities were measured (Luciferase Assay System, Promega). 
See Supplementary Data for the initial setup of the complementation system.
mutation-accumulation procedure
AdGLΔPOL was subjected to 10 serial viral passages on semiconfluent 
cultures of 911 cells expressing Ad pol variants. For the first passage, 
the infections were carried out in 24-well plate wells at 0.15 pfu/cell. All 
subsequent passages were performed in six-well plate wells using 300, 30 
and 3 μl of the harvested previous infection for inoculation. At 3 or 4 days 
after each inoculation, those wells were harvested where virtually all cells had 
been infected—as judged from green fluorescent protein (GFP) expression 
on day 2—and for which the cytopathic effect (CPE) had become abundant. 
Harvested infections, consisting of dislodged cells and medium, were freeze-
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thawed and cleared by centrifugation before being used as inocula for the next 
passage. To test for any polymerase-proficient recombinants within the virus 
populations, we performed PCRs on the polymerase region and screened for 
replication ability on non-complementing cells (i.e. 911 cells). Although one 
of the initial AdGLΔPOL stocks tested positive for a minute subpopulation of 
recombinants, all the passaged virus populations—intermediate and final—
were negative.
preparation of viral pools containing approximately 50 clones each
Two different approaches were taken to prepare 50-clone virus pools from the 
passaged virus populations of the mutation-accumulation experiment. The first 
approach entailed infection of 911.pol-HA cells in duplicate at 100, 50 and 25 
pfu/well in a six-well plate. Of the duplicate sets of infections, one served as an 
intra-experiment plaque assay titration and was therefore overlaid with 0.5% 
agarose (Invitrogen) medium. From the other set, the infection containing 
nearest to 50 clones (as inferred from the intra-experiment titration) was 
harvested—by collecting cells and medium—at full CPE (day 14). The second, 
presumably more accurate approach to obtain near 50-clone pools involved 
the pooling of 50 mostly single-clone infections. For this approach, multiple 
96-well plates—seeded with 911.pol-HA cells—were infected with such an 
MOI that the majority (i.e. about 80%) of the wells were non-infected. The 
contents of 50 randomly selected infection-positive wells were harvested—
after the occurrence of full CPE—and pooled together. In this procedure, 
the observed fraction of wells found to be infection-negative allowed for the 
calculation—using the Poisson distribution—of the average number of clones 
in an infection-positive well. Multiplication of this average clone number with 
50 (i.e. the number of pooled infections) gave an approximation of the total 
number of clones in the pooled population.
massively parallel sequencing and data analysis
(Procedures for the pilot massively parallel sequencing (MPS) run performed 
on the spiked test sample can be found in Supplementary Data.) From each 
50-clone virus pool obtained in the mutation-accumulation experiment, a 
6.5-kb fragment was PCR amplified by Phusion DNA polymerase (Finnzymes/
NEB), purified and size selected using the SureClean PCR cleanup kit (Bioline) 
and, after electrophoresis, the JetSorb gel extraction kit (Genomed) (see 
Supplementary Data for primer sequences). For each purified product, 100 ng 
was fragmented by nebulization according to Illumina’s ‘Preparing Samples 
for Sequencing Genomic DNA’ document. Fragment libraries—size selected 
for fragments of 200–300 bp—were subsequently prepared using Illumina’s 
‘Preparing Samples for ChiP Sequencing of DNA’ document. The libraries 
were subjected to 32 cycles of single-end sequencing by an Illumina Genome 
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Analyzer II (GAII) instrument using one flowcell lane per sample. Image analysis 
and base calling were performed by Illumina’s Genome Analyzer pipeline 
(GAPipeline) using default parameters. Sequence reads passing the default 
Illumina chastity filter (threshold = 0.6) were outputted—by the GERALD 
module of the GAPipeline—in read files of the SCARF format. These files 
served—after their conversion to a suitable format—as input for the short read 
analysis pipeline SHORE (http://1001genomes.org/downloads/shore.html) 
(38). SHORE carried out alignments [through invocation of GenomeMapper 
(39)], performed quality filtering (i.e. masking of bases with assigned quality 
values below a set threshold) and generated forward and reverse consensus 
summaries (i.e. base counts per position in the reference sequence). Details 
on the workflow and parameter settings used can be found in Supplementary 
Data. MPS was also employed to obtain the complete sequences of several 
individual Ad genomes. Briefly, an Illumina multiplexed sequencing run was 
performed in one GAII flow cell, after which the resulting data sets were 
analyzed using the ELAND aligner of the GAPipeline and the Velvet algorithm 
for de novoassembly (http://www.ebi.ac.uk/∼zerbino/velvet/) (40).
directed evolution procedure
HAdV-5ΔPOL was subjected to 10 serial passages on SKOV-3 cells expressing 
the Ad pol variants and then successively to 10 such rounds on SKOV-3.
pol-HA cells. The passaging procedure was as described for the mutation-
accumulation procedure except for the following distinctions. First, each 
infection was harvested by collection of only culture medium (i.e. without 
cells). Second, harvesting took place at the first sign of CPE, which was 
mostly at day 3. Third, the MOIs of the successive infections were strived to 
be kept relatively low. The latter was sought to be achieved by choosing, for 
each passage, a suitable narrow range of inoculation doses (e.g. 36, 12 and 
4 μl of the harvested media of the previous passage) and by subsequently 
harvesting from among the resultant infections one exhibiting only a modest 
level of CPE. Virus stocks and passaged populations of HAdV-5ΔPOL all 
tested negative for any polymerase-proficient recombinants (see mutation-
accumulation procedure above).
cell killing assays
For cytotoxicity assays, semiconfluent cell cultures grown in 96-well plates 
were infected at the indicated MOIs. The infections were performed in 
duplicate (pools) or in triplicate (clones). Cell viabilities were measured on 
day 6 (911.pol-HA) or between days 10 and 15 (SKOV-3.pol-HA, SKOV-3.
PP, SKBR-3.PP, PC-3.PP and VH10.PP) using the WST-1 reagent (Roche). For 
plaque size assays, semiconfluent SKOV-3.pol-HA cell cultures in six-well 
plates were infected for 2 h at low MOI, washed and then overlaid with 0.5% 
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agarose (Invitrogen) medium. On day 11, cells were fixed by adding either 
1% formaldehyde on top of the overlays or pure methanol directly to the 
cells. Cells were then, respectively, stained by applying a 0.5% crystal violet 
solution in 25% methanol or by performing 3,3'-diaminobenzidine (DAB) 
immunohistochemistry, probing for Ad fiber expression (4D2, Abcam). DAB 
reactions were enhanced by complementing the DAB solution (product 
D5905, Sigma-Aldrich) with NiCl2 and CuSO4  (both to a final concentration 
of 0.03% w/v).
protein immunoblot analysis
Semiconfluent cultures of SKOV-3.pol-HA cells in 24-well plate wells 
(∼1.5 × 105 cells/well) were incubated with 1000 VP/cell for 2 h. At 24 and 
36 h after infection, cell lysates were made using 100 μl/well of RIPA lysis 
buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate 
and 1% NP40) supplemented with protease inhibitors. Lysate aliquots (10 μl) 
were boiled in reducing sample buffer and subjugated to sodium dodecyl 
sulfate–polyacrylamide gel electrophoreses (SDS–PAGE) using a two-layer 
resolving gel composed of 12% (top) and 15% (bottom) polyacrylamide. After 
electroblotting to polyvinylidene difluoride membranes, blots were probed 
by anti-fiber tail (4D2, Abcam) and anti-E1A [M73 (41)] monoclonals, a rabbit 
antiserum raised against an ADP peptide [P63-77 (42); a kind gift from Dr 
W. S. M. Wold] and matching horseradish peroxidase-coupled secondary 
antibodies. Immunologically detected proteins were visualized by enhanced 
chemiluminescence.
Reverse transcriptase-polymerase chain reaction
SKOV-3.PP cells in six-well plate wells (∼5 × 105 cells/well) were infected at 
1000 VP/cell for 1.5 h. At 8 and 24 h after infection, total RNA was isolated 
according to the Total RNA Isolation/NucleoSpin RNA II kit (Macherey-Nagel). 
First-strand cDNA synthesis, using oligo(dT)20 primers, was performed on 
250 ng of total RNA by the SuperScript III Reverse Transcriptase (Invitrogen) 
according to the manufacturer’s instructions. One microliter portions of the 
reverse transcriptase reactions were subsequently used in PCRs using specific 
primer pairs listed in Supplementary Data.
statistical analysis
The P-values assigned to the observed forward and reverse frequencies of a 
given minor variant indicate the probabilities of obtaining such frequencies 
or higher if they were to be due to sequencing errors. For the calculation 
of  P-values, we assumed a Poisson distribution of errors, analogously to 
Wang et al. (43), and took as error rate estimates the 97.5th percentiles of the 
observed minor variant frequency distributions (see Supplementary Data for 
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summary statistics). Usage of such high estimates of the error rate—instead of 
taking for instance the average of the minor variant frequency distributions—
is thought to accommodate, at least partially, the presumed heterogeneity of 
the actual error rate (44).
ResUlts
candidate mutator ad polymerases and their ability to support ad 
replication
To render Ad pol more error prone, we mutated residues putatively involved 
in maintaining polymerization fidelity. By extrapolation from data on other 
polymerase species, 19 Ad pol residues were selected for mutation (Figure 
1). The selected residues roughly fall into two categories, those putatively 
involved with proofreading and those implicated in (geometric) selection 
of the incoming nucleotide. In total, 23 Ad pol mutants were generated 
(Supplementary Table S1), each engineered with a single amino acid 
substitution. Three of the targeted residues—N417, F421 and M689 (i.e. no. 
4, 5 and 13 in Figure 1)—were represented by more than one mutant.
The newly engineered Ad pol mutants were assessed for their ability to 
support productive Ad replication. To this end, a trans-complementation 
assay was set up that involves lentiviral vector-mediated expression of Ad pol 
variants in cells, and the subsequent infection of these cells by a polymerase-
defective reporter Ad vector (Supplementary Figure S1).
A first complementation assay revealed that nine of the Ad pol mutants 
supported productive replication of the polymerase-defective vector (Figure 
2A shows green fluorescent protein (GFP) expression on day two for this 
experiment). The complementing mutants were T286I, N417A, F421Y, S506T, 
V585A, M689N, Y690F, D827A and S834E. Besides that they were associated 
with infected cells becoming brightly green fluorescent (indicating viral genome 
replication), these mutants also gave rise, eventually, to ‘green comets’ and/
or plaques, demonstrating the production of viable progeny virus. Regarding 
the size and onset of such foci, marked variation was observed among the 
mutants, with M689N and Y690F lagging furthest behind. In summary of this 
assay and several subsequent, independent assays, all Ad pol mutants were 
assigned arbitrary complementation classes (Figure 2B).
identification of mutator ad polymerases
Ad pol mutants capable of supporting viral replication were subsequently 
analyzed for their proneness to cause mutations. For this purpose, a mutation-
accumulation and sequencing scheme was devised for the direct assessment 
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Figure 1. ad pol residues targeted for mutation. Twenty-three single-amino acid 
substitution mutants of Ad pol were generated by mutation of nineteen selected residues 
implicated in governing replication fidelity (see also Supplementary Table S1). (a) The 
respective putative f29 pol homologues of the targeted Ad pol residues are depicted in 
the context of a f29 pol structure (Protein Data Bank code 1XI1) determined by Kamtekar 
et al. (47). The cartoon representation on the left shows the domain organization of f29 pol 
while the right diagram points out the targeted residues. Protein structure visualizations 
were by Polyview-3D (http://polyview.cchmc.org/) using image rendering by PyMol. (B) The 
mutated residues reside in several of the most highly conserved polymerase sequence 
motifs, the locations of which are shown in linear representations, to scale, of the f29 and 
Ad polymerases. Depicted are the ‘Exo’ motifs I, II and III (59), the (S/T)Lx2h motif (46) 
(indicated by the asterisk) and the ‘Pol’ regions I, II and III (72), which are also, respectively, 
known as polymerase motifs C, A and B (73). (c) Sequence alignments of conserved motifs 
of Ad and f29 polymerases. The respective conserved motifs are underlined. Invariable 
residues are shown in bold face. Blue numbers point to the targeted Ad pol residues and 
their respective putative f29 pol homologues. Secondary structures known for f29 pol (47) 
and those predicted for Ad pol are, respectively, shown above and below the alignments. 
Closed bars indicate α-helices while open arrows represent β-strands. The upper and lower 
predictions for Ad pol were, respectively, by PredictProtein (http://www.predictprotein.org) 
and SABLE (http://sable.cchmc.org).
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variants (Figure 3A). Central to this scheme is the employment of a MPS 
technology to perform ‘deep sequencing’ of virus DNA obtained from multi-
clone virus pools.
To implement this strategy, we first established a safe maximum to the 
number of viral clones that could be pooled while permitting detection of 
single-clone mutations. For this, we performed a pilot sequencing run on a 
3.1-kb DNA fragment spiked with several minority mutants (Table 1). Analysis 
of this run demonstrated false positive-free mutation scoring using a minimal 
minor variant prevalence cutoff value of as low as 0.17% (Supplementary 
Figure S2), a cutoff that would theoretically allow a single-clone mutation 
to be detected in a pool of 588 even-sized clones. Based on this outcome, 
Figure 2. ability of candidate 
mutator ad polymerases 
to support full-fledged ad 
replication. (a) A trans-com-
plementation system (see 
Supplementary Figure S1 for its 
components) was employed to 
assess the ability of the various 
Ad pol mutants to support Ad 
replication. Control 911 cells 
or 911 cell populations stably 
expressing the respective Ad 
pol variants were infected 
with a polymerase-defective 
Ad vector (AdGL∆POL). The 
mutants’ abilities to trans-
complement AdGL∆POL 
were assessed by monitoring 
vector-encoded reporter gene 
expression. The images show 
GFP at 2 days post-infection. 
‘pol-HA’ stands for HA-tagged 
Ad pol, which is parental to 
the other Ad pol variants. The 
exposure time was the same 
for all pictures. Not discernible 
under this setting was the very 
weak GFP signal in infected cells 
that do not trans-complement 
the polymerase defect (e.g. 
911 cells). Mutants of the 
different polymerase domains 
are color-coded as in Figure 1 
(exonuclease, red; palm, green; 
fingers, yellow). (B) Summary 
of the abilities of the Ad pol 
mutants to complement the 
polymerase-defective vector. 
The numbers in the columns 
denoted by a pound symbol (#) correspond to the residue numbers assigned in Figure 
1. The depicted complementation classes (-, +, ++, and +++) were arbitrarily assigned to 
reflect the differential patterns of complementation abilities observed for the mutants in 
several independent experiments (e.g. Figure 2A).
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passaging on mutant Ad pol cells titration
6.5 kb PCR on pool of ~50 viral clones
high-throughput sequencing
Figure 3. identification of mutator ad polymerases. (a) Mutation-accumulation and 
deep sequencing scheme. A polymerase-defective vector, AdGL∆POL, was subjected to 
10 serial infection rounds on candidate mutator Ad pol-expressing cell populations. For 
each passaged virus population, the potential mutation load buildup was assessed by deep 
sequencing (using a MPS technology) of a 6.5-kb virus DNA fragment obtained from a 
‘50-clone’ virus pool. After mapping of the sequence reads to the reference sequence, 
single-base substitutions were scored using a minor variant frequency cutoff value of 0.25% 
and a minimal sequencing depth requirement of 1200, both of which conditions were to be 
met for both the forwardly and reversely mapped read distributions. See Supplementary 
Figure S3 for details on mappings and minor variant detection. (B) Substitution score 
distributions over the length of the sequenced fragment. The grey background columns 
indicate, per 100-nt interval, the number of positions included in the analysis (i.e. the 
number of positions for which the minimal sequencing depth requirement was met). The red 
columns display the single-base substitutions scores. ‘Stock 1’ and ‘stock 2’ represent two 
independently prepared 50-clone pools of non-passaged viruses. Sample names marked 
with an asterisk (*) indicate the use of an alternative pooling method to obtain the ‘50-
clone’ pools. See text for details. (c) Total number of substitutions found per analyzed pool. 
For a given substitution, the assigned P-value range (shade of gray) relates to the higher 
of the two P-values estimated for the forward and reverse occurrence of that substitution. 
See the statistics section for P-value estimations. Further, see Supplementary Table S2 
for the substitution scores expressed relative to the amount of DNA analyzed. (d) Base 
substitution spectra of the identified mutator Ad polymerases. The relative frequencies 
of the different types of substitutions were corrected for the GC content (of ~60%) of the 
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we opted to sequence a 6.5-kb fragment from virus pools containing ∼50 
clones each, thus allowing for some experimental variations in clone size and 
number.
All Ad pol mutants capable of Ad replication, including the parental 
HA-tagged Ad pol (i.e. pol-HA), were included in a mutation-accumulation 
experiment involving 10 serial passages of the polymerase-defective Ad vector 
(Figure 3A). However, passaging using the two most weakly complementing 
mutants, M689N and Y690F, was discontinued prematurely as these mutants 
proved unable to sustain multiple-round viral propagation. From the 10 
times passaged virus populations and, additionally, from 2 non-passaged 
virus stocks, virus pools were prepared containing near 50 clones each. 
Subsequently, from each prepared viral pool, a 6.5-kb Ad genome fragment, 
spanning from the gene for pIX to that for pTP, was amplified and sequenced 
by MPS. After mapping of the short sequence reads, base substitutions were 
scored by imposing—on both the forwardly and reversely mapped read 
analyzed sequence. (e) The f29 pol homologues of Ad Pol residues T286 and F421 have 
previously been shown to entertain direct contacts with single-stranded DNA (ssDNA) (47). 
The concerned residues are depicted, with side chains, in a cartoon representation of f29 
pol, additionally displaying the cocrystallized ssDNA bound in the exonuclease active site. 
See Figure 1 for protein structure and visualization.









F R F R
1 1393 A → C 25.0 16.9 14.8 <1×10-14 <1×10-14
1395 A → C 25.0 22.0 14.0 <1×10-14 <1×10-14
2 1398 C → T 6.25 6.75 6.07 <1×10-14 <1×10-14
3 1790 A → G 1.56 1.78 1.84 <1×10-14 <1×10-14
1792 C → T 1.56 1.71 3.22 <1×10-14 <1×10-14
4 1806 A → C 0.39 0.61 0.56 6.5×10-13 <1×10-14
5 2293 C → T 0.10 0.09 0.03 0.56 1.0
2295 T → C 0.10 0.08 0.13 0.63 0.46
aThis pilot deep sequencing run was performed on a spiked test sample consisting of a 
3.1-kb DNA fragment spiked with several minority fragments, each containing a single or 
double nucleotide polymorphism. Depicted in this table are the frequencies with which the 
spiked variants occurred in the sequence read alignments. See Supplementary Data and 
Supplementary Figure S2 for more information on the sequencing run, the read alignment, 
and for an exemplification of minor variant detection.
bThe P-values associated with the observed forward (F) and reverse (R) frequencies indicate 
the probabilities of obtaining such frequency levels or higher if they were due to sequencing 
errors. See the statistics section for the estimation of P-values.
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distributions—a local sequencing coverage depth requirement of 1200 and 
a minor variant frequency cutoff value of 0.25% (Supplementary Figure S3).
The base substitution scores found for the analyzed viral pools revealed 
that among the Ad pol mutants tested, all but one (i.e. S834E) displayed a 
degree of mutator activity (Figures 3B and C and Supplementary Table S2). 
Mutants T286I and F421Y were identified as the most distinctive mutators. 
With respect to the types of substitutions found, these two, but also the 
intermediate-level mutators S506T and D827A, exhibited a strong bias toward 
transitions, especially the transition involving the exchange of a G:C base pair 
for an A:T base pair (Figure 3D). Interestingly, the strongest of the identified 
mutators (T286I and F421Y) are both mutants of residues likely involved in 
stabilization of the displaced primer terminus at the exonuclease active site 
during proofreading (Supplementary Table S1). The putative homologues 
of these residues in Φ29 polymerase entertain direct contacts with single-
stranded DNA (Figure 3E; 45–47).
directed evolution using mutator polymerases yields virus pools 
with enhanced tumor cell killing potency
Next we investigated whether the identified mutator Ad polymerases could 
serve to facilitate the directed evolution of Ad. To this end, Ad pol variants 
N417A, F421Y, S506T, D827A, S834E and pol-HA, which together represent a 
wide range of mutator activities, were put into service in a directed evolution 
scheme involving multiple viral infection rounds on the human ovarian 
carcinoma cell line SKOV-3 (Figure 4A). Subjected to this selection scheme 
was an Ad5-based virus that, apart from the polymerase-disrupting deletion, 
is completely wild type. Further, the passaging conditions were chosen to 
strongly select for any faster growing mutants (see ‘Materials and Methods’ 
section for details).
Of the virus populations that had underwent the evolution procedure, 
several were found to have gained an enhanced cytolytic activity on the target 
SKOV-3 cells (Figure 4B). Interestingly, the observed cytotoxic potencies 
(Figure 4C) of the populations correlate with the mutator abilities (Figure 
3C) of the Ad pol mutants used during bioselection. For example, directed 
evolution employing the highest level mutator, F421Y, proved to have yielded 
the most cytolytically potent virus population. Subsequent plaque size 
assessment on SKOV-3 cell monolayers further revealed the heterogeneity of 
the F421Y-bioselected population, with a considerable fraction of the viruses 
displaying a large plaque phenotype (Figure 4D).
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Figure 4. directed evolution of ad using mutator ad polymerases. (a) Conceptual 
directed evolution scheme to achieve enhanced tumor cell killing. A HAdV-5-based virus, 
which otherwise from its polymerase-disrupting deletion is fully wild-type in sequence, is 
subjected to iterative rounds of infection on tumor cell populations. Initial virus passaging on 
mutator Ad pol expressing cells results in genetically diverse pools from which viruses with 
an acquired growth advantage are enriched for in later passages. Red diamonds represent 
mutations. Green circles indicate an acquired selective advantage. (B) Virus populations 
bioselected using the indicated Ad pol variants were analyzed for cytotoxicity on their 
target cells. SKOV-3 cells were infected at the indicated MOI’s and cell viabilities were 
assessed by WST-1 assay. Exonuclease domain mutants are shown in red, fingers domain 
mutants in blue. (c) A 12-fold decrease in IC50 was observed for the virus population 
bioselected using Ad pol mutator F421Y. The inversed IC50 values were calculated from 
the cytotoxicity assay above and normalized to that of the pol-HA-bioselected pool. Error 
bars indicate 95% confidence intervals. (d) A subpopulation of the F421Y-bioselected 
viruses forms large plaques on SKOV-3 cell monolayers. Cells were grown under an agarose 




characterization of bioselected virus clones reveals overexpression 
of the adenovirus death protein
From the F421Y-bioselected pool, two individual viral clones (F421Y-c1 and 
F421Y-c2) were isolated and further characterized. In a cell killing assay, 
both clones displayed an increased ability to kill SKOV-3 cells (Figure 5A), 
with each registering a difference with the non-bioselected ‘stock’ virus of 
at least a 100-fold (Figure 5B). Furthermore, on SKOV-3 cell monolayers, 
both clones were found to give rise, exclusively, to ‘large’ plaques (shown in 
Figure 5C for clone F421Y-c1). Apart from on SKOV-3, increased cell killing 
abilities were also observed on human breast (SKBR-3) and prostate (PC-3) 
carcinoma cell lines, and, to a lesser extent, on untransformed fibroblasts 
(VH10) (Supplementary Figure S4). In contrast, killing of a standard Ad 
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Figure 5. characterization of isolated bioselected viral clones F421Y-c1 and F421Y-c2. 
Two clones with a large plaque phenotype were isolated from the F421Y-bioselected virus 
population and further characterized. Cell killing ability on SKOV-3 cells was assessed 
by a cytotoxicity (a and B) and a plaque size (c) assay. Error bars for the inversed IC50 
columns indicate 95% confidence intervals. For the plaque size assay, cells were grown 
under an agarose layer and were visualized by immunohistochemistry for Ad fiber protein 
expression. See Supplementary Figure S4 for cell killing abilities on other (tumor) cell lines. 
(d) Sequencing of the genomes of the two clones revealed a shared mutation located 
within the splice acceptor site of the ADP-encoding exon. Mutations are indicated by red 
ticks. Blue numbers correspond to the respective positions in the wildtype HAdV-5 genome 
(accession no. AC_000008). See Supplementary Tables S3 and S4 for all detected mutations 
and their predicted consequences for primary protein structures. (e) The bioselected clones 
show highly increased levels of ADP expression. SKOV-3 cells were harvested for protein 
immunoblot analysis at 24 and 36 h after their infection. Blots were immunologically probed 
for Ad proteins E1A, fiber and ADP.
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Viral genome sequencing revealed seven and eight mutations for 
the respective clones, including one shared by the two (Figure 5D and 
Supplementary Table S3). All mutations were scrutinized for having any 
conceivable relevant functional consequences. Of those that were found 
to change primary protein structure (Supplementary Table S4), none were 
obvious candidates to underlie the observed phenotype. Further, with 
respect to non-protein-coding functions, only the single common mutation, 
at position 29378 of the HAdV-5 genome, was identified by us as being 
potentially functionally relevant. The concerned mutation would affect a 
splice acceptor (SA) site preceding the exon encoding the adenovirus death 
protein (ADP) (31,42,48), a protein known to be required for efficient virus-




































Figure 6. viral clones F421Y-c1 and F421Y-c2 show a deregulated e3 splicing pattern 
strongly favoring the production of adp-encoding mRnas. RT–PCRs were performed 
with primer sets discriminating between E3 and ML promoter-derived ADP-encoding 
mRNAs. These primer sets, respectively indicated by closed and open triangles, have 
a common reverse primer (targeting the ADP-coding sequence) but consist of different 
forward primers (targeting the first E3 exon and the 3rd leader of the ML tripartite leader 
sequence). Depicted are all mRNA species recognized by these primer sets [according to 
Ad2 and Ad5 transcritption maps (42,48,49)]. E3 mRNAs (i.e. a, c, d, e and i) are shown 
in green while ML mRNAs (i.e. d’ and e’) are depicted in blue. Within the E3 transcription 
unit, the splice donor and acceptor sites involved with splicing of the shown mRNAs are, 
respectively, depicted by open and closed diamonds. The red arrow points to the splice 
site found to be mutated in the bioselected clones. Further depicted are the relevant 
polyadenylation signals (pA), E3 proteins (12.5K, 6.7K, 19K and ADP) and leader sequences 
of the ML transcription unit (1, 2, 3 and y). The RT–PCR results show highly increased levels 
of E3- but not ML-derived ADP mRNAs. Furthermore, the altered alternative splicing of E3 
transcripts was found to go at the expense of mRNA species a/c and i. The two asterisks 
next to the gel-image denote newly identified minority ML-derived ADP mRNAs. These 
variants presumably carry instead of the y-leader sequence one of two longer ‘x-leader’ 
exons (also denoted by asterisks) that would overlap with the first E3 exon. For control 
RT–PCRs on cellular β-actin and viral E1A mRNAs see Supplementary Figure S5.
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Therefore, the ADP levels were investigated by immunoblot analysis 
at different time points after virus infection (Figure 5E). Importantly, both 
bioselected clones were found to exhibit highly elevated levels of ADP 
expression. Moreover, considerable levels of ADP were already detectable 
24 h after infection, at which time the control virus showed no noticeable 
levels of ADP.
the overexpression of adp correlates with altered splicing of e3 
transcripts, not major late transcripts
The ADP gene, although embedded in the Ad E3 region, is considered an 
element of both the E3 and the major late (ML) transcription units (Figure 6, 
on the left). Early in infection, ADP is translated from two scarce E3 promoter-
derived mRNAs, termed d and e (48,49). Later in infection, however, ADP is 
mostly translated from two highly abundant ML promoter-derived mRNAs, 
termed d’ and e’ (42). Importantly, splicing of both ADP mRNA types—E3 and 
ML-derived—critically involves utilization of the splice acceptor site found to 
be mutated in the bioselected viruses.
To provide evidence for any altered splicing dynamics involving ADP-
encoding transcripts, we performed a reverse transcriptase–PCR analysis 
using primer sets allowing discrimination between the two ADP mRNA types 
(Figure 6). Control reactions were performed on cellular β-actin and viral E1A 
mRNAs (Supplementary Figure S5). Significantly, both bioselected clones 
exhibited markedly increased levels of the E3-derived ADP mRNAs (i.e. d 
and/or e), especially early and also late in infection. By marked contrast, no 
such elevations were observed for the ML-derived ADP mRNAs (d’ and/or 
e’). Interestingly, the elevated levels of d and/or e mRNAs were found to be 
accompanied by an all-but-disappearance of the two normally abundant E3-
derived mRNA species, a and c (48,49), which code for E3 proteins 6.7K and 
19K. Furthermore, the normally lesser abundant mRNA i, encoding E3-12.5K, 
was also virtually absent. Thus, for both bioselected viruses, the splicing 
dynamics of E3 transcripts were found to be severely altered, displaying a 
marked shift in favor of the production of ADP-expressing mRNAs.
discUssion
In the present study, we describe the development and validation of a 
conceptually new ‘accelerated evolution’ approach to Ad engineering that 
depends—for obtaining genetic diversity—on the error-prone viral genome 
replication achieved by engineered versions of the Ad polymerase. First, we 
report on the generation of several mutator Ad polymerases that sustain Ad 
replication. Next, we demonstrate that viral replication using such ‘sloppy’ 
Ad polymerases accelerates the adaptation to the selective pressures exerted 
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by a directed evolution scheme aimed at increasing the oncolytic potency of 
Ad. Together, these findings demonstrate that mutator Ad polymerases can 
facilitate bioselection protocols for the isolation of Ads with new phenotypes. 
Interestingly, the specific application of our approach to enhance oncolytic 
Ad was found to yield viral mutants exhibiting high and early overexpression 
of the ADP, an outcome that is directly relevant for designing and engineering 
new, more potent oncolytic Ads (2,3,8–11). Importantly, neither the identified 
mutation nor any other mutations with similar implicated effects (i.e. early cell 
lysis due to untimely ADP overexpression) have previously been isolated in 
bioselection studies involving chemical or physical mutagens (12,14).
To render Ad pol more error prone, we mutated Ad pol residues 
implicated in maintaining polymerization accuracy. In general, replication 
fidelity of proofreading-proficient DNA polymerases is governed by two main 
mechanisms: incoming nucleotide selection—based mainly on nascent base 
pair geometry—and exonucleolytic excision of misinserted nucleotides, i.e. 
proofreading (50,51). Accordingly, we aimed to compromise either of these 
functions of Ad pol by introducing substitutions within conserved motifs of 
either the nucleotide-binding pocket or the exonuclease active site. Since for 
Ad pol there is only limited structure–function information, we drew heavily 
from data available on other polymerase species (Supplementary Table S1).
Most of the Ad pol mutants constructed in this study were unable to 
support full-fledged Ad replication. Very generally, mutants non-supportive 
of virus replication might be either directly or indirectly—i.e. through global 
structural changes—impaired with respect to one or more essential aspects 
of viral genome replication (e.g. DNA binding, protein-primed initiation, 
transition between initiation and elongation, polymerase catalytic activity, 
strand-displacement and processivity). Strikingly, among the defective mutants 
were all those with substitutions of the universally conserved exonuclease 
residues contributing to the metal ion binding framework of the exonuclease 
active site (i.e. mutants D283A, E285A, D422A, Y580A and D584A). Previously, 
analogous substitutions in other viral polymerases—those of RB69, HSV and 
CMV—did prove compatible with virus replication (52–54). In contrast, for 
Φ29 polymerase, the concerned residues are known not only to be vital for 
exonucleolytic activity but also to play an essential role in strand-displacement 
functionality during polymerization (55,56). Speculatively, our data on Ad pol 
reflects a similar such dual role for these invariantly conserved residues.
To reveal any mutator activities of Ad pol mutants that were supportive 
of Ad replication, we performed ‘deep sequencing’—by MPS—on pools 
of viruses replicated by the respective polymerases. Previously, deep 
sequencing has proven a powerful means to detect low-prevalence mutations 
in heterogeneous samples, such as virus populations, tumors and/or pooled 
samples (43,44,57,58). Here, we exploited Illumina’s MPS technology to 
detect point mutations in a 6.5-kb viral DNA fragment obtained from near 
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50-clone pools of viruses that had undergone 10 viral replication rounds. 
Importantly, this approach enabled us to obtain direct molecular evidence for 
any mutational buildups in a procedural context that, with its multiple-round 
viral passaging on cells, resembles a directed evolution regime.
Of the Ad pol mutants that sustained multiple-round viral replication, 
several displayed a degree of mutator activity. The strongest of these were 
T286I and F421Y, respectively, mutants of exonuclease motifs I and II (59). 
These two mutators, as well as the weaker mutator N417A, carry replacements 
of residues whose counterparts in Φ29 are important for primer terminus 
stabilization—putatively through direct binding (47)—at the exonuclease 
active site during proofreading (45,46). Another of the identified mutators, 
S506T, carries a substitution within the ‘S/TLx2h’ motif of the exonuclease 
domain (46). Akin to the above mutants, its mutator activity could result from 
a lesser ability to stabilize primer termini during proofreading. However, 
considering the buried state of the homologous residue in Φ29 polymerase 
(47), any such impact might be through indirect effects. Further, also D827A 
was identified as an intermediate-strength mutator. Residue D827, which is 
non-highly conserved, is putatively located on a loop structure connecting 
two α-helices of the fingers domain (see Figure 1, residue no. 15). Thus, 
the D827A substitution might have indirect effects on incoming nucleotide 
selection, perhaps through an altered or more flexible relative positioning 
of the two helices, as has been suggested for mutator activity-yielding 
substitutions at similar positions in Pyrococcus furiosus polymerase (60).
The mutation rates—at the viral level—achieved by Ad pol mutants T286I 
and F421Y are within the range of those reported for highly evolvable RNA 
viruses, indicating perhaps a particular suitability of these mutants for directed 
Ad evolution. For the two pools of F421Y mutant-replicated viruses (i.e. pools 
‘F421Y’ and ‘F421Y*’), the observed respective substitution loads were 73 
and 100 per million base pairs (Supplementary Table S2). These numbers 
would correspond to a substitution rate, per viral passage, of 0.26 and 0.36 
per Ad5 genome length equivalent (i.e. 36 kb). Considering that the latter of 
these measures is probably the more accurate (given the pooling methods 
used) and, furthermore, that these measures only represent the non-lethal 
mutations, we expect that viruses replicated by the F421Y mutant—and, by 
analogy, the T286I mutant—underwent genomic mutation rates of at least, 
but probably greater than, 0.4 per viral generation. By comparison, for 
several ‘rapidly evolving’ riboviruses (i.e. measles virus, poliovirus, rhinovirus 
and vesicular stomatitis virus), estimates for the per-genome per-generation 
mutation rate ranged from 0.26 to 2.3 (61). Likewise, the genomic mutation 
rates for the fast adapting retroviruses have been estimated at a mean of 0.3 
per viral generation (62).
Mutator Ad polymerases successfully served in a directed evolution 
regime aimed at increasing the oncolytic potency of Ad. Ad pol mutants 
163mutAtor Ad pol-bAsed dIrected evolutIon
5a
were employed to replicate Ad—through trans-complementation—in a 
viral passaging scheme performed on the human ovarian carcinoma cell 
line SKOV-3. Resultant ‘bioselected’ virus populations that had undergone 
replication by either intermediate level (S506T and D827A) or strong (F421Y) 
mutators were found to have gained an increased cytolytic activity on the 
target cell line. In contrast, populations subjected to replication by weak 
and non-mutators (i.e. N417A and S834E, respectively) showed no evidence 
of any fitness gain relative to the control passaged virus population. These 
outcomes, combined with the mutation loads found in individual bioselected 
clones, demonstrate that engineered mutator Ad polymerases can be used 
to generate the genetic diversity needed to effectively facilitate directed Ad 
evolution.
A common mutation seen in the two isolated bioselected clones (at position 
29 378 of the HAdV-5 genome) affects a splice acceptor site known to be 
critically involved in the generation of ADP-encoding mRNAs (42,48). Given 
that ADP is crucial for efficient cell death and virus release (32), its implication 
with the observed enhanced cytotoxic phenotype is highly conceivable. 
The ADP gene resides in the E3 region and is accordingly expressed, albeit 
relatively scarcely, from E3 promoter-derived mRNAs early in infection 
(42,48,49). However, ADP is additionally and much more abundantly expressed 
from major late promoter-derived transcripts arising later in infection (>24 h 
p.i.) (42). Both isolated virus clones exhibited dramatically elevated levels 
of ADP, the overproduction of which already became noticeable early in 
infection. Furthermore, the splicing pattern of E3 transcripts was found to 
be severely affected, with the generation of ADP-encoding mRNAs being 
strongly favored at the expense of other E3 mRNA species. In contrast, the 
levels of ADP-encoding mRNAs originating from the major late promoter 
were relatively unaffected. Thus, these data indicate an untimely expression of 
ADP that is mechanistically attributable to an increased utilization—within E3 
transcripts—of the mutated splice acceptor site preceding the ADP-encoding 
sequence.
Several previous studies that aimed to enhance Ad’s oncolytic potency 
have rationally sought to overexpress ADP or other cell death-inducing 
proteins (2,3,6–11). The ADP-overexpressing viruses generated in these 
studies were found to exhibit accelerated cell-to-cell viral spread in vitro, 
and improved antitumor efficacy in vivo. These data thus illustrate the direct 
relevance of our bioselected, ADP-overexpressing viral mutants for oncolytic 
virotherapy. Notably, the ‘ADP splice-site mutation’ identified here may be 
directly implementable in the context of existing designs of oncolytic Ad 
vectors. For example, vectors already endowed with tumor specificity might 




Taken together, our data validate a new, evolution-based bioengineering 
approach for Ad. In general, evolution-based engineering methods—i.e. 
methods based on genetic diversification and phenotypic selection—are 
powerful tools to isolate viruses with new or improved properties (63). 
Important advantages of these ‘random’ engineering methods over rational 
design are that they do not require an in-depth mechanistic insight and, 
furthermore, that they have the potential to yield unanticipated solutions 
to virus engineering problems. Existing viral random engineering methods 
can be divided into two general types: conventional forward genetics, which 
employs mutagens to bring about genome-wide mutagenesis, and the more 
modern approaches that combine in vitro genetic diversification techniques 
(64,65) with viral library-based selection (63). Both of these methods have 
been applied with some success to Ads in the past (12–14,66,67). However, 
the usefulness of the latter of these methods for Ad engineering has—in 
comparison to that for AAV (68) or retrovirus (69) engineering—been limited 
due to the difficulty of generating sufficiently complex adenoviral libraries. 
Recently, there has been significant progress in this respect. Different studies 
explored a site-specific recombination system to transfer plasmid-based Ad 
fiber-peptide libraries directly into replicating Ads, thus bypassing major 
efficiency bottlenecks in Ad library generation (i.e. large genome handling 
and transfection, and virus rescue from naked viral DNA) (66,67).
With the ability to achieve genome-wide genetic diversification, our viral 
polymerase-based approach bears some similarity to traditional strategies 
relying on mutagens. However, major conceptual and practical distinctions 
exist. First, while mutator viral polymerases cause mutations directly, 
mutagens do so through the infliction of DNA damage. This is of relevance 
because not all mutagen-induced DNA lesions—like cross-links produced by 
nitrous acid (70)—can be bypassed by polymerases or repaired (16,70). In this 
regard, the greater part of the lethality seen after mutagen exposure may be 
due to collateral viral inactivation—consequential to irresolvable DNA lesions 
and damaged protein components—rather than bona fide genetic mutations 
(17). Importantly, this mutagen-associated excess lethality compromises the 
effective complexities of the diversified populations (17). While these issues 
are not so much a problem in single mutational-pulse experiments (because 
the amount of input virus can be chosen sufficiently high), they thwart schemes 
involving repeated mutagenic treatments, e.g. following each replication 
round. This points to a second, very important distinctive aspect of the 
polymerase-based approach, namely that it naturally allows repeated rounds 
of mutagenesis and selection. Thus, our approach is particularly suitable for 
directed evolution procedures involving multiple mutagenic viral passages, 
allowing for the possibility of generating compound mutants.
Thus, the Ad engineering approach described here is essentially an 
accelerated form of evolution that, regarding viral mutation rate levels, 
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matches RNA virus evolution (see above). This is of interest because it is well 
established that the rapid evolution of RNA viruses can be effectively exploited 
for directed evolution purposes. For example, many of the most promising 
oncolytic riboviruses were the (coincidental) result of multiple-passage 
adaptation to growth in tissue culture cells (19). Furthermore, there are many 
recent examples where the adaptabilities of riboviruses (such as rhinovirus, 
coxsackievirus, vesicular stomatitis virus, sindbis virus, tick-borne encephalitis 
virus and avian influenza) and retroviruses (HIV-I and MLV) have been 
deliberately exploited to achieve specific vectorological goals. For example, 
riboviruses were evolved to exhibit enhanced target cell killing (18), altered or 
expanded receptor specificity (18,20,27,28), altered protease specificity (21) 
and ability to grow in cells of other host species (22,23). Likewise, retrovirus 
adaptability has been exploited to optimize viral envelope glycoprotein-
pseudotyped recombinant vectors (24–26). Thus, with appropriate selective 
conditions imposed, similar aims for Ad may be achievable by our rapid 
evolution approach. In this regard, a general aim would be to restore or 
optimize recombinant Ad vectors (e.g. retargeted vectors) with impaired or 
limited function. Further, a captivating specific goal would be to generate 
human Ad derivatives capable of productive infection of mouse cells. Such 
mouse-adapted viruses would help realization of a permissive mouse model 
for replication-competent human Ad infection, potentially an invaluable tool 
for preclinical safety and efficacy studies (71).
The mutator polymerase-based Ad engineering approach presented here 
should be easily implementable by others, offering great practical flexibility 
and choice regarding the design of evolution regimes. There are two general 
ways recommended to adopt the system. Mutator viral polymerases might be 
stably expressed in target cells—e.g. using lentiviral vectors, as in our study—
or, alternatively, be encoded for by the virus itself. In the first approach, one 
might consider using instead of a polymerase-defective virus, a polymerase-
proficient one. This would save the reintroduction of the polymerase gene 
into any promising viral mutants (or, conversely, the introduction of promising 
acquired mutations into a wild-type virus). However, in such a setting, due to 
the co-presence of wild-type and mutator polymerases within the infected 
cells, the level of mutation is likely to be compromised somewhat. Therefore, 
it may be advantageous for this purpose to use Ad pol mutants exhibiting 
hyper-mutator phenotypes. In this regard, our unpublished data shows that 
some of the viable polymerase mutations identified in this study can be 
combined, thereby generating yet higher level mutators. Finally, the second 
approach to adopt the system—introduction of the mutator polymerase gene 
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Figure s1. components of the ad pol trans-complementation system. (a) Lentiviral 
vectors for the stable expression of Ad pol variants in cells. Shown are representations of 
a lentiviral vector (in the proviral state) and the different transgenic configurations used. 
IRES, internal ribosomal entry site; PURO, puromycin resistance gene; HA, hemagglutinin 
(HA) tag; ∆U3, deletion of the U3 region; RRE, HIV-I Rev responsive element; cPPT, HIV-I 
central polypurine tract; CMV, human cytomegalovirus promoter; PRE, human hepatitis 
B virus post-transcriptional regulatory element. (B) Lentiviral expression – in the E1-
complementing cell line 911 – of HA-tagged versions of wild-type Ad pol (pol-HA) and 
the D422A mutant Ad pol (D422A). Immunofluorescence analysis was performed using 
an HA-tag-specific primary antibody. (c) Representation of the genome of AdGL∆POL, 
a polymerase-defective HAdV-5 based reporter vector. E1 and E3 regions are deleted, 
with the former replaced by GFP and luciferase (luc) gene expression cassettes. The 
polymerase-disrupting deletion ‘∆POL’ corresponds to positions 7312 to 7882 of the 
wild-type HAdV-5 genome (accession no. AC_000008). Green and blue arrows respectively 
represent coding and promoter sequences. Adenovirus genes depicted are polymerase 
(pol), pTP, pIX, pIVa2, and the i-leader protein (i). Red bars represent leader exons (1, 2, 
i, and 3) of the major late transcription unit. All components are depicted to scale. MLP, 
major late promoter. (d) Trans-complementation of the polymerase-defective reporter virus 
by both wild-type Ad pol (‘pol_PURO’) and pol-HA but not by D422A. 911 cells and 911 
cells stably expressing the respective polymerases were infected with AdGL∆POL. Images 
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Figure s2. deep sequencing to detect low-prevalence mutations: analysis of a spiked 
test sample. Deep sequencing was performed on a 3.1-kb DNA fragment that was spiked 
with five minority sequences, each of which contained a single or double nucleotide 
polymorphism. The sequence reads were mapped against the reference sequence allowing 
up to two mismatches, after which low-quality bases were masked. (a) Forward and reverse 
sequencing depth distributions over the length of the sequenced fragment. (B) Positions in 
the reference sequence for which both the forward and reverse mappings passed a minimal 
sequencing depth requirement of 1200. (c) Local frequencies of base-calls around the 
spiked positions. Results represent those of the forwardly mapped reads. S1 to S5 specify 
the positions of the spiked polymorphisms. The color coding of the arrows correspond to 
that of the spiked minority bases. (d) Minor variant frequencies for the forward and reverse 
mappings. Depicted per position are the frequencies of all three possible minor variants 
(i.e. of the non-consensus base occurrences). The spiked minor variants are shown in red. 
The indicated 97.5th percentiles of the observed minor variant frequencies were used as 
error rate estimates for the calculation of P-values (see Statistics section in the main article). 
The data shown are for positions for which both the forward or reverse coverage level were 
above 1200. (e) Exemplification of mutation scoring using a minimal coverage requirement 
of 1200 and minor variant frequency requirements of 0.01%, 0.05%, or 0.17%. Shown – for 
positions with forward and reverse sequencing depths of minimally 1200 – are the minor 
variant occurrences for which both the forward and reverse observed frequencies were 
above a set cutoff value, indicated by the red line. For a given minor variant, the diamond 
and its associated ‘error bars’ respectively represent the average and the respective absolute 
values of the observed forward and reverse frequencies. The spiked minor variants are 
shown in red; their associated numbers indicate their respective positions in the reference 
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Figure s3. deep sequencing to detect minor variants in pools of passaged viruses. Viral 
DNA fragments obtained from pools of viruses replicated by different Ad pol variants were 
subjected to deep sequencing. Resultant sequence reads were mapped to the reference 
sequence allowing up to two edit operations (i.e. mismatches or gaps), after which low-
quality base calls were masked. Using the forwardly and reversely mapped base-call 
distributions, substitutions were scored by imposing a local coverage depth requirement of 
1200 and a minor variant frequency cutoff value of 0.25% (both of which requirements were 
to be met for both the forward and reverse mappings). (a) Forward and reverse sequencing 
depth distributions over the length of the sequenced fragment.  (B) Minor variant frequency 
plots showing the scored substitutions. Depicted are all minor variant occurrences for 
which both the forward and reverse frequencies were above 0.02% (including only those 
positions for which the minimal sequencing depth requirement was met). Diamonds and 
their associated ‘error bars’ respectively represent the average and the respective absolute 
values of the observed forward and reverse frequencies. Minor variants were scored as 
bona fide substitutions (indicated in red) when their forward and reverse frequencies were 
























































Figure s4. cell killing abilities of the bioselected viral clones F421Y-c1 and F421Y-c2. 
Shown are cytotoxicity assays on 911 cells (a) and SKOV-3, SKBR-3, PC-3, and VH10 cells 


































Figure s5. Reverse transcriptase-pcR analysis controls: cellular β-actin and viral e1a. 
These are controls reactions for the RT-PCRs performed to detect ADP-encoding mRNAs 
(main article, Figure 6). 12s and 13s are splice variants of E1A. 




table s1. Ad pol mutants examined in this study
no.a
ad pol 
mutant putative functions of the substituted residueb
mutator characteristics-yielding substitutions of homologous residues in other 
polymerasesc
1 D283A Exo catalytic activity; metal ion binding; strand displacement (Φ29) (1) Φ29: D12A (2,3); T4: D112A/N (4); Sce δ: D321G/N (5); HSV: D368A (6) 
2 E285A Exo catalytic activity; metal ion binding; strand displacement (Φ29) (1) Φ29: E14A (2,3); T4: E114A (4); Sce δ:E323Q (5); HSV: E370A (6) 
3 T286I Stabilization of the primer terminus at exo active site Φ29: T15I (7); Sce δ: C324R (5) 
4 N417A/D Stabilization of the primer terminus at exo active site Φ29: N62D (7); PRD-1: N71D (8) 
5 F421A/S/Y Stabilization of the primer terminus at exo active site Φ29: F65Y/S (9) 
6 D422A Exo catalytic activity; metal ion binding; strand displacement (Φ29) (1) Φ29: D66A (2,3); T4: D219A/N (4); Sce δ: D407N (5); HSV: D471A (6); CMV: D413A (10) 
7 S506T Involvement in exo activity; requirement for interaction with the 
terminal protein (11); primer binding (?)
Φ29: S122T/N (9) 
8 L507T Involvement in exo activity; primer binding (?) Φ29: L123T/A (9); T4: L287A (4); Sce δ: L479S (5) 
9 Y580A Involvement in exo activity; strand displacement (Φ29) (1) Φ29: Y165F/C (3,12); T4: Y320A/Q/F (4); RB69: Y323F (13); HSV: Y577F/H (6,14) 
10 D584A Exo catalytic activity; metal ion binding; strand displacement (Φ29) (1) Φ29: D169A (3,12); T4: D324A/N (4); HSV: D581A (6,14) 
11 V585A Formation of part of the exo active site T4: V325A (15) 
12 G666A dsDNA binding; tuning between pol and exo activities Φ29: G228A (16) 
13 M689K/N Formation of part of the hydrophobic pocket that binds the base and 
ribose portions of the incoming nucleotide; role in base discrimination 
and/or partitioning to exo site
T4: L412M (17); Sce δ: L612F/M/K/G/N (18); RB69: L415F/G (19);  Eco I: I709A/F/M/N (20); 
Sce α: L868F/M/W/V (21); Taq I: I614K/N/Q (22); Sce ε: M644F (23) 
14 Y690F Interaction with the ribose of the incoming dNTP; role in preventing 
incorporation of NTPs
Φ29: Y254F/V (24,25); Eco I: E710A (26)
15 D827A Indirect involvement in incoming nucleotide binding (?) (Pfu: T471G/A, Q472G/A/P, D473G/A (27))
16 S834E Indirect involvement in incoming nucleotide binding (?) (Taq I: A661E (28))
17 L838A Formation of part of the nascent base-pair binding pocket; involvement 
in positioning the templating nucleotide; controlling base-pairing 
correctness
Φ29: L384R/Q (29); RB69: L561A (30,31); Taq I: T664R (28) 
18 Y844A Hydrophobic interaction with the base of the incoming – or the 
templating (Eco I) – nucleotide; critical role in checking correctness of 
base pairing
Φ29: Y390F/S (24); RB69 Y567A (31-34); Eco I: Y766S/A (35-37); Sce α: Y951E/P (38) 
19 G845A dsDNA binding (Φ29) (39); role in the insertion of correct nucleotides 
(Sce α)
Sce  α: G952Y/A (40) 
aThe residue numbers 1 to 19 correspond to those assigned to the selected Ad pol residues in 
Figure 1. 
bListed are functions ascribed to homologous residues in polymerases of other organisms. 
Uncertain or debated functions are followed by a parenthesized question mark. (See 
Supplementary References for literature cited here).   
cDepicted are those substitutions that were found – in the referenced studies – to either 
diminish exonuclease activity, affect the pol/exo balance, lower replication fidelity, or give 
a mutator phenotype in vivo. Substitutions of residues not evidently homologous to that of 
Ad pol are parenthesized. (See Supplementary References for literature cited here).   
Abbreviations: exo, exonuclease; pol, polymerase; Eco, Escherichia coli; Sce, Saccharomyces 
cerevisiae; HSV, herpes simplex virus; CMV, cytomegalovirus ; Taq, Thermus aquaticus ; Pfu, 
Pyrococcus furiosus.
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mutator characteristics-yielding substitutions of homologous residues in other 
polymerasesc
1 D283A Exo catalytic activity; metal ion binding; strand displacement (Φ29) (1) Φ29: D12A (2,3); T4: D112A/N (4); Sce δ: D321G/N (5); HSV: D368A (6) 
2 E285A Exo catalytic activity; metal ion binding; strand displacement (Φ29) (1) Φ29: E14A (2,3); T4: E114A (4); Sce δ:E323Q (5); HSV: E370A (6) 
3 T286I Stabilization of the primer terminus at exo active site Φ29: T15I (7); Sce δ: C324R (5) 
4 N417A/D Stabilization of the primer terminus at exo active site Φ29: N62D (7); PRD-1: N71D (8) 
5 F421A/S/Y Stabilization of the primer terminus at exo active site Φ29: F65Y/S (9) 
6 D422A Exo catalytic activity; metal ion binding; strand displacement (Φ29) (1) Φ29: D66A (2,3); T4: D219A/N (4); Sce δ: D407N (5); HSV: D471A (6); CMV: D413A (10) 
7 S506T Involvement in exo activity; requirement for interaction with the 
terminal protein (11); primer binding (?)
Φ29: S122T/N (9) 
8 L507T Involvement in exo activity; primer binding (?) Φ29: L123T/A (9); T4: L287A (4); Sce δ: L479S (5) 
9 Y580A Involvement in exo activity; strand displacement (Φ29) (1) Φ29: Y165F/C (3,12); T4: Y320A/Q/F (4); RB69: Y323F (13); HSV: Y577F/H (6,14) 
10 D584A Exo catalytic activity; metal ion binding; strand displacement (Φ29) (1) Φ29: D169A (3,12); T4: D324A/N (4); HSV: D581A (6,14) 
11 V585A Formation of part of the exo active site T4: V325A (15) 
12 G666A dsDNA binding; tuning between pol and exo activities Φ29: G228A (16) 
13 M689K/N Formation of part of the hydrophobic pocket that binds the base and 
ribose portions of the incoming nucleotide; role in base discrimination 
and/or partitioning to exo site
T4: L412M (17); Sce δ: L612F/M/K/G/N (18); RB69: L415F/G (19);  Eco I: I709A/F/M/N (20); 
Sce α: L868F/M/W/V (21); Taq I: I614K/N/Q (22); Sce ε: M644F (23) 
14 Y690F Interaction with the ribose of the incoming dNTP; role in preventing 
incorporation of NTPs
Φ29: Y254F/V (24,25); Eco I: E710A (26)
15 D827A Indirect involvement in incoming nucleotide binding (?) (Pfu: T471G/A, Q472G/A/P, D473G/A (27))
16 S834E Indirect involvement in incoming nucleotide binding (?) (Taq I: A661E (28))
17 L838A Formation of part of the nascent base-pair binding pocket; involvement 
in positioning the templating nucleotide; controlling base-pairing 
correctness
Φ29: L384R/Q (29); RB69: L561A (30,31); Taq I: T664R (28) 
18 Y844A Hydrophobic interaction with the base of the incoming – or the 
templating (Eco I) – nucleotide; critical role in checking correctness of 
base pairing
Φ29: Y390F/S (24); RB69 Y567A (31-34); Eco I: Y766S/A (35-37); Sce α: Y951E/P (38) 
19 G845A dsDNA binding (Φ29) (39); role in the insertion of correct nucleotides 
(Sce α)
Sce  α: G952Y/A (40) 
aThe residue numbers 1 to 19 correspond to those assigned to the selected Ad pol residues in 
Figure 1. 
bListed are functions ascribed to homologous residues in polymerases of other organisms. 
Uncertain or debated functions are followed by a parenthesized question mark. (See 
Supplementary References for literature cited here).   
cDepicted are those substitutions that were found – in the referenced studies – to either 
diminish exonuclease activity, affect the pol/exo balance, lower replication fidelity, or give 
a mutator phenotype in vivo. Substitutions of residues not evidently homologous to that of 
Ad pol are parenthesized. (See Supplementary References for literature cited here).   
Abbreviations: exo, exonuclease; pol, polymerase; Eco, Escherichia coli; Sce, Saccharomyces 
















stock 1 38 5869 2.2 ×105 1 4.5
stock 2 54 5809 3.1 ×105 0 0.0
pol-HA 26 5189 1.3 ×105 0 0.0
T286I 48 6320 3.0 ×105 23 76.3
N417A 42 6296 2.6 ×105 4 15.3
F421Y 47 6162 2.9 ×105 21 72.7
S506T 36 6291 2.3 ×105 8 35.3
V585A 41 5619 2.3 ×105 2 8.7
D827A 33 5670 1.9 ×105 7 37.4
S834E 44 6109 2.7 ×105 0 0.0
pol-HA* 58 6341 3.6 ×105 1 2.7
F421Y* 55 6314 3.5 ×105 35 100.1
aVirus pool sizes were estimated based on intra-experiment titrations during pool 
preparations.
bPositions in the reference sequence for which both the forwardly and reversely mapped 
base distributions had a minimal coverage level of 1200.
cThe estimated total amount of analyzed DNA sequence is the arithmetic product of ‘pool 
size’ and ‘positions analyzed’.
dThe substitution scores as found in Figure 3C. Shown are only the substitution scores for 
which both the forward and reverse observed minor variant frequencies had associated 
P-values smaller than 1 x 10-4.
eThe substitution scores (column ‘absolute substitution score’) are expressed here relative 
to the respective DNA amounts analyzed (column ‘total amount analyzed’).
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table s3. Mutations found in two bioselected clones.
clone positiona Base changeb
F421Y-c1 1,419 G  A
7,243 G  A
8,251 C  A
9,835 C  T
16,036 G  A
17,576 G  A
29,378 C  T
F421Y-c2 9,114 C  G
11,581 G  A
20,374 C  T
28,638 T  A
29,378 C  T
31,726 A  G
34,301 C  T
35,229 A  Δ
aPosition in HAdV-5 genome (accession no. 
AC_000008)
bThe indicated base change is for the direct strand. 
‘∆’ stands for a deleted base.






F421Y-c1 8,251 C  A direct i-leader protein L92M C,D
9,835 C  T opposite pTP R255H A,B,C,D,E,F
17,576 G  A direct pV V346M A,B,C,D,E,F
F421Y-c2 9,114 C  G opposite pTP Q495H A,B,C,D,E,F
11,581 G  A direct L1 52/55K V178M A,B,C,D,E,F
28,638 T  A direct E3 6.7K I31N Ce
31,726 A  G direct fiber T229A C
35,229 A  Δ opposite E4orf1 Frameshiftd A,B,C,D,Ef
aPosition in HAdV-5 genome (accession no. AC_000008)
bThe indicated base change is for the direct strand. ‘∆’ stands for a deleted base.
cHAdV subgroups across which the affected amino acids are conserved.
dThe base deletion results in a frameshifted, shorter protein: the last 27 amino acids of 
E4orf1 are replaced by 7 other residues. 
eE3 6.7K does not exist outside HAdV-5 subgroup C.
fSix of the 27 deleted residues are conserved across the indicated subgroups. E4orf1 is not 
known by us to exist in subgroup F. 
186
5b
sUpplementaRY pRocedURes and mateRial
Rationale for selecting ad pol residues to be mutated
A panel of twenty-three single-amino-acid substitution mutants of Ad pol 
was generated by site-directed mutation of nineteen selected residues 
thought to be important for governing replication fidelity (Figure 1 and 
Supplementary Table S1). In our picking of residues to modify, we were led 
by the consideration that only Ad pol’s accuracy of polymerization was to be 
targeted – any other detrimental effects on functions necessary for faithful 
adenovirus genome replication were ideally to be avoided. For example, the 
efficiency of polymerization – or its protein-primed initiation – was preferably 
not to be compromised. To achieve this goal, in addition to drawing from 
what is known about Ad pol itself, we tapped into the wealth of data available 
on DNA-polymerases of other organisms, such as the Φ29, T4, RB69, and 
PRD1 bacteriophages, herpes simplex virus (HSV), cytomegalovirus (CMV), 
Escherichia coli, Thermus aquaticus (Taq), Pyrococcus furiosus (Pfu), and 
Saccharomyces cerevisiae. Eleven of the selected Ad pol residues, all located 
within the exonuclease domain, have been implicated – mostly through 
their homologues in other polymerase species – with proofreading function. 
The eight other targeted residues make part of either the fingers domain or 
the palm domain and are thought to play important roles in incoming base 
selection and/or tuning between polymerase and exonuclease activities. 
Among the mutations of residues putatively involved in proofreading were 
those aimed at specifically abolishing the catalytic activity of the exonuclease 
domain. These substitutions, which were meant to rigorously knock-out 
exonucleolytic activity, concern the highly conserved residues D283, E285, 
D422, Y580, and D584 (Figure 1 and Supplementary Table S1, assigned 
amino acid no. 1, 2, 6, 9 and 10). These are the key residues thought to be 
involved in metal ion binding and catalysis. Importantly, substitutions of the 
homologues of these residues in polymerases of Φ29, T4, RB69, and HSV 
have previously been shown to render these polymerases gravely impaired 
(or effectively inactive) with respect to the ability to catalyze exonucleolytic 
hydrolysis (2-4,6,12-14). Furthermore, a D422A mutant of Ad pol has already 
been shown by Brenkman et al. to be exonuclease deficient (41).
Ad pol residues thought to be otherwise (than catalytically) involved in 
proofreading were also subjected to mutation. Three of these, namely T286, 
N417, and F421 (no. 3-5), were selected for their suspected direct involvement 
– based on studies on their homologues in Φ29 – in stabilization of the primer 
terminus at the exonuclease active site (7,9). Two other residues targeted for 
mutation were S506 and L507 (no. 7 and 8), both of which make part of to 
the (S/T)Lx2h motif (9) (Figure 1). These residues putatively play important 
roles in proofreading, possibly through (indirect) interaction with the ssDNA 
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primer, as has been suggested for their homologous counterparts in Φ29 
polymerase (9). Finally, the last residue within the exonuclease domain that 
was mutated in this study was V585 (no. 11). Substitution of its homologue 
in T4 polymerase had led to an in vivo mutator phenotype, possibly due to 
functional disturbance of a neighboring catalytic residue, which, in Ad pol, is 
D584 (no. 10) (15).
Further singled out for mutation were three amino acid residues residing 
in the conserved Pol II (or Motif A) region of the palm domain (Figure 1). One 
of these residues, G666 (no. 12), is located in the Y/IxGG/A motif, a region 
believed to be involved in tuning between polymerase and exonuclease 
activities (16,42). The other two residues, M689 and Y690 (no. 13 and 14), 
might make part of the incoming nucleotide binding pocket and, as such, 
could play important roles in the geometric selection of nucleotides, which 
has been suggested for their putative homologues in other polymerases 
(17-26). 
Within the fingers domain, with its prominent role in the binding of 
incoming nucleotides, a total of five residues were selected for mutation. Two 
non-highly conserved residues were chosen based on the speculation that 
their respective substitutions could have indirect effects on base selecting 
properties. One of these residues, D827 (no. 15), is seemingly located in 
the connecting loop between two helices of the fingers domain (Figure 1). 
Positioned as such, it might functionally resemble similarly located Pfu DNA 
polymerase residues, mutation of which previously led to strong mutator 
phenotypes (27). The other lesser-conserved residue that was targeted, S834 
(no. 16), which seems to be situated in a second helix of the fingers domain of 
Ad pol (Figure 1), is positioned just before highly conserved residues thought 
to be directly involved in catalytic and base-selection functions. Mutation of 
residues at this approximate location in Taq DNA polymerase I has previously 
given rise to increased in vitro and in vivo mutation rates (28). Further targeted 
for mutation in the fingers domain were two highly conserved residues, 
L838 and Y844 (no. 17 and 18), both of which were selected based on their 
presumed critical roles in controlling base-pairing correctness (24,28-38). 
Finally, another target was G845 (no. 19), a highly conserved residue to which 
different functions have been ascribed for different polymerases. In Φ29 it 
would be involved in dsDNA binding (39), while in S. cerevisiae polymerase 
alpha, a familiy A polymerase, it is suspected to be critical for the insertion of 
correct nucleotides (40).
construction and production of lentiviral vectors
Lentiviruses used in this study were self-inactivating, third-generation HIV-I-
derived vectors (43,44). LV plasmids expressing wild-type Ad5 pol and the 
mutant Ad5 pol D422A were made by insertion of previously described cDNAs 
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(41) into the basal LV plasmids pRRL-cPPT-CMV-X-PRE-SIN (45) or its derivative 
pLV.CMV.IRES.PURO (46). C-terminal HA-tagging of these two polymerases 
involved PCR-amplification using a reverse primer harboring an HA-tag 
coding sequence (see below for the primer sequence). For the generation of 
polymerase mutants other than D422A, point mutations were introduced – in 
a LV plasmid expressing HA-tagged Ad5 pol – by a site-directed mutagenesis 
technique involving ‘inversed’ PCR of the parental plasmid and subsequent 
self-ligation of the PCR product (see below for the primer sequence pairs). 
Lentivirus production, which was performed as described previously (47), 
involved the co-transfection of LV plasmids with helper plasmids encoding 
HIV-1 gag-pol, HIV-1 rev, and the VSV-G envelope. Lentivirus stocks were 
titrated using a HIV-1 p24 antigen enzyme-linked immunosorbent assay kit 
(ZeptoMetrix Corp., New York, NY, USA).
generation of polymerase-defective adenovirus vectors
Generation of the polymerase-defective Ad vectors involved two basal Ad 
genome-containing plasmids. The first of these, pAdGL, was described 
previously and contains an E1- and E3-deleted HAdV-5 genome, with, at 
the place of E1, two tandem expression cassettes encoding GFP and firefly 
luciferase (46). The second basal plasmid, pAd, carries within its plasmid 
backbone of pShuttle (48) the complete HAdV-5 genome of pTG3602 (49). 
These plasmids were modified, in several cloning steps, to contain a 571-bp, 
polymerase-affecting deletion (ΔPOL; corresponding to nt 7312 to 7882 of 
the HAdV-5 genome; accession no. AC_000008). First, through splicing by 
overlap extension-PCR (see below for primer sequences), a chimeric DNA 
fragment was generated that consisted of two ‘deletion-flanking’ fragments 
(of approximately 1 kb each) with, spliced in between them, a chloramphenicol 
resistance gene (Camr), obtained from pGP618 (50). Subsequently, this ‘ΔPOL.
CAM’ fragment served as a selectable donor in homologous recombination 
[in E. coli BJ5183 (51)] with acceptor plasmids pAdGL and pAd, allowing the 
generation of pAdGLΔPOL.CAM and pAdΔPOL.CAM. Finally, the excision of 
Camr (by virtue of two PCR-introduced SwaI sites) yielded pAdGLΔPOL and 
pAdΔPOL. The viral genomes of these two plasmids were released by PacI 
digestion and subsequently transfected into 911.AdPol cells for viral rescue 
of, respectively, AdGLΔPOL and HAdV-5ΔPOL.
initial setup of the ad pol trans-complementation system
A polymerase complementation system was set up to test Ad pol mutants for 
their ability to support the functions necessary for productive Ad replication 
(Supplementary Figure S1). This system employs a polymerase-defective 
Ad reporter vector that is completely dependent – for its replication – on 
a functional Ad pol (mutant) being provided in trans. Such a polymerase 
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complementation strategy is analogous to previously taken approaches in 
studies that investigated variants of HSV (14,52) and RB69 (32) polymerases.
The E1- and E3-deleted polymerase-defective Ad vector generated for this 
study, AdGLΔPOL, accommodates a polymerase gene-disrupting deletion 
at a location not known to harbor any other essential elements than the 
polymerase sequence (Supplementary Figure S1C). Importantly, at the site 
of this partial polymerase gene-deletion, an extra stop codon was introduced 
such that only a severely truncated Ad pol (encoded by the first forth of the Ad 
pol open reading frame) was producible. Of note, Amalfitano et al. previously 
showed that an Ad vector with an essentially similar polymerase deletion was 
effectively rendered unable to replicate, except when provided with Ad pol in 
trans (53). To facilitate monitoring of viral replication, the AdGLΔPOL genome 
was additionally equipped with CMV promoter-driven reporter genes for 
GFP and firefly luciferase. Transfection of the AdGLΔPOL genome into (E1-
complementing) cells engineered to express wild-type Ad pol resulted in the 
rescue of viable AdGLΔPOL virions.
The Ad polymerase complementation system further involved the use of 
lentivirus (LV) vectors for achieving stable expression of Ad pol variants in 
cells (Supplementary Figure S1A). In this regard, the above mentioned viral 
rescuing of AdGLΔPOL was conducted using cells transduced with a LV-vector 
encoding wild-type Ad pol. Initially, in order to detect the heterologous 
expression of Ad pol in these cells, immunofluorescence (IF) was performed 
for which we made use of a lab-generated anti-serum raised against an Ad pol/
pTP complex. Although detection by this means proved to be achievable, the 
procedure suffered from a low signal-to-background ratio (data not shown). 
Therefore, since more unambiguous detectability was preferred, we opted to 
equip the Ad pols of this study with HA-tags at their C-termini. Supplementary 
Figure S1B shows that lentiviraly expressed HA-tagged versions of wild-type 
Ad pol and a mutant Ad pol, namely D422A, were readily detectable by IF 
using an HA-tag specific antibody. Both these polymerases were found to 
localize to both the nucleus and the cytoplasm, with a higher intensity of 
detection observed in the nucleus.
To ascertain that Ad pol’s ability to replicate the Ad genome was not 
affected by its fusion to an HA-tag, a pilot complementation experiment was 
carried out (Supplementary Figure S1D). Cells expressing the HA-tagged 
versions of either wild-type Ad Pol or the D422A mutant were infected with 
the polymerase-defective vector AdGLΔPOL. Alongside these infections were 
those of positive control cells expressing (non-tagged) wild-type Ad Pol and 
negative control cells not expressing any Ad pol. The results of GFP expression 
analysis at 52 hours post infection show that HA-tagged Ad pol is as efficient 
as non-tagged Ad pol to complement AdGLΔPOL. Thus, a C-terminal HA-tag 
proves to be compatible with Ad pol’s functions necessary for Ad genome 
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replication. Interestingly, the results further reveal that the one mutant taken 
along, D422A, is unable to complement the polymerase-defective vector. 
Thus, although the D422A mutant had previously been shown to achieve 
polymerization in an in vitro setting (41), it seems not to sustain complete Ad 
replication.
pilot deep sequencing run on a spiked test sample 
To probe the utility of massively parallel sequencing (MPS) for the detection of 
minority mutations, we performed a sequencing run on a spiked test sample. 
A 3.1-kilobase-pair (kb) DNA fragment was spiked with several minority 
fragments, each of which differing from the original fragment by only a 1- 
or 2-nucleotide variation. The resulting sample, which contained spikes with 
theoretical prevalences of 25, 6.25, 1.56, 0.39, and 0.1%, was run on a Solexa/
Illumina Genome Analyzer (I) instrument to obtain approximately 20 million 
20-mer raw reads. These reads were mapped, allowing up to two mismatches, 
against the 3.1-kb reference sequence using the ELAND aligner of Illumina’s 
Genome Analyzer data analysis pipeline. Resultant forward and reverse 
mappings – representing only reads passing the default Illumina chastity 
filter (threshold = 0.6) – were subjected to single-base masking to exclude 
bases with phred quality values lower than 29. These operations finally led 
to forwardly and reversely mapped base-call distributions exhibiting average 
coverage depths of respectively 7096 and 6134 high-quality bases. Notably, 
considerable variation in the coverage depth was observed along the length 
of the reference sequence (Supplementary Figure S2A). Nonetheless, as 
much as 84% of the reference sequence was found to be covered – in both 
the forward and the reverse orientation – by at least 1200 high-quality base-
calls per position (Supplementary Figure S2B).
Of the spiked mutations, those with prevalences of 25, 6.25, 1.56, and 
0.39% were found to be distinctively present in both the forward and the 
reverse distributions (Supplementary Figures S2C and S2D). Furthermore, 
each of these spikes was found with approximately its expected prevalence 
(Table 1). By contrast, the spike with expected prevalence of 0.1% (spike no. 
5) did not as prominently stand out from local levels of ‘background’ base-
calls. 
Directed by the above-obtained base-call distribution data we defined 
generalizable filtering rules that allowed for the confident scoring of minority 
mutations. The first of these rules disallows from the analysis any positions 
for which either forward or reverse coverage levels are below a certain set 
minimum. This rule was found necessary to protect against the relatively 
high background base-call levels seen at positions where the coverage levels 
dropped. The second filtering rule conditions that a given minor sequence 
variant may only be scored as a bona fide mutation when present – with 
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prevalences above a set cutoff value – in both the forward and reverse 
distributions. Applied to the spiked test sample data, the combination of 
these rules allowed the scoring of spiked mutations 1 to 4 without picking up 
any false-positives. Specifically, with the minimal coverage level set arbitrarily 
at 1200, a mutation prevalence-cutoff value of as low as 0.17% permits scoring 
of only those four spikes (Supplementary Figure S2E). Of note, for all the thusly 
‘scored’ spikes, both the forward and reverse observed frequencies would 
have very low estimated probabilities of occurring solely as a consequence of 
random sequencing errors, i.e. all P-values were below 1 × 10-12 (Table 1). By 
contrast, the ‘non-scored’ spike could not be significantly distinguished from 
background sequencing errors (all P-values above 0.4).
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oligonucleotides used for cloning, sequencing, and reverse 
transcriptase-pcRs
name sequence
ha-tag (YpYdvpdYa) addition to the ad pol c-terminusa
Forward GACGTATGTTCCCATAGTAACGC
Reverse GTCACGTGCTctaAGCGTAATCCGGAACATCGTATGGGTACGGCATCTCGATC















E3 ADP 1 CCTGAAACACCTGGTCCACT
E3 ADP 2 GCGTTGGTTGTGTTGGTCAT
ML ADP 1 CGAGAAAGGCGTCTAACCAG
ML ADP 2 GCGTTGGTTGTGTTGGTCAT
aThe forward primer is CMV promoter-specific. The reverse primer anneals to the C-terminus 
of Ad pol. The HA-tag encoding sequence is shown in red font. The new stop codon is in 
boldface.
bThe indicated primers were used to construct a recombination donor fragment (‘ΔPOL.
CAM’) carying a chloramphenicol resistance gene (Camr) at the site of a partial Ad 
polymerase gene deletion. First, two ‘deletion flanking’ fragments were generated using 
the Lpol and Rpol primer sets, and a Camr-containing fragment using the Cam primer 
set. Then, to generate ΔPOL.CAM, these three fragments were fused by performing two 
sequential splicing by overlap extension-PCRs using appropriate combinations of primers. 
The respective sequences providing the overlaps between the three fragments are color-
coded blue and green. Underlined sequences indicate introduced restriction enzyme 
recognition sites.
cPrimer sets E3 ADP and ML ADP have a common reverse primer.
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F421A gccGACGAGATCGTGCTCGCC GCCGTTGATGTTGTGGCC KasI











































G845A cgTCGTTTGCCACCAAGC cGTAGAGGGCGTTGGACA MluI
aThe indicated primer pairs were used for an ‘inversed’ PCR on a lentiviral vector plasmid 
encoding HA-tagged HAdV-5 DNA polymerase. Resultant PCR products were subsequently 
self-ligated to obtain plasmids encoding the respective mutants. Red fonts indicate base 
substitutions. Boldfaced nucleotides show the codons mutated to encode the amino acid 
changes indicated in the first column. Underlined sequences represent the newly generated 
restriction enzyme recognition sites (depicted in the last column) used for identification of 
positive clones.
oligonucleotides used for the construction of ad pol mutants
194
5b
Workflow for the analysis of deep sequencing data obtained from 
passaged virus pools
Sequencing data obtained from the passaged virus pools were outputted by 
the Genome Analyzer Pipeline (GAPipeline) in read files of Illumina’s SCARF 
file format. These files included only reads passing Illumina’s default chastity 
filter (i.e. reads that among their first 25 bases have maximally one base with 
a chastity value less than 0.6). Subprograms ‘preprocess’ and ‘mapflowcell’ of 
the short read analysis pipeline SHORE (http://1001genomes.org/downloads/
shore.html) were used for mapping of the reads against the reference 
sequence. The alignments were performed allowing up to 2 mismatches 
and/or gaps. The SHORE subprogram ‘consensus’ was used – separately for 
the forward and reverse mappings – to generate base counts per position in 
the reference sequence. Individual base masking was performed (by SHORE 
consensus) using a quality value cutoff of 30. Resultant forward and reverse 
‘consensus_summary.txt’ files served for mutation scoring using a sequencing 
depth requirement of 1200 and a prevalence cutoff value of 0.25%. See the 
table on the next page for further details on the data analysis workflow.
Workflow f r the analysis of deep sequencing data obtained from 




Sequencing data obtained from the passaged virus pools were outputted by the Genome Analyzer 
Pipeline (GAPipeline) in read files of Illumina’s SCARF file format. These files included only reads 
passing Illumina’s default chastity filter (i.e. reads that among their first 25 bases have maximally 
one base with a chastity value less than 0.6). Subprograms ‘preprocess’ and ‘mapflowcell’ of the 
short read analysis pipeline SHORE (http://1001genomes.org/downloads/shore.html) were used for 
mapping of t e reads against the reference sequence. The alignm nts were performed allowing up 
to 2 mismatches and/or gaps. The SHORE subprogram ‘consensus’ was used – separately for the 
forward and reverse mappings – to generate base counts per position in the reference sequence. 
Individual base masking was performed (by SHORE consensus) using a quality value cutoff of 30. 
Resultant forward and reverse ‘consensus_summary.txt’ files served for mutation scoring using a 
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programa Relevant parameters notes
Custom Perl scriptb s_N_sequence.txt Input read file (Illumina SCARF format)
reads_0.fl Output read file (SHORE format)
SHORE preprocess -f Ref.fa Reference sequence file (fasta format)
-i IndexFolder
SHORE mapflowcell -o FlowcellFolder See note belowc
-f IndexFolder/Ref.fa.shore
-n 2                 Maximum no. of mismatches plus gaps
-g 2                Maximum no. of gaps
Custom Perl scriptd map.list Input file (= output of mapflowcell)
CustomOutputFolder Output files: for.list and rev.list
SHORE consensus -n 0001 Arbitrary ID
-f IndexFolder/Ref.fa.shore
-o AnalysisFolder
-i for.list         (or rev.list) Input: for.list or rev.list (not map.list)
-q 30 Quality value cutoff for base masking
-v Required for ‘consensus_summary.txt’
-r
Custom Perl scripte consensus_summary.txt Forward input file
consensus_summary.txt Reverse input file
MutationScoreFolder Output: mutation score files
1200 Coverage depth requirement
0.25 Minor variant frequency cutoff (%)
aSee workflow diagram above for an overview of the data analysis workflow. SHORE is 
a short read analysis pipeline (http://1001genomes.org/downloads/shore.html) (54) . Its 
subprogram ‘mapflowcell’ invokes the aligner GenomeMapper (55). (See Supplemental 
References for literature cited here)
bA Perl script was used to convert between SCARF and SHORE read file formats. Of note, 
this conversion entailed inferring ‘Sanger’ base quality scores (needed for SHORE) from 
the ‘Illumina’ base quality scores (present in the SCARF format). Furthermore, since SCARF 
files lack chastity value information (which SHORE files do accommodate), each base in the 
generated ‘reads_0.fl’ files was assigned the maximum chastity value.
cThe read files-containing folder structure normally built by the SHORE subprogram 
‘illumina2flat’ – i.e. ProjectFolder/FlowcellFolder/LaneFolder/ReadFolder/LengthFolder – 
was created manually and appropriately populated – in its ‘LengthFolders’– by the above-
generated ‘reads_0.fl’ files.
dThis script divides the forwardly and reversely mapped reads of the ‘map.list’ file (generated 
by the SHORE subprogram ‘mapflowcell’) over two new alignment files: ‘for.list’ and ‘rev.
list’.
eThis mutation scoring Perl script uses as its input the forward and reverse mapping-derived 
‘consensus_summary.txt’ files. These files, which were outputted by the SHORE subprogram 
‘consensus’ in the folder ‘AnalysisFolder/ConsensusAnalysis/supplementary_data’, contain 
A, G, C, and T base counts – both quality filtered and unfiltered – per position in the 
reference sequence.
command line programs and parameters used for the analysis of 
deep sequencing data obtained from passaged virus pools
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summary statistics for minor variant frequencies found in deep se-
quencing data
meana 97.5th percentilea,b
forward reverse forward reverse
spiked test sample sequencing run
with spikes 2.4×10-4 3.1×10-4 8.9×10-4 1.2×10-3
without spikes 1.8×10-4 2.7×10-4 8.9×10-4 1.2×10-3
virus pool sample sequencing runs
stock 1 1.9×10-4 1.7 ×10-4 1.0 ×10-3 9.0 ×10-4
stock 2 1.6×10-4 1.5 ×10-4 8.1 ×10-4 6.8 ×10-4
pol-HA 1.9 ×10-4 1.8 ×10-4 1.1 ×10-3 1.0 ×10-3
T286I 1.9 ×10-4 1.8 ×10-4 7.5 ×10-4 6.7 ×10-4
N417A 1.7 ×10-4 1.6 ×10-4 7.9 ×10-4 6.6 ×10-4
F421Y 2.2 ×10-4 1.9 ×10-4 7.8 ×10-4 6.8 ×10-4
S506T 1.9 ×10-4 1.8 ×10-4 8.1 ×10-4 7.2 ×10-4
V585A 1.8 ×10-4 1.7 ×10-4 9.3 ×10-4 8.3 ×10-4
D827A 1.7 ×10-4 1.6 ×10-4 8.2 ×10-4 7.5 ×10-4
S834E 1.8 ×10-4 1.6 ×10-4 7.7 ×10-4 6.8 ×10-4
pol-HA* 1.8 ×10-4 1.8 ×10-4 8.6 ×10-4 7.6 ×10-4
F421Y* 2.1 ×10-4 1.9 ×10-4 7.4 ×10-4 6.4 ×10-4
aThe statistics are for positions for which both forward and reverse 
coverage levels were above 1200.
bThe 97.5th percentiles were taken as error rate estimates used for the 
calculation of P-values for minor variant occurrences (See the statistics 
section in the main article).
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Human adenovirus (Ad)-derived vectors are widely being developed and 
used for gene therapy (1), oncolytic virotherapy (2) and vaccine delivery  (3). 
Despite the many advances made in these fields, existing vectors are often 
not effective, specific, and/or safe enough. Therefore, major goals in Ad 
vectorology currently are to improve the selectivity and efficiency of target 
cell transduction (4), and, concerning oncolytic vectors, to enhance cell killing 
ability and viral spread (5). This thesis describes studies aimed at improving 
Ad vectors with respect to both these aspects.
The first part of this thesis is about genetic capsid modification for Ad 
retargeting. It focuses on exploiting Ad capsid proteins pIX and fiber as sites 
for the incorporation of cell-targeting ligands. chapter 2 describes a new, 
transient pIX-pseudotyping approach that facilitates rapid analysis of pIX-
ligand fusions in the context of the Ad capsid. This new system is used in chapter 
3 to analyze the utility of a single-chain T-cell receptor (scTCR) as targeting 
ligand anchored to pIX’s C-terminus. Finally, in chapter 4, analogously to 
the pIX-pseudotyping approach, a fiber-pseudotyping approach is taken to 
allow convenient functional testing of new recombinant Ad fibers. Also in this 
chapter, a new fiber variant displaying a single-chain antibody fragment (scFv) 
was assessed for its suitability for Ad retargeting. Following these chapters 
on genetic capsid modifications, chapter 5 describes the development 
and validation of a new directed evolution approach for Ad that is based on 
mutator versions of the Ad-encoded polymerase. This evolution approach is 
employed to increase Ad’s ability to lyse cancer cells. 
Protein IX is a minor capsid protein located buried between the hexons 
that constitute the faces of the capsid icosahedron. Its capsid surface-
exposed C-terminus (6) has previously shown to be a very useful locale for the 
introduction heterologous polypeptides, including small peptide ligands but 
also larger protein domains (7-11). In this regard, the inclusion of an alpha-
helical spacer sequence into liganded pIX constructs was shown to improve 
accessibility of the ligand (9). Thus, pIX has general utility as a genetic anchor 
for viral display of foreign protein sequences. However, the conventional way 
to test new pIX variants for functionality in the virus particle – i.e. genetic 
incorporation into the virus – is cumbersome as it involves time-consuming 
steps as in vitro modification of the viral genome and subsequent virus rescue 
from naked viral DNA. Therefore, a more convenient system for routine 
functional testing of new pIX fusion proteins in the context of the Ad particle 
was developed (chapter 2). The new approach entailed the use of LV vectors 
to generate helper cell lines stably expressing the pIX variant of interest. These 
cells then served to trans-complement a pIX-deleted Ad vector, thus yielding 
Ad vectors that were phenotypically pseudotyped with the concerning pIX 
variant. The use of LV vectors for providing pIX in trans proved very robust 
and practical: the pIX levels were at least as high as seen late during Ad5 
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infection, showed low variability among cells, and were sustained over time. 
Moreover, the pIX-expressing cells were fully able to trans-complement the 
pIX-deleted vector, both regarding capsid loading of pIX and restoration of 
heat stability of the virus. Thus, LV vector-based pIX-pseudotyping of Ad is 
feasible and provides a system for easy testing of new pIX variants in the 
context of Ad particles.
Next, the above pIX-complementation system was put into service to test a 
single-chain T-cell receptor (scTCR) for applicability as an Ad targeting ligand 
genetically displayed on pIX (chapter 3). T-cell receptors (TCRs) determine a 
T-cell’s specificity by binding to intracellular protein-derived peptide fragments 
in complex with major histocompatibility complex (MHC) class I molecules. 
TCRs specific for tumor-associated peptide-MHC complexes exist (12) and 
have been extensively explored to target genetically engineered T-cells to 
tumors (13). Further, Peng et al. recently demonstrated – for the first time – 
that TCRs, or derivatives thereof, also have utility as virus targeting devices 
(14). They showed that genetic fusion of a scTCR to the attachment protein of 
measles virus led to peptide-MHC complex-specific virus-cell entry and cell-
to-cell fusion. The thusly demonstrated concept of TCR-based viral targeting 
is very attractive as it grants access to a new class of targets: intracellular 
antigens. In this regard, targets of particular interest may be cancer-testis 
(CT) antigens, a class of antigens that is highly restricted to tumors (15). 
Previously, another immunoglobulin superfamily member derivative, a single-
chain antibody fragment, already proved functionally displayable on Ad via 
genetic fusion to pIX (16). Therefore, it was hypothesized that a pIX-scTCR 
fusion may likewise be functionally incorporated into Ad capsids. A scTCR 
directed against the CT antigen melanoma-associated antigen (MAGE)-A1 
was fused – via an alpha-helical spacer sequence – to the C-terminus of pIX. 
The pIX-scTCR proved capsid incorporable and, moreover, showed evidence 
of mediating viral transduction by specific interaction with the cognate 
peptide-MHC complex. These results represent a first indication that scTCRs 
can be used as genetic Ad targeting ligands by fusion to pIX.
Given the usefulness of LV vector-based pIX-pseudotyping for the 
functional assessment of novel liganded pIX molecules (described in chapter 
2), an analogous approach was taken to test recombinant Ad fibers. Previously, 
it has been shown that wild-type fiber-expressing cell lines – generated by 
stable transfection through clonal selection – were able to trans-complement 
a fiber gene-deleted Ad vector (17,18). Additionally, a ‘transient transfection/
infection’ procedure has proven to allow phenotypical fiber-pseudotyping 
of Ad (19). This latter procedure entails a large-scale transfection with fiber 
variant-expressing plasmids followed by the coordinated infection with 
a fiber-gene deleted virus. Aiming to extend this pseudotyping concept, 
chapter 4 describes that LV vectors can be used as a convenient alternative 
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tool to generate fiber variant-expressing cell populations employable for 
fiber-pseudotyping of Ad. Importantly, the fiber (variant)-expression cassettes 
used for this purpose had to be engineered to include the tripartite leader 
(TPL) sequence. TPL – a short 5’ untranslated region found in major late-
promoter-derived mRNAs – is known to function in cis to allow translation 
of late mRNAs in the context of host protein synthesis shut-off (20-24). 
Additionally, the TPL sequence has been shown to have a cis-stimulatory 
effect on transgene-expression in the absence of Ad infection (25,26). LV 
vectors incorporating the TPL sequence – proximally to the fiber start codon 
– were shown to generate fiber variant-expressing cell populations with 
characteristics favorable for pseudotyping experiments (i.e. expression levels 
were considerable, sustainable in time, and homogeneous among individual 
cells). Moreover, cells lentivirally transduced to express a modified fiber 
allowed for phenotypic fiber-pseudotyping of a fiber gene-deleted Ad vector.
Additionally in chapter 4, the newly established transient Ad fiber-
pseudotyping system was employed to assess the suitability – for Ad 
retargeting purposes – of a new, scFv-bearing chimeric fiber. Generally, 
antibodies, and their derivatives like scFvs, are not likely candidates for 
genetic Ad capsid incorporation because of biosynthetic incompatibilities: 
antibody polypeptides are routed to the endoplasmic reticulum (ER), while Ad 
capsid proteins are synthesized in the cytoplasm and migrate to the nucleus. 
Thus, when fused to a capsid component (and rid of their signal sequence), 
scFvs are forced to fold in the reducing environment of the cytosol, which is 
potentially problematic due to the lack of chaperone assisted folding and 
disulfide bridge formation (27). Indeed, a previous study showed that a scFv 
was not functional when displayed on a de-knobbed fiber (28). However, 
scFvs may be engineered for optimized stability in a reducing milieu, resulting 
in intrabodies or hyperstable antibodies (29-33). Previously, such stabilized 
antibodies have indeed been shown to be functionally displayable on the Ad 
capsid by genetic fusion to either pIX or fiber (16,34). In view of these favorable 
results, scFv800E6, a tumor antigen-directed scFv that was previously reported 
be structurally robust and thus to functionally fold in a reducing environment 
(35-37), was evaluated here for Ad capsid incorporation as part of a genetic 
fusion to a de-knobbed chimeric fiber. It was found that this ‘800E6 fiber’ was 
able to trimerize (by virtue of a heterologous trimerization domain) and to 
achieve a degree of specific binding to its cognate target Her2/neu. However, 
this fiber showed only a low degree of capsid incorporation and, moreover, 
was unable to detectably mediate antigenic target binding by Ad. Further 
investigation into the intra- and extracellular redox states of the 800E6 fibers 
subsequently revealed that immediately upon cell lysis these fibers form large 
covalent aggregates through intermolecule disulfide bonds. Thus, it appears 
that a large fraction of the cysteines within the scFv moieties tend to engage 
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in non-canonical disulfide bridges (rather than the canonical intradomain 
bridges). Importantly, these findings strongly suggest improper cytosolic 
folding of the scFv. Thus, the particular chimeric fiber tested here was found 
not suited for Ad retargeting. Moreover, its scFv constituent, despite being 
reported to have robust structural framework, appeared to suffer from typical 
problems associated with the biosynthetic incompatibility between antibodies 
and Ad capsid proteins.
The folding difficulties encountered for the scFv in chapter 4 are thought 
to be generic to complex, disulfide bridge-containing secretory proteins being 
artifactually expressed in the cytosol (28). Therefore, other immunoglobulin 
superfamily member-based molecules, like the scTCR used in chapter 3, could 
be expected to be similarly affected. While for the concerning pIX-scTCR 
fusion this was not specifically tested, preliminary unpublished data on scTCRs 
fused to fiber indeed show evidence of exactly the same phenomenon as seen 
for 800E6 fiber (i.e. covalent aggregation due to disulfide linkages upon cell 
lysis). Therefore, barring fusion partner-specific effects, many of the scTCR 
moieties present in pIX-scTCR fusion molecules may be improperly folded and 
thereby putatively be non-functional. The seeming discordance between the 
pIX and fiber data – regarding the successful use of an immunoglobulin-like 
retargeting ligand – may then be explained by pIX-scTCR being present with 
many more copies per capsid than 800E6 fiber (with a ~67 times difference if 
assuming 100% pIX and 10% fiber loading).
While chapters 2 to 4 describe ways to improve Ad vectors by rational 
design, chapter 5 deals with a new random engineering procedure for Ad. 
In general, virus engineering approaches based on genetic diversification 
followed by phenotypic selection have great potential to generate new or 
improved gene therapy vectors and oncolytic agents (38-43). The major benefit 
of such procedures is that they do not require a priori mechanistic knowledge 
to obtain new desired viral traits. Various distinct types of methodologies exist 
that could be considered a form of random virus engineering (see chapter 1, 
part iii). First there are the conventional forward genetics screens that make 
use of mutagens to cause genome-wide mutagenesis. Second, there are the 
more recent approaches that employ in vitro genetic diversification – mostly 
on viral genomic subfragments – followed by viral library-based selection. 
Finally, there are the viral adaptation schemes – mostly conducted with RNA 
viruses – that rely on spontaneous viral mutation.
In chapter 5, a new concept for Ad engineering is described that relies on 
error-prone viral genome replication by modified versions of the adenovirus-
encoded DNA polymerase (Ad pol) (44). To set up this ‘accelerated 
evolution’ approach, individual Ad pol residues implicated in maintaining 
polymerization fidelity, as extrapolated from other polymerase species, were 
targeted for mutation. This generated several single-amino-acid substitution 
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mutants of Ad pol that, while supportive of viral replication, exhibited an 
increased proneness to cause mutations. The respective mutator abilities of 
these mutants were revealed by a deep sequencing strategy allowing direct 
assessment of mutational buildups in viral pools. The two strongest of the 
identified mutator polymerases, T286I and F421Y, were both mutants of 
residues implicated in stabilizing the primer terminus at the exonuclease active 
site during proofreading. To validate the utility of the approach, the newly 
engineered mutator mutants of Ad pol were employed in an evolution regime 
that was aimed at increasing Ad’s cytolytic activity in ovarian carcinoma cells. 
Importantly, this multi-passage evolution procedure led to the accelerated 
evolution towards the desired, selected-for phenotype. Characterization 
of individual viral clones generated in this manner demonstrated a strong 
and early overexpression of the Adenovirus Death Protein (ADP), a protein 
necessary for efficient cell lysis and viral release (45-47). Further analysis of 
these bioselected clones provided evidence for an increased utilization – 
within Ad’s early E3 transcripts – of a mutated splice acceptor site preceding 
the ADP-encoding exon. Altogether, this work demonstrated that engineered 
‘sloppy’ Ad polymerases can serve to provide the genetic diversity needed 
for efficient directed evolution of adenovirus. A distinctive feature of this 
mutator viral polymerase-based Ad engineering approach is that it intrinsically 
permits mutagenesis and selection over successive viral infections rounds. 
This property makes this approach particularly suitable for multiple-passage 
viral adaptation schemes, allowing for the possibility of individual viruses to 
acquire multiple beneficial mutations.
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Het doel van het werk dat beschreven is in dit proefschrift is het verbeteren 
van de selectiviteit en effectiviteit van oncolytische adenovirusvectoren. Twee 
benaderingen zijn genomen om dit doel te bereiken: (i) genetische modificatie 
van virale capside-eiwitten om het infectieprofiel (op celtransductieniveau) 
van het virus te verbeteren (hoofdstukken 2 t/m 4), en (ii) artificiële evolutie 
om de cytolytische potentie van adenovirus te verhogen (hoofdstuk 5). 
In hoofdstuk 1, deel II wordt kort de biologie van de adenovirussen 
geïntroduceerd en wordt beschreven hoe van deze virussen vectoren kunnen 
worden gemaakt. Vervolgens wordt in hoofdstuk 1, deel III een overzicht 
gegeven van de verschillende artificiële evolutiemethoden die gebruikt zijn 
om virale vectoren te genereren en te verbeteren.
De hoofdstukken 2 en 3 richten zich op modificatie van het adenovirus 
capside-eiwit ‘IX’ (pIX). Doel hiervan is door de incorporatie van ‘targeting’ 
liganden een veranderde receptorspecificiteit te bewerkstelligen. Het pIX is 
aanwezig op het oppervlak van het icosahedrische adenoviruscapside, waar 
het functioneert als ‘cement’ tussen de veel grotere hexoneiwitten. Eerder 
is gebleken dat de C-terminus van pIX gebruikt kan worden als anker om 
peptideliganden (en andersoortige polypeptiden) genetisch in het adenovirale 
capside te bouwen. In hoofdstuk 2 wordt een nieuw ‘pseudotyping’ systeem 
beschreven waarmee het mogelijk wordt om op snelle wijze nieuwe pIX-
ligand combinaties te testen op functionaliteit. Hierbij worden lentivirale 
vectoren gebruikt om celpopulaties te maken die stabiel de nieuwe pIX-
varianten tot expressie brengen. Door zulke celpopulaties met een pIX-
gedeleteerd adenovirus te infecteren kunnen virussen gemaakt worden die 
fenotypisch gepseudotypeerd zijn met de betreffende pIX fusies. Dit systeem 
maakt het mogelijk om nieuwe pIX varianten te testen zonder dat daarvoor 
het adenovirale genoom hoeft te worden gemodificeerd.
In hoofdstuk 3 wordt het bovengenoemde pIX-pseudotyperingssysteem 
toegepast voor de analyse van een nieuw pIX fusie-eiwit. Dit eiwit bevat 
een enkele-keten T-cel receptor (scTCR) als ‘targeting’ ligand. De gebruikte 
scTCR is gericht tegen het intracellulaire ‘cancer-testis’ (CT) antigeen 
‘melanoma-associated antigen-A1’. Het chimère pIX molecuul bleek efficiënt 
te worden geïncorporeerd in het adenovirale capside. Bovendien gaven 
virustransductiestudies aan dat het capside-gekoppelde scTCR een zekere 
mate van doelceltransductie kon bewerkstelligen via specifieke interactie met 
het corresponderende peptide-MHC complex.
Volgens dezelfde methode is een fenotypisch pseudotyperingssysteem 
opgezet voor modificatie van de ‘fiber’ van het adenovirus (hoofdstuk 4). 
De adenovirale fiber bestaat als een homotrimere staafvormige structuur 
die verankerd is aan de ‘penton-base’. Deze bevindt zich op elk van de 
twaalf hoekpunten van het icosahedrische adenovirale capside.  Het naar 
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buiten gerichte C-terminale ‘knob’ domein van de fiber is verantwoordelijk 
voor binding met de primaire receptor van het adenovirus, de ‘Coxsackie 
and adenovirus receptor’ (CAR).  Met zijn natuurlijke rol in de binding van 
celoppervlakkenreceptoren in het achterhoofd, ligt het voor de hand de 
adenovirus fiber te modificeren in strategieën die beogen het infectieprofiel van 
adenovirus te veranderen. Om het versneld testen van nieuwe fibervarianten 
mogelijk te maken werd een op lentivirale vector-gebaseerde, adenovirus 
fiber-pseudotyperingssysteem opgezet en gevalideerd. Dit systeem werd 
gebruikt om een nieuwe chimère fiber te testen. De betreffende fiber bevatte 
als ‘targeting’ ligand een enkele-keten antilichaam (scFv) gericht tegen het 
tumor-geassocieerde antigeen Her2/neu.  De fiber-scFv fusie was in staat 
stabiele trimeren te vormen en bleek bovendien een zekere mate van specifieke 
binding met de corresponderende receptor te bewerkstelligen. Echter, de 
nieuwe fiber vertoonde problemen met betrekking tot capside incorporatie-
efficiëntie, Her2/neu-bindingsfunctionaliteit in de context van het capside, 
en de vouwing van het scFv-gedeelte. De betreffende nieuwe fibervariant 
bleek daardoor niet geschikt voor adenovirus ‘targeting’. Bovendien wezen 
de resultaten op een algemene biosynthetische incompatibiliteit tussen 
adenovirale capside-eiwitten en immunoglobuline-achtige ‘targeting’ 
liganden.
Hoofdstuk 5 beschrijft de ontwikkeling en validatie van een nieuwe op 
evolutie gebaseerde methode ter verbetering van adenovirale vectoren. Tot 
op heden zijn de meeste adenovirale vectoren gegenereerd door gerichte 
genetische modificatie. Hoewel deze rationele manier van virale vector 
ontwikkeling goede resultaten heeft geboekt, wordt ze vaak gehinderd door 
onze beperkte kennis van alle complexe virale structuur-functie relaties. 
Daarom kunnen strategieën gebaseerd op mutatie en selectie (zie hoofdstuk 
1, deel III) een nuttig alternatief en/of aanvullende aanpak vormen voor het 
verbeteren van virale vectoren. Het is bijvoorbeeld al veelvuldig aangetoond 
dat de hoge mutatiesnelheden van RNA-virussen eenvoudig gebruikt kunnen 
worden om in evolutie-experimenten specifieke vectorologische doelen 
te bereiken. Daarom werd in Hoofdstuk 5 onderzocht of een artificiële 
evolutieprocedure gebaseerd op ‘mutator’ versies van het adenovirus 
polymerase gebruikt kon worden voor het  genereren van verbeterde 
adenovirale vectoren. Om een dergelijk systeem te ontwikkelen, werd getracht 
de intrinsieke mutatie snelheid van adenovirus replicatie te verhogen door 
gerichte modificatie van het door adenovirus-gecodeerde DNA-polymerase. 
Dit werd gedaan door mutatie van residuen in de gebieden die geïmpliceerd 
zijn in nucleotideselectie en ‘proofreading’. Sneller muterende polymerase 
mutanten konden vervolgens geïdentificeerd worden dankzij een mutatie-
accumulatie en ‘deep-sequencing’ strategie. Tenslotte werd de mutator 
polymerase-gebaseerde artificiële evolutiemethode gevalideerd door een 
evolutie-experiment gericht op het verhogen van de oncolytische potentie van 
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adenovirus. Dit leverde virale mutanten op met een verhoogde en vervroegde 
expressie van het Adenovirus Death Protein (ADP), een adenovirus eiwit dat 
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